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ABSTRACT 
The blood-borne virus, hepatitis C (HCV), is causing an increasing burden of chronic 
and terminal liver disease, world-wide. The development of successful drug 
treatments for this infection has been hampered by the lack of an efficient and 
physiologically relevant in vitro model of viral pathogenesis. The recent 
characterisation of the JFH1 clone of HCV, which is capable of both infection and 
replication in some types of cell lines, has revolutionised the potential of in vitro HCV 
research. Yet very few studies have been able to investigate the pathogenesis of HCV 
in normal, healthy hepatocytes, and none has examined the effects of such infection 
on other human liver cells. 
This thesis presents the techniques and results of work to optimise human primary 
liver cell cultures, in order to permit investigation of the JFH1 clone of HCV. A 
protocol was developed for the isolation of healthy human hepatocytes from 
surgically resected liver tissue. Methods for the non-viral transfection of primary 
hepatocytes were then optimised and compared. Finally, the expression of a JFH1 
replicon (incorporating the luciferase marker gene) was assessed in human primary 
hepatocytes, both in monoculture and in three-dimensional co-culture with hepatic 
stellate cells (HSCs). 
The level of expression of the JFH1 replicon in human primary hepatocytes was 
considerably lower than that found in the human hepatoma Huh7 cell line, as 
expected, and highly dependent upon the batch of primary cells used. Hepatocytes 
which were grown in co-culture with HSCs showed some evidence of a greater 
capacity to support the translation and replication of JFH1. Luciferase was largely 
undetectable by 48 hours, particularly in hepatocyte-HSC co-cultures, suggesting 
that innate anti-viral mechanisms are preserved in these cultures. Further studies, to 
examine the intriguing dialogue between these models and JFH1, now have the 
potential to provide unique insights into the pathogenesis of HCV in the human liver. 
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1. INTRODUCTION 
1.1 The hepatitis C virus 
1.1.1 Clinical aspects of hepatitis C virus infection 
1.1.1.1 Epidemiology and natural history of HCV 
Hepatitis C virus (HCV) was identified in 1989 as the leading cause of non-A, non-B 
hepatitis"'. Humans are the only natural hosts. Infectious particles of hepatitis C 
virus are circulated in the blood of infected individuals. The virus may therefore be 
transmitted by procedures such as blood transfusion, haemodialysis, intravenous 
drug use, tattooing or invasive medical procedures using inadequately sterilized 
instruments. In the UK, blood products have been screened for evidence of HCV 
since 1991 and high standards of medical practice have virtually eradicated iatrogenic 
transmissions of HCV. Recreational intravenous drug use is now the most common 
route of transmission in the UK. In developing countries however, blood transfusions 
and the re-use of medical instruments remain common routes of infection with HCV. 
Vertical transmission, from mother to baby, is also possible and is most likely to occur 
through contact with bodily fluids during the perinatal period. Sexual transmission 
has been documented but appears to be a far less frequent mode of transmission, 
epidemiologically f2.31. There have also been outbreaks of acute HCV infection in men 
who have sex with men (MSM), sometimes associated with pre-existing HIV 
infection 14-61. Following the discovery of HCV, screening of donated blood has 
substantially reduced the transmission risk from blood products and intravenous 
1 
drug use is now the most common risk factor for transmission of the virus in the 
UK [7) 
. 
During the acute phase of an infection, around 20% of people who contract the virus 
will successfully eliminate it from their circulation. The remaining majority become 
chronic carriers of HCV181. The mechanism of natural HCV eradication is unclear. It is 
largely unknown why only a minority of those infected with the virus avoid persistent 
infection. A number of studies have found that female gender correlates with higher 
rates (42% vs. 20%) of spontaneous clearance, perhaps due to an association with 
oestrogen hormone levels'91. There is also some evidence that a very young age at 
time of acquisition is associated with higher levels of HCV clearancel10l. Co-infection 
with chronic hepatitis B correlates with a3 to 4-fold higher rate of HCV clearance, 
purportedly due to due to reciprocal inhibition of viral replication1101, whereas co- 
infection with HIV is known both to worsen the outcome of HCV infectiontl'1, and to 
reduce the likelihood of treatment-related HCV clearance1lz''3ý Interestingly 
however, a recent study of an HIV-infected cohort has found that those who acquire 
HCV by heterosexual transmission are more likely to clear the infection than if it is 
contracted by another route (odds ratio = 2.811141) 
One common finding is that patients who develop symptoms and/or signs of an 
acute hepatitis after acquiring HCV are more likely to clear the virus (relative 
risk =1.7191); usually within 3 months of the onset of the illness1151. A vigorous early 
immune response may therefore be responsible for both the acute illness and the 
subsequent recovery from infectionl91 and the finding that strong CD4+ and CD8+ T- 
cell responses increase rates of HCV clearance corroborates this hypothesis 116,171 The 
specific major histocompatibility (MHC) class 11 alleles HLA-DRB1*1101 and HLA- 
2 
DQB1*0301 are associated with HCV eradication and this is thought to be due to 
more effective antigen presentation(18,191 
Despite the critical role of this early response to hepatitis C infection, acute infection 
is usually asymptomatic and, even in those in whom a chronic infection is 
established, no symptoms may be apparent for 10-20 years. During this period 
however, the patient remains viraemic and therefore their blood and, to a lesser 
extent other bodily fluids, may infect others during this time, through percutaneous 
or mucous membrane exposure. Furthermore, increasing levels of liver inflammation 
and fibrosis may develop in response to the infection during this asymptomatic 
phase, meaning that by the time noticeable symptoms cause the patient to present 
for investigation, significant and sometimes irreversible liver disease has often 
already occurred. 
Many of those with chronic HCV infection will eventually die of non-liver related 
causes but, if untreated, approximately 20% are estimated to develop cirrhosis in the 
20 years after acquisition. Of these, 25% will progress to liver failure or 
hepatocellular carcinoma (HCC) within a further 5 years 1201. The natural progression 
of chronic HCV infection is further outlined in Figure 1.1. 
Many different HCV strains have been identified by examination of their genomes. 
These strains can be grouped into six main types of HCV virus, named genotypes 1-6. 
The geographical distribution of the different genotypes varies widely, as shown in 
figure 1.2. In the UK, genotype 3 strains have been the most prevalent historically, 
followed by genotypes 1 and 2(211. Infection with HCV genotype 3 is particularly 
associated with the build-up of excessive fat in liver cells, known as hepatic steatosis, 
although this can occur as a result of any HCV infection12Z1. 
3 
Acute hepatitis C virus infection J 
15%-30% 70%-85% 
Recovery Chronic hepatitis C 
virus infection 
Mild Moderate Severe N 
A 
20% 
End stage liver disease 
1%-4% 
per year 
Liver } Death Hepatocellular 
transplantation ý-ý--ý-- carcinoma 
Figure 1.1: Flow chart showing the progression of disease in patients who 
acquire hepatitis C infection (from Patel et al. [231) 
4 
C 
b 
. 
a 
Distributed widely in northern Europe 
and USA. Associated with IDUs 
.a Found predominantly in older 0 
HCV4nfected individuals from 
Mediterranean countries and 
Far East 2 Commonest genotype worldwide. 
Older age groups, risk factors 
generally ill-defined 
3 
" 
a 
Distributed widely in IDUs, 
6 
particularly from Europe j 
a Found in IDUs in Hong Kong, 
Vietnam and (more recently) 
Australia 
b 
- 
\4 
Widely distributed in Middle East. 
Associated with past medical 
5 treatment (eg. Bilharria injections) 
a 
a Found commonly 
only in South Africa 
0-050 
Figure 1.2: Evolutionary tree of the principal genotypes of HCV that are found in 
industrialized countries and their main epidemiological associations 
- 
distance from the centre point indicates amount of genomic sequence 
change (and thus proportional duration of evolution). Scale indicates 
number of nucleotide substitutions per site (from Simmonds et 01.1241). 
5 
1.1.1.2 The burden of chronic hepatitis C infection 
Hepatitis C virus (HCV) can cause chronic hepatitis, cirrhosis, liver failure and 
hepatocellular carcinoma (HCC). The last three sequelae are associated with 
significant mortality rates. The longer term effects of chronic infection with the virus 
mean that hepatitis C is an increasingly serious and costly global healthcare problem. 
The World Health Organization estimates that around 3% of the population (170 
million people) are chronically infected worldwide (see also figure 1.3). In England 
and Wales, diagnoses of HCV increased by 10% during 2007(251. As screening rates for 
HCV have increased, so have the medical and financial. burdens attributable to the 
virus. It is likely that the prevalence of the virus, as well as the prevalence of its 
diagnosis, will continue to rise, thus increasing HCV-related healthcare costs around 
the world. 
In England and Wales, studies have shown that around 0.4-0.7% of the population 
has been infected with the hepatitis C virus [7,81. The majority of an estimated 250,000 
chronically infected people are likely to be unaware of their status, although a high 
percentage may already have mild liver disease 1261. The costs of treating 
decompensated liver cirrhosis due to chronic hepatitis C infection are predicted to 
increase enormously if this "silent epidemic" remains undiagnosed and untreated[261 
and the Department of Health is running a national campaign ("FaCe It") to increase 
public and medical awareness of the risks of HCV infection (271. 
6 
6I 
Figure 1.3: Global population prevalence of hepatitis C, 2001, as estimated by 
reported detections of HCV antibodies. Circles indicate the prevalence 
in the indicated islands. Unshaded areas indicate those for which no 
data was available (from the World Health Organization[281) 
7 
Furthermore, in high risk groups of active intravenous drug users the rate of infection 
has been found to be between 30 and 50%1291. Rates are evidently higher in males 
and a higher prevalence has been found in London compared to the rest of the UK. 
Unsurprisingly perhaps, the prevalence of infection increases in those who have 
injected for longer. In all risk-groups studied, there are geographical variations in 
prevalence within the UK: between, for example, inner city populations and more 
rural populations, most likely due to differences in the migrant proportion of the 
population. 
The Department of Health published an action plan for preventing, detecting and 
treating HCV in 2004[271 but a recent audit showed that fewer than 40% of all primary 
care trusts were implementing it effectivelyl251. Whatever the original mode of HCV 
acquisition, the prevalence of cirrhosis and hepatocellular carcinoma due to HCV 
infection is predicted to rise dramatically over the next decade171 and therefore 
improved understanding of this infectious agent's pathogenesis is urgently required. 
1.1.1.3 Current treatment strategies 
No preventative or curative vaccine is available for HCV. Current treatment for HCV 
aims to reduce inflammation and slow or halt progression of liver damage by 
eradicating the virus. The current recommended treatment strategy in the UK uses 
combination therapy with pegylated recombinant alpha-interferon and oral ribavirin. 
Interferons occur naturally in the body and can directly inhibit viral replication, whilst 
also having a number of beneficial effects on the immune response. Pegylation (the 
attachment of a large molecule called polyethylene glycol (PEG)) of interferon is 
thought to protect it from degradation and so confers prolonged bioavailability and 
therefore enhanced efficacy. Ribavirin is a purine nucleoside analogue. Its 
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mechanism of action is unclear but it may act to inhibit the NS5B RNA-polymerase. 
Increasing the doses and/or the duration of treatment generally increases the chance 
of achieving a sustained virological response (defined as the absence of detectable 
HCV RNA in the peripheral blood, sustained for 6 months after the end of treatment) 
but, equally, often decreases treatment compliance due to an increase in side effects 
such as haemolysis and depression [301 
Standard durations of treatment are usually between 6 and 12 months depending on 
the HCV genotype and quantified viral response, as determined by the viral 
concentration in peripheral blood. A rigorous clinical assessment, sometimes 
including liver biopsy, is required before treating HCV infection (described further in 
the NICE guidelines1311 and by Strader et al. [321). Significant and persistent side effects 
of treatment are common and include fatigue, malaise, myalgia, psychiatric 
disturbance and blood disorders. The absence of either a simpler care pathway or a 
better-tolerated treatment regimen may contribute significantly to the fact that only 
around 20% of diagnosed chronic HCV carriers ever receive treatment, whilst not all 
of this minority will complete the course. Treatment can render the virus 
undetectable in up to 90% of people with genotypes 2 and 3 and up to 50% of people 
with genotype 1'33'. 
New possibilities for anti-HCV therapy include new interferon adjuvants (for example 
human serum albumin), which reduce the frequency of doses required, and 
interferon inducers (such as the toll-like receptor (TLR-) agonists CPG10101 and 
isatoribine, and the antiprotozoal agent nitazoxanide), which stimulate both the 
innate and humoral immune response pathways. A number of pharmaceutical 
companies are working to design small molecule HCV protease inhibitors (such as 
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telaprevir which inhibits NS3-4a and is currently in phase III trials) and NS5B 
polymerase inhibitors (either nucleoside analogues such as R1626 or non-nucleoside 
inhibitors such as VCH-759), which have potential to improve both the effectiveness 
and the specificity of HCV treatment [301. Caspase inhibitors, to reduce hepatocyte 
apoptosis, and therapeutic vaccines against HCV envelope glycoproteins are also 
under investigation[33) 
The relatively non-specific agents currently used in the treatment of hepatitis C 
infection are testament to a lack of understanding of the effects of the virus on host 
cells. An immense amount of research using hepatoma-derived cell lines has 
provided many, sometimes conflicting, insights into the viral life-cycle of HCV. These 
discoveries are beginning to enable the development of new therapeutic agents, but 
the in vivo response to these drugs is currently unpredictable. 
1.1.2 An overview of hepatitis C virus research 
1.1.2.1 Discovery and molecular structure of the hepatitis C virus 
From the late 1970s, researchers had been searching for a causative agent for non-A, 
non-B hepatitis (NANBH). A blood-borne aetiology seemed clear but nothing could 
be isolated in cell cultures or reliably visualised using electron microscopy. Finally, 
Choo et al. 111 constructed a cDNA library from the serum of a patient with NANBH 
using random primers. One clone was found to be associated with other NANBH 
infections and it encoded a virus with genetic similarity to flaviviruses. Ultimately, 
this newly discovered agent was assigned to its own genus, Hepacivirus, within the 
Flaviviridae family. 
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As a single-stranded RNA virus, HCV is prone to uncorrected replication errors which 
lead to a virus population with multiple genome variants, also known as a quasi- 
species', within each infected patient. Nonetheless, consensus sequences have been 
derived which show there to be six main genotypes. The genome is now known to 
consist of a 9.6 kb positive strand of RNA which encodes a single polyprotein. 
Translation of the genome is mediated by an internal ribosome entry site contained 
in the well-conserved 5' non-translated region (NTR). The resulting polyprotein is 
processed by cellular and viral proteases to yield mature, functional viral proteins 
(see figures 1.4 and 1.5). 
Core protein forms the nucleocapsid of HCV and is perhaps the most studied of all 
the individual HCV proteins. It has been shown to interact with the endoplasmic 
reticulum (ER) during maturation cleavage by signal peptide peptidase (see figure 5) 
and subsequently associates with lipid droplets for transport within the cell134). 
Further work suggests that this association of HCV core protein with lipid is essential 
for the production of infectious virus from the host cel11351 
In addition to its structural function enclosing the viral RNA, core protein has also 
been found to affect various aspects of cellular signalling, lipid metabolism, 
transcription and apoptosis1361. Many findings have been derived from single gene 
transfection studies and some have yielded conflicting or heterogeneous results. For 
example, it has been shown that HCV core protein derived from genotype la virus 
represses nuclear factor KB (NF-KB; a transcription factor involved in inflammatory 
signalling and cell proliferation), whereas core protein from other genotypes of HCV 
* In virological terms, quasispecies describes a population of genomic mutants that becomes 
distributed, over time, around the master sequence during an RNA virus infection. 
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did not have this effect [371. A number of studies have also investigated the effect of 
HCV core protein on the tumour suppressor p53. One such study found that the two 
proteins co-localise and that low levels of core protein increase the activity of p53 
but that, conversely, over-expression of HCV core protein inhibited itt38) 
The El and E2 genes encode two envelope glycoproteins which form glycosylated 
heterodimers during cellular processing before becoming the key transmembrane 
proteins on the mature virus envelope. These glycoproteins have been shown to be 
important for virus attachment and binding during initiation of infection, associating 
with CD-81, SR-B1 and claudin-1 cell surface receptors 139,401 A hypervariable domain 
(HVR1) at the 3' end of E2 is the site of many HCV mutations and therefore the 
source of most of the heterogeneity between quasispecies. Furthermore, this 
variability must be a key factor in evading a neutralising antibody response. 
A very small polypeptide, p7, is encoded between the main structural and non- 
structural genes of HCV, with a largely uncertain role in the viral life cycle. It has 
been shown to form hexamers, with ion channel function, and may function as a 
viroporin to confer infectivity. This role in facilitating the entry of HCV into the host 
cell means that the p7 protein is also a potential target for antiviral drugs such as 
amantadine[411 
At the N-terminal end of the non-structural segment of the HCV polyprotein, NS2 has 
been found to be cleaved from NS3 by an auto-protease mechanism and its 
subsequent activity, if any, is unknown. In contrast, NS3 has more than one function. 
The N-terminal portion of NS3 possesses serine-specific protease activity and may 
also inhibit the signalling for the innate immune response, whereas the C-terminal 
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Figure 1.4: Diagram showing the genome map and polyprotein structure of HCV. 
NTR = non-translated region; gp = glycoprotein; p= protein. (from 
Anzola and Burgos1421) 
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Figure 1.5: Schematic representation of the processing, interactions and cellular 
distribution of the proteins derived from the HCV genome. The 
proteins are closely associated with the cellular membranes during 
their post-translational processing and/or subsequent functionning 
(from the European HCV Database1431) 
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functions as an RNA helicase, which is therefore essential for virus replication. These 
functions ensure that NS3 is of great interest as a target for new antiviral agents. 
NS4A remains closely associated with NS3 (see figure 1.5), and seems to be required 
as a cofactor for the serine-specific protease function. It may also be responsible for 
association of the non-structural proteins with cellular membranes. NS4B, a very 
hydrophobic protein, is known to localise to the ER and may alter membrane 
conformation during HCV replication. It might also be associated with lipid-mediated 
viral transport within cells. 
NSSA is a phosphorylated zinc-containing metalloprotein with a number of putative 
functions, particularly related to the regulation of replication. It has been the site of 
cell-culture adaptive mutations in in vitro research and may modulate the interferon 
response. It, too, possesses a membrane-associating domain which presumably 
anchors it within the viral replication complex. 
Finally, NSSB plays a key role in viral replication, being an RNA-dependent RNA 
polymerase. A complementary negative strand is synthesized and used as a template 
for genomic RNA replicates. Despite this key function, sequence variability in the 
NSSB gene is common. This diversity means that the NS5B gene is often one of the 
main regions used to determine the genotype of a patient's infection. 
As has been noted, much of the early research into the pathogenesis of HCV focused 
on exploring the effects of single genes, and their proteins, on the function and 
signalling of tumour cell lines (most notably the hepatoma cell lines HepG2 and 
Huh7). The relationship between these in vitro effects and the in vivo pathogenesis 
of an intact virus on normal human liver cells is inadequately understood. For this 
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reason, the conclusions drawn from such research are, at best, putative and, at 
worst, unclear and even misleading. Even with more recent approaches to HCV 
research, described below, the processes underlying viral replication, assembly and 
release remain poorly understood. 
1.1.2.2 The biology of the hepatitis C virus 
Although the HCV genome has been well characterised, understanding of the virus 
life cycle (as pictured in figure 1.6) is far from complete. HCV can be found in 
hepatocytes and peripheral blood mononuclear cells. Differentiated adult 
hepatocytes express a number of receptors which are associated with lipids and have 
also been associated with HCV infection. CD81 is a common tetraspanin protein with 
many functions and is expressed on almost all cell types. It has been hypothesised 
that CD81 binds to an HCV surface protein but this may not be sufficient to allow 
infection on its own. Scavenger receptor 131 (SR-B1) functions to transport both high 
and low density lipoproteins across the hepatocyte cell membrane and has also been 
shown to bind an HCV envelope protein. The low density lipoprotein receptor (LDL- 
R) functions, as its name suggests, to bind and endocytose lipoproteins and has also 
been found to act as an HCV receptor 1391. More recently another family of cell- 
surface proteins, the claudins, has also been demonstrated to mediate the entry of 
HCV into host cells. Claudins are highly conserved tetraspanin proteins that are 
essential in the formation of tight junctions between cells. At least twenty isotypes 
exist, of which claudins-1, -6 and -9 have been found to act as co-receptors for 
HCV1401. Many researchers now speculate that HCV is associated with lipoprotein 
complexes in the peripheral circulation and that this facilitates both immune evasion 
and the infection of naive cells (391. 
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Figure 1.6: Schematic diagram of the HCV life-cycle, showing its entry into, 
processing within, and release from the host hepatocyte (from 
Lindenbach and Rice [4`1). 
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After release from the endosome and uncoating of the viral envelope and capsid, 
through mechanisms which are unclear, HCV RNA functions directly as mRNA and is 
translated by cellular ribosomes. Synthesis, processing and transport of viral proteins 
have been shown to be highly associated with the endoplasmic reticulum of infected 
hepatocytes. Viral and host cell enzymes function to replicate the viral RNA via the 
synthesis of a negative-strand template. The new viral RNA is surrounded by a newly 
assembled nucleocapsid and the whole is encapsulated by a lipid rich membrane 
before budding from the host cell as mature virions. The processes by which new 
viral proteins and RNA are packaged and released from the host cell in this way 
remain almost entirely unknown. 
Research into the pathogenesis of HCV and the development of therapeutics has 
been hampered by the lack of a robust, in vitro method for virus culture145). The 
development of successful, specific therapies for any disease often depends on a 
precise understanding of its pathogenesis. It is possible to draw some conclusions 
from knowledge of the HCV genome by analogy with related viruses. The 
chimpanzee is the only permissive animal model for HCV but ethical considerations 
severely limit the use and scope of this model for research. Evidence of the outcome 
of chronic HCV infection is easily available by histological study of clinical liver 
specimens. However, to understand the mechanisms behind such damage, studies 
of cellular responses to viral entry, protein expression and replication are required. 
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1.1.2.3 Cell culture models for hepatitis C 
Since HCV is thought to replicate mainly in hepatocytes, these cells are the obvious 
choice for investigating the viral life cycle. However, the low percentages of infected 
hepatocytes, the presence of relatively few genomes per cell, and the error-prone 
nature of reverse transciption polymerase chain reaction (RT-PCR) means that 
reliably-representative liver-derived virus is hard to isolate and clone for further 
investigation 146,471 Another problem is that the availability of primary human 
hepatocytes is limited; as is their durability in in vitro culture conditions (further 
discussed in chapter 3). 
Liver-cell lines, principally Huh7 and derived-clones, have been the main cell type 
using for investigating the pathogenesis of HCV. The Huh7 cell line was derived in 
1982 from a well-differentiated human hepatocellular carcinoma [481. These cells 
proliferate easily in culture with a doubling time of around 35-40 hours (481. Huh7s 
are relatively well differentiated, producing various plasma proteins such as 
albumin, ceruloplasmin and alpha-1 antitrypsin as well as a few carbohydrate- 
metabolizing enzymes such as glucose-6-phosphatase (G6Pase) and fructose 1,6- 
diphosphatase (FDPase)1481. Unfortunately, although the phenotype of the original 
tumour is well maintained, these cells are not fully representative of normal healthy 
hepatocytes. Huh7 cells lack cytochrome P450 function and their ready proliferation 
in vitro is uncharacteristic compared to primary hepatocytes. For the same reasons, 
they may not retain normal mechanisms or levels of signalling when challenged or 
cultured with other cells. 
19 
1.1.2.4 Replicons of the hepatitis C virus 
Serum-derived HCV comprises a heterogeneous and unique mixture of genomic 
variants within the quasi-species; a disadvantage in the search for reproducible 
results and broadly-applicable conclusions. Early research therefore sought 
consensus sequences of HCV from patients with very high viral titres. These 
sequences were used to generate full length HCV RNA clones, such as H77, which 
were infectious by inoculation into chimpanzees but still failed to replicate to any 
detectable level in unmodified human liver cell-culture systems1491 
Replicons are RNA or DNA sequences that replicate from a single starting point. 
Wild-type HCV RNA essentially functions as a replicon but, since it appeared to lack 
the ability for robust replication in vitro, modified replicons (some with alternative 
or additional internal ribosome entry site (IRES) sequences) were created. 
Subgenomic replicon systems for HCV were developed first1491, allowing examination 
of viral RNA synthesis and the functions of viral proteins. First generation replicons 
carried selectable neomycin-resistance genes on a bicistronic sequence: where 
translation of the resistance marker was initiated by the HCV IRES and translation of 
the non-structural genes was mediated by an inserted encephalo-myocarditis virus 
(EMCV) IRES, as shown in figure 1.7 below. 
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Figure 1.7: General structure of (a) sub-genomic replicons of HCV and (b) the full 
length infectious replicon JFH1 (from Bartenschlager1491 and 
Pietschman et al. 1501). Further examples of replicons are given in 
chapter5. 
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After producing stably transfected cell lines, a few neomycin-resistant cell colonies 
were isolated and found to contain replicating RNAtsl, s2l, though this was most 
successful with selected highly permissive clones of Huh-7 cell lines. The 
spontaneous development of cell culture-adaptive mutations within the viral 
genome gave increased levels of replication1S31, but at the expense of infectivity in 
the chimpanzee, indicating substantial modification from wild-type HCV. Indeed, 
mutations causing hyperphosphorylation of the NS5A protein, which are found after 
cell-culture adaptation, have been shown to reduce replicative capacityt491. 
Using highly-permissive cell lines, genomic replicons could be inserted to express the 
structural proteins of HCV150'541 but these replicons could not couple RNA replication 
with virus particle assembly. It seemed that either the cell-line adaptations or the 
changes to the replicative efficiency were responsible for the failure to produce 
infectious virus. 
So the generation, from the JFH1 clone of HCV, of a novel replicon which replicates 
without cell culture-adaptive mutations in the Huh7 cell line was a highly important 
developmentIS5'561 Wild-type genotype 2a virus was isolated from a Japanese 
patient who presented with acute fulminant hepatitis. The consensus sequence of 
this virus was designated Japanese fulminant hepatitis clone 1(JFH1). A subgenomic 
replicon was initially derived from this consensus sequence and was shown to 
replicate at high levels in unmodified Huh-7 cellst55,56] 
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1.1.2.5. Infectious hepatitis C virus in cell culture 
The JFH1 clone has been modified by the addition of structural genes, as shown in 
figure 1.7, and this full-length genome permits generation of infectious virus particles 
and also retains infectivity in the chimpanzee(571. Several successful chimeric 
genomes have also been produced, most of which produce even higher titres of 
infectious HCV virus in culture than JFH1. More importantly, these chimeras enable 
the study of more common genotypes including genotype la, lb and 3a, although so 
far only the JFH1 non-structural genes support efficient virus production. 
These constructs have all been developed and investigated in Huh7 cells. However, 
as previously noted, these tumour-derived cells do not retain all the functional 
characteristics of in vivo hepatocytes. In addition, continuous cell lines cannot offer a 
physiologically reliable model in which to examine the mechanisms by which HCV 
infection affects the cell cycle and cell death. A number of obstacles therefore still 
hamper those who seek a robust culture system of greater relevance to the in vivo 
situation. 
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1.2. Primary hepatocyte culture systems 
1.2.1. The human liver 
1.2.1.1. An introduction to hepatocytes 
The human liver is a large organ which receives nutrient-rich blood from the portal 
vein and oxygenated blood from the hepatic artery. A membrane, known as 
Glisson's capsule, surrounds a vascular tissue mass which is comprised of several 
types of cells. Up to 80% of the total mass is made up of parenchymal cells called 
hepatocytes. These cells perform a wide range of complex functions, including 
synthesis of proteins, lipoproteins and bile salts; modification of carbohydrates; 
storage of various substances; and they are also responsible for the processing and 
excretion of numerous endogenous and exogenous molecules. Hepatocytes 
therefore exhibit large nuclei and large amounts of intracellular storage granules, 
endoplasmic reticulum and mitochondria are evident on microscopy. A high level of 
both active and passive cell transport is thus required for the cells' excretory and 
metabolic functions and this is supported by a specific histological architecture. 
Liver cells are normally organised within a three-dimensional polygonal unit called a 
lobule (figure 1.8). Within the lobule, single-cell layers of cuboidal hepatocytes are 
arrayed in a radial pattern around a central venule. Each layer is adjacent to a 
sinusoid, which carries blood and is bounded by a fenestrated epithelium. Microvilli 
on the sinusoidal surface of hepatocytes project into the sinusoid and facilitate 
efficient nutrient and oxygen transfer. On the non-sinusoidal faces of each 
hepatocyte, bile canuliculi form and transport excreted substances back towards the 
bile duct in the portal triad. 
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Figure 1.8: Schematic diagram of the three-dimensional structure of the human 
liver lobule, showing its blood supply and the cords of cuboidal 
hepatocytes (from Cunningham and Van Horn1581) 
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1.1.1.1. An introduction to hepatic stellate cells 
Hepatic stellate cells (HSCs), also called Ito cells or fat-storing cells, comprise around 
5-8% of cells in the normal healthy liver. HSCs are of mesenchymal descent and in 
healthy tissue they normally appear to exist in a quiescent state. Long processes 
extend from the cell body, hence the name stellate (star-like). These projections 
wrap around adjacent sinusoids and are also in close contact with numerous 
hepatocytes. Quiescent HSCs are known to store lipid droplets containing vitamin A 
but many of their functions remain unclear. 
Hepatic stellate cells become activated during liver disease or other damage. 
Activated HSCs exhibit a marked increase in proliferation, contractility and 
chemotactic mobility. These processes are accompanied by a change to a 
myofibroblast-like morphology and loss of cytoplasmic lipid droplets. Activated HSCs 
can also secrete type 1 collagen and remodel the surrounding extra-cellular matrix, 
leading to fibrosis. HSCs synthesise transforming growth factor 0 (TGF-ß), which also 
promotes liver fibrosisr59l. Further, it has been demonstrated that the activation of 
HSCs correlates with the degree of fibrosis[601 and iron deposition[611 during hepatitis 
C infection. As fibrosis is such a key event in the pathogenesis of chronic HCV 
infection, HSCs are of great interest in any study investigating the cellular and 
molecular basis of the fibrotic process. 
In addition, HSCs have been found to adhere to, and encourage proliferation of, 
hepatocytes during liver regeneration after hepatic injury (621, probably through the 
exchange of growth and chemotactic factors. HSCs can exert both positive and 
negative influences on hepatocyte proliferation, including production of hepatocyte 
growth factor (HGF), which is up-regulated after liver injury 1631. 
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1.2.2. In vitro culture of primary liver cells 
1.2.2.1 Isolation, culture and functional assessment of primary hepatocytes 
Primary adult hepatocytes are fairly large cells with a naturally cuboidal morphology 
and contain numerous organelles. They are complex cells whose membranes are 
readily susceptible to damage by physical or chemical means. As such they are 
difficult to isolate successfully and reliably. The number, quality and viability of the 
isolated cells are all dependent on a number of factors, such as the vascular 
architecture of the tissue used and the expertise and speed with which the isolation 
procedure is performed. The quality, quantity and structure of the liver tissue used 
also impacts upon the yield and viability of hepatocytes obtained from each tissue 
preparation. The further confounding factor of donor heterogeneity, which is 
particularly marked when obtaining human cells, adds an additional and significant 
source of variation (discussed further in chapter 3). 
Isolation of primary hepatocytes was first carried out in the 1960s using mechanical 
and enzymatic digestion of rat liver1641. The technique was modified, most notably by 
Seglen et 01.1651, to become a two-step collagenase perfusion technique that is widely 
used as a basis for most hepatocyte isolation work today. The existing vasculature of 
the liver lobe or segment is cannulated and a series of buffer solutions is perfused 
through the tissue. The first buffer solution usually performs the dual function of 
flushing the tissue of blood and disrupting cell-cell junctions by means of a calcium 
chelating agent. The second buffer solution contains a collagenase (usually tissue- 
specific) which digests much of the extra-cellular matrix. This then enables the 
hepatocytes to be gently liberated from the treated tissue with a minimum of 
mechanical force. Generally the capsule can be teased apart using forceps and the 
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liver cells flushed from any undigested tissue using warmed culture medium. 
Following a mesh filtration step to isolate a suspension of single cells, several low- 
speed centrifugation steps are generally used to isolate and purify the parenchymal 
cell fraction. 
The hepatocytes obtained by these methods will rapidly suffer decreases in both 
viability and differentiated function if not cultured in an appropriately supportive 
environment. A number of methods for prolonging both viability and function exist; 
however, most require conditions that are both physically supportive and hormonally 
enriched. Substances which mimic the support of the in vivo extra-cellular matrix are 
commonly used, along with serum, insulin, steroid hormones and growth factors. 
Few hepatocytes will spontaneously proliferate in in vitro culture conditions and, if 
grown on standard tissue culture plastic-ware, they will usually die within one week. 
The physical fragility of hepatocytes also makes them intolerant of removal (or 
passage) into new culture environments after they have adhered to the initial culture 
surface. Specialized media and growth matrices can in some cases maintain viability 
and function for several months. Unfortunately a dilemma exists in that additives 
which promote proliferation tend to encourage dedifferentiation, whereas 
substances which promote the maintenance of differentiated hepatocyte function 
also minimise progress through the cell cycle. 
In vitro hepatocyte function can be measured in several ways. Albumin production 
and urea metabolism can be measured easily but are maintained even in relatively 
poorly differentiated cell cultures. Demonstration of cytochrome P450 function is a 
far more sensitive measure of continued hepatocyte-specific function. The 
cytochrome P450 (CYP450) protein family comprises a large number of iron- 
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containing enzymes which metabolise thousands of different substrates. CYP450 
enzymes are mainly associated with mitochondrial or endoplasmic reticulum 
membranes and, in hepatocytes, act on diverse substrates including bilirubin, 
ethanol, steroid hormones, and exogenous drugs. Furthermore, their activity can be 
induced or inhibited by some exogenous compounds. Differentiated hepatocytes are 
therefore of great interest to the pharmaceutical industry for investigating drug 
metabolism and toxicities. 
1.2.2.2. Isolation and culture of primary hepatic stellate cells 
Hepatic stellate cells (HSCs) can also be isolated from liver tissue by digestion. Due to 
the more robust nature of these mesenchymal-derived cells, isolation protocols can 
make use of more aggressive enzymatic or mechanical digestion techniques than 
those used for hepatocyte isolation, while still yielding viable cells. Mincing and 
stirring may therefore be used after perfusion and digestion of tissue. This may help 
to maximise the numbers of HSCs obtained as, by their nature, they are likely to be 
closely associated with the extra-cellular matrix. 
Most methods developed for the isolation of hepatic stellate cells employ sequential 
perfusions of the tissue and treatment of the resulting cell suspension, using 
collagenases and a protease called pronase, in order to digest the tissue fully. 
Deoxyribonuclease is also used to digest DNA released from lysed cells, which can 
otherwise cause clumping of cells in the suspension. Unfortunately, these methods 
preclude the concurrent isolation of hepatocytes as they cause too much 
parenchymal cell damage. Some protocols do exist to isolate the HSC fraction after 
the hepatocytes have been extracted[661; the advantage being that the same tissue 
can yield both cell types, thus maximising its potential. 
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The second, and equally important, stage of HSC isolation is fractionation of the non- 
parenchymal cell suspension obtained by any of the above methods. Due to their 
relatively high lipid content, HSCs have the lowest density of any hepatic cell type 
and can be purified by density gradient centrifugation. Following isolation, HSCs 
usually must be cultured in vitro for at least a week, to allow proliferation and 
generation of sufficient numbers of cells for use in studies. Rat HSCs can be passaged 
and maintained for up to one year (Amanj Saeed, University of Nottingham, personal 
communication). Unlike hepatocytes, HSCs tend to proliferate readily in in vitro 
culture and are tolerant of passage onto other culture surfaces. 
1.2.3. HCV replication in three-dimensional co-cultures of liver cells 
The characteristics of in vivo hepatocytes, in particular their conformation and 
expression of cell surface moieties, may be significantly altered by the process of the 
two-step isolation procedure. Ongoing culture in the physiologically most relevant 
conditions possible is therefore essential to reconstitute normal phenotypic traits. 
Media constituents and culture substrate are most important for prolonging viability 
and function of primary hepatocytes in conventional single-layer plating conditions. 
However, culture in a three-dimensional "spheroid" formation has been found to 
confer additional benefits: increased longevity and the maintenance of differentiated 
function and both intra- and extra-cellular structures(671 
It is known that liver-specific functions are somewhat stabilised in hepatocytes co- 
cultured with non-parenchymal cells168'691. Use of a novel in vitro hepatocyte culture 
method has demonstrated that static co-culture of rat hepatocytes and hepatic 
stellate cells leads to the formation of self-organising three-dimensional 
spheroids (70,711. It has been shown that the in vitro co-culture of hepatocytes with 
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HSCs can significantly prolong hepatocyte-specific cytochrome P450 functiont'Z1. 
Proliferation also seems to be enhanced 1731, in contrast with "normal" in vitro 
hepatocyte culture, in which the ready proliferation of in vivo cells is lost. Related 
studies have also demonstrated that, in 3D co-cultures of hepatocytes and HSCs, 
significant histological similarities to in vivo liver architecture can be seen (711, Most 
interestingly, a supportive extra-cellular matrix of collagen and fibrin develops 
around these organised aggregates of hepatocytes. This feature of the hepatocyte- 
HSC co-culture system is likely to make it particularly useful for investigating fibrotic 
processes. These functions of HSCs, both in vivo and in vitro, make them a logical cell 
type to study in parallel with hepatocytes when investigating the pathogenesis of 
HCV in primary liver cells. 
Three-dimensional cultures of hepatocytes are thus of interest in the study of 
hepatitis C infection for several reasons. Firstly, as already documented, they retain 
more of the functional and structural characteristics of in vivo cells and any finding 
should therefore have greater relevance to the clinical situation. Secondly, spheroids 
have also been shown to be more permissive to HCV infection, presumably due to 
improved generation or retention of cell surface receptors and cellular functions that 
confer susceptibility to HCV. Thirdly, cells in a three-dimensional structure are likely 
to develop and maintain cell polarity, cell-cell interactions and therefore cell-cell 
signalling, to a far greater extent than plated cells. 
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1.2.4. Using HCV replicons in a human primary liver cell culture model 
A small number of studies have evaluated the susceptibility of human primary 
hepatocytes to HCV infection or replication in vitro. Wild-type virus in patient serum 
samples has been shown to infect primary hepatocytes in monoculture and the cells 
can subsequently support replication of HCV RNA174'751. Importantly, consistent 
susceptibility was seen between hepatocyte preparations from different donors, 
supporting a theory of universal susceptibility of human primary hepatocytes to HCV 
infection [751. However, virus replication varied in both duration and extent depending 
upon genotype and quasispecies and was, in most cases, detectable only between 3- 
5 days after inoculation [741. In a later study the average number of HCV RNA copies 
ranged from between 0.18 to 36 genome copies per hepatocyte(751. 
Low density lipoproteins (LDL) and soluble forms of the low density lipoprotein 
receptor (LDL-R) have been shown to inhibit or enhance, respectively, the ability of 
HCV to infect primary hepatocytest76'"ý, reinforcing the evidence from Huh-7 studies 
which identified LDL-R as a possible HCV receptor. Modulation of LDL-R expression 
similarly modulated the efficacy of wild-type HCV infection. Again, there was good 
concordance of findings between different preparations of primary cells but, 
interestingly, these findings do not corroborate evidence from studies using HCV 
pseudoparticles (HCVpp; in which HCV envelope glycoproteins are wrapped around a 
retroviral core) or insect-derived virus-like particles (VLPs; in which HCV envelope 
and core proteins are combined into non-infectious particles lacking the viral RNA), 
which have found that LDL-R is not required for infection to occur [78,791. HCV 
replication in primary hepatocytes has also been shown to be susceptible to 
interferon-a, as it is in vivo1801. It has more recently been reported that primary 
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hepatocytes exposed to proliferative cytokines supported productive infection with 
wild-type virus but that such treatment sometimes led to selection of viral 
quasispecies1811. 
Alternative approaches have involved: in vitro culture of primary hepatocytes from 
chimpanzees or humans with chronic HCV infection 1741; or infection of fetal primary 
hepatocytes or adult hepatocyte cell lines, using infected patient serum [821. All of 
these systems are disadvantaged either by functional dissimilarities with primary 
adult cells or by the unavoidable variability of virus found in patient serum. Further 
detailed discussion of some of these model systems and previous studies which have 
utilised HCV replicons is presented in section 5.1. 
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1.3. Research questions 
Cultivation of a defined HCV clone in primary human hepatocytes is desirable for a 
number of reasons. Firstly, it is important to confirm (or indeed refute) data on the 
life cycle and pathogenesis of HCV which have been derived from studies in less- 
differentiated cell lines, such as the Huh7 clones. Secondly, it is anticipated that in 
vitro studies of normal primary hepatocytes which are exposed to HCV replication 
and/or infection would mimic, more closely than Huh7s, the pathophysiology seen in 
vivo. Such a model would thus be expected to enable unique evidence about the 
cellular effects of HCV infection to be obtained. In particular, it is hypothesised that 
highly differentiated and durable co-cultures of primary hepatocytes and HSCs will 
provide a superior system in which to examine the mechanisms of HCV-induced 
hepatocellular damage and cell death. Further, a hepatocyte-HSC co-culture model 
would allow additional examination of the effects of HCV on cell-cell signalling, HSC 
activation and the fibrotic remodelling of the extra-cellular matrix, all of which are of 
relevance to the pathogenesis of HCV, as previously discussed. Ultimately, it is hoped 
that establishing replication and/or infection of HCV in differentiated hepatocytes 
would enable more physiologically relevant evaluation of both the antiviral and the 
inductive functional effects of new anti-HCV compounds. 
Originally, the intention of the present studies was to investigate how expression of 
the HCV core protein affected the function of primary hepatocytes and HSCs in 3D 
co-culture. However, during the first year of work it became evident that 
experimental work using the newly developed JFH1 replicon would, in many cases, 
be of more importance and greater interest to the research community than studies 
based on single-gene transfection. In addition, as the majority of other research 
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teams began to use this new clone in established cell-line culture systems, it was 
important to assess alternative cell culture models within this contemporaneous 
context. 
Following the generation of the highly replication-competent JFH1 replicon1ss), the 
research questions were therefore altered to the following: 
i. To what extent does JFH1 replicate in monocultures of human primary 
hepatocytes? 
ii. To what extent does JFH1 replicate in three-dimensional co-cultures of 
human primary hepatocytes with hepatic stellate cells? 
iii. To what extent, and by what mechanisms, does the translation and/or 
replication of JFH1 modulate the viability and functional capacity of human 
primary hepatocytes, in mono-culture and co-culture? 
The ambition was also to examine whether primary human hepatocytes are 
permissive to infection by the full-length JFH1 HCV virus and, if so, whether they 
would sustain viral replication and the production of viral particles. 
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1.4. Aims 
The aims of this project were to: 
0 establish and optimise the techniques required for reliable isolation of fresh 
human primary hepatocytes from resected liver tissue; 
0 optimise at least one method for non-viral transfection of primary 
hepatocytes; 
0 investigate the levels of expression and replication of subgenomic JFH1 
replicons in human primary hepatocytes, both in monoculture and in three- 
dimensional co-culture with hepatic stellate cells. 
0 measure the effect of JFH1 expression and replication on the viability, 
hepatocyte-specific function and lipid content of human primary 
hepatocytes, both in monoculture and in three-dimensional co-culture with 
hepatic stellate cells. 
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I. S. Thesis outline 
This thesis reviews the work carried out to establish reliable and effective methods of 
human hepatocyte isolation (Chapter 3) and of primary hepatocyte transfection 
(Chapter 4). A more detailed introduction to each of these subjects is presented at 
the beginning of each of these chapters. 
Chapter 5 presents a detailed review of current methods used for examining and 
measuring the replication of HCV in vitro. The methods and results of experiments to 
examine the evidence for expression, and replication, of the JFH1 replicon in 
monocultures and co-cultures of human primary hepatocytes, are presented and 
compared with those obtained using the Huh7 cell line. 
Finally, chapter 6 contains a summary and appraisal of all of the work presented, 
along with a discussion of the opportunities created for further studies. 
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2. GENERAL MATERIALS AND METHODS 
2.1. General materials 
All chemicals were sourced from Sigma Aldrich© unless otherwise stated. 
2.1.1. Buffers for isolating rat hepatocytes 
Hanks' HEPES buffer, stock solution (10X) 
A 10X stock solution was made using 1I autoclaved de-ionised water containing: NaCl 
(1.37 M, 80 g/I); KCI (54 mM, 4 g/I); KH2PO4 (4.4 mM, 0.6 g/I); Na2HP04.12H20 
(3.6 mM, 1.2 g/I); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
(200 mM, 47.6 g/I); NaOH (100 mM, 4 g/I), pH 7.4 (target value). Hanks' HEPES 1X 
buffer was prepared as required by diluting the 10X solution with autoclaved de- 
ionised water. 
Glucose-bicarbonate solution 
Autoclaved de-ionised water (50 ml) containing: NaHC03 (0.74 M, 3.1 g/50 ml); 
D-glucose (0.28 M, 2.5 g/50 ml); L-methionine (0.1 M, 0.75 g/50 ml) (Gibcom). 
25 mM EGTA solution 
1M NaOH (2.5 ml) and 0.48 g EGTA were dissolved in 25 ml 1X Hanks' HEPES 25 ml, 
and then made to 50 ml with 1X Hanks' HEPES buffer. 
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250 mM CaCl2 solution 
Autoclaved de-ionised water (50 ml) containing 1.84 g CaCI2. 
Buffer A comprised 400 ml 1X Hanks' HEPES buffer with 8 ml glucose-bicarbonate 
solution and 4 ml EGTA solution (pH 7.4). 
Buffer B comprised 200 ml 1X Hanks' HEPES buffer with 4 ml glucose-bicarbonate 
solution, 2 ml CaCI2 solution and, added just before use, 20000 Units type IV 
collagenase (C-5138 Sigma-Aldricho) (pH 7.4). 
All solutions were sterilised before use, by filtration using 0.05 µm filters. 
2.1.2. Cell culture media for liver cells 
Medium 1 
William's Medium E (Gibco®) (500 ml), supplemented by the addition of 50 ml fetal 
calf serum (PAA Laboratories©), 2 mM L-glutamine (Gibco®), 0.2 U/ml penicillin 
(Gibco®), 0.2 µg/m) streptomycin (Gibco®), 0.5 ng/mI amphotericin B (Gibco®), 5 mM 
nicotinamide and 10 µg/ml bovine pancreas insulin (final concentrations of 
supplements indicated in each case). 
Medium 2 
William's Medium E (Gibco®) (500 ml), supplemented by the addition of 2 mM 
L-glutamine (Gibco®), 0.2 U/ml penicillin (Gibco®), 0.2 vg/ml streptomycin (Gibcom), 
0.5 ng/ml amphotericin B (Gibco®), 5 mM nicotinamide and 10 Vg/ml bovine 
pancreas insulin (final concentrations of supplements indicated in each case). 
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Medium 3 
Dulbecco's Modified Eagle's Medium (Gibcoo) (500 ml), supplemented by the 
addition of 50 ml fetal calf serum Gold (PAA Laboratories©), 2 mM L-glutamine 
(Gibco®), 0.2 U/ml penicillin (Gibco®), 0.2 µg/ml streptomycin (Gibco®), 0.5 ng/ml 
amphotericin B (Gibcoo) (final concentrations of supplements indicated in each case). 
Medium 4 
Dulbecco's modified Eagle's medium (Gibco©) (500 ml), supplemented by the 
addition of 50 ml fetal calf serum (PAA laboratories®), 2 mM L-glutamine (Gibco®), 
0.2 U/ml penicillin (Gibco®), 0.2 µg/ml streptomycin (Gibco®), 0.5 ng/ml 
amphotericin B (Gibco®) (final concentrations of supplements indicated in each case). 
Medium 5 
William's Medium E (Gibco©) (500 ml), supplemented by the addition of 50 ml fetal 
calf serum (PAA Laboratoriesm), 2 mM L-glutamine (Gibcoo), 0.2 U/ml penicillin 
(Gibco®) and 0.2 µg/ml streptomycin (Gibco®) (final concentrations of supplements 
indicated in each case). 
Medium 6 
William's Medium E (Gibco°) (500 ml), supplemented by the addition of 2 mM 
L-glutamine (Gibco®), 0.2 U/ml penicillin (Gibco®), 0.2 µg/ml streptomycin (Gibco®), 
5 mM nicotinamide and 10 µg/ml bovine pancreas insulin (final concentrations of 
supplements indicated in each case). 
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2.1.3. Collagen coating of plastic cell culture plates 
Cell culture plates (Nunclon® Primeria®) were coated with collagen as follows: a 
working solution of 0.05 mg/ml type I rat-tail collagen (Upstate Cell Signalling 
Solutions®) was prepared in phosphate-buffered saline. Working solution (1 ml) was 
added to each well of a 6-well tissue culture plate and incubated for 2 hours at room 
temperature, or overnight at 4°C. The collagen solution was then discarded and the 
culture wells rinsed with phosphate buffered saline prior to use. 
2.1.4. Poly-DL-lactic acid coating of plastic cell culture plates 
Single 3 cm diameter plastic cell culture wells (Nunclono) were coated with poly-DL- 
lactic acid (PLA) in order to create a low-adhesion and hydrophobic surface for 
spheroid cell culture. For each well to be coated, 1.5 mg anhydrous PLA (Sigma) was 
dissolved in 1 ml trifluoroethanol (TFE). This solution was added to the well and the 
plate was placed in an oven at 50°C until all liquid had evaporated. The wells were 
then sterilised by exposure to ultraviolet light for 30 minutes and stored in anhydrous 
conditions at 
-20°C until use. Just prior to use, each well was rinsed using sterile 
phosphate buffered saline. 
2.1.5. Other cell preparation materials 
Lockertex® polyester gauze mesh (PE/MO/64/45) was purchased from Clarcor UK. 
lOX Hank's Buffered Salt Solution and Percoll® (Amersham Biosciences®) were mixed 
in the ratio 1: 9 to form an isotonic solution with a density of 1.07 g/ml and stored at 
4°C until use. 
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Trypan Blue dye was purchased ready for use in a 0.4% (w/v) solution. 
Phosphate buffered saline (PBS) was prepared by dissolving 1 PBS tablet in 200 ml of 
deionised water to produce a 1X PBS buffer (0.01 M phosphate, 0.0027 M potassium 
chloride and 0.137 M sodium chloride, adjusted to pH 7.4). The buffer solution was 
autoclaved prior to use. 
2.1.6. Microscopy 
Except where stated, cell cultures were examined using a Leica© DM IRB Microscope, 
with EBQ100 UV lamp, and photographed using a Qlmaging QICAM 1384 camera and 
QCapture image capture software. 
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2.2. General cell preparation and culture methods 
2.2.1. Primary rat liver cells 
2.2.1.1. Isolation of primary rat hepatocytes 
To obtain fresh rat primary hepatocytes, male rats (Wistar strain) between 180 g and 
500 g in weight were first killed by cervical dislocation. The abdomen was rapidly 
dissected and the liver removed. The two largest liver lobes were placed on a 
sintered glass platform and their main vessels cannulated in parallel for perfusion 
with the buffers, which had been pre-warmed to 37°C. Buffer A was perfused for 
10 minutes, during which accurate placement of the cannulas was checked by 
examining for warming, swelling and blood clearance from the lobes. Buffer B was 
then perfused, with recirculation of the buffer solution, for 15-20 minutes until the 
tissue was judged to appear sufficiently digested. The lobes were then removed to a 
Petri dish containing medium 1 at 37°C and the Glisson's capsule gently teased apart 
using forceps. The tissue was then flushed with further medium 1, both to halt the 
action of the collagenase in the digestion solution and to release the maximum 
numbers of hepatocytes. Liberated cells in suspension were then separated from any 
remaining undigested tissue by filtering through a polyester gauze mesh with 64 µm 
apertures. 
The liver cell suspension was decanted into two conical ended centrifuge tubes and a 
total of approximately 100 ml was centrifuged for 5 minutes at low speed (50g), with 
minimum acceleration and deceleration forces, to pellet the hepatocyte-rich fraction. 
The supernatant was removed and retained for isolation of hepatic stellate cells. The 
pellets were re-suspended in further medium 1 and the centrifugation step repeated, 
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to rinse the cells. Following this step, the hepatocyte pellets were re-suspended in 
20 ml of medium 1 and combined in a single conical-ended centrifuge tube. An equal 
volume of 90% Percoll solution was added and the tube was inverted, gently, to mix 
the contents. This mixture was centrifuged again, under the same conditions, in 
order to enrich the proportion of viable hepatocytes obtained. 
The pellet obtained from this final centrifugation step was resuspended in medium 1 
or 2, depending on the requirements of the ongoing experiment, and hepatocyte 
viability and numbers were determined using a Trypan Blue exclusion method1831, as 
follows. Briefly, 20 µl of the cell suspension was added to 20 µl of Trypan Blue dye in 
a sterile capped tube and inverted briefly to mix. This mixture was introduced, by 
capillary action, into the chamber of an Improved Neubauer haemocytometer and 
the chamber was examined by light microscopy at 100x magnification. Total 
hepatocyte numbers were counted in the entire 1 mm delineated field of the 
haemocytometer (X). Hepatocytes which showed evidence of the blue dye in their 
cytoplasm and nucleus (and were therefore assumed to have damaged cell 
membranes) were counted as dead cells (Y). The proportion of live hepatocytes was 
calculated as: 
`_Yx 100% 
X 
The concentration of viable hepatocytes, per ml of cell suspension, was calculated as: 
(x 
- 
Y) x 20,000 
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2.2.1.2. Culture of rat primary hepatocytes 
For standard control monoculture, hepatocytes were plated into collagen-coated 
6-well plates at a target density of 105/cm2. Each culture well was washed with 
phosphate buffered saline prior to use, then approximately 900,000 viable 
hepatocytes were seeded to each well in a total of 1.5 ml medium 1. After 2 hours 
incubation (37°C in 5% C02), to allow cell attachment, the medium was aspirated and 
replaced with medium 2 for ongoing incubation. Thereafter, medium changes were 
carried out every 48 hours. 
2.2.1.3. Isolation of rat primary hepatic stellate cells (HSC) 
The supernatants obtained at each stage of hepatocyte preparation, described 
above, were combined and centrifuged twice more at 50 g, discarding the pellet on 
each occasion. Finally, the remaining supernatant was centrifuged at 250 g to pellet 
an HSC-rich fraction. The pellet was resuspended in medium 3 prior to culture. 
2.2.1.4. Culture of rat primary hepatic stellate cells 
The HSC-rich suspension was plated into a 75 cm2 tissue culture flask with a total of 
20 ml of medium 3. The flasks were incubated at 37°C in 5% CO2 and the medium 
was exchanged after overnight incubation. Thereafter, the medium was changed 
every 3 days. When 80-90% confluent, the cells were either used in co-culture as 
described in chapter 5, or passaged to encourage proliferation and activation, as 
follows: 
The cell-culture medium was removed and 5 ml EDTA-trypsin solution (pre-warmed 
to 37°C) was added to each flask. The flask was incubated at 37°C for about 
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5 minutes or until visible cell detachment began to occur. Pre-warmed medium 3 
(5 ml) was added and the cells detached and separated using a cell scraper. The 
resultant cell suspension was centrifuged for 5 minutes at 250 g. The pelleted cells 
were re-suspended in medium 3, with half of the volume plated into each of two 
further 75cm2 tissue culture flasks, for repeat culture as previously described. 
2.2.2. Huh7 cell line 
2.2.2.1. Culture of the Huh7 cell line 
Standard tissue-culture plastic-ware was used, with no additional treatment. Huh7 
cells were cultured and manipulated in a containment level 2 laboratory. 
Huh? cells were cultured in monolayers on 75 cm2 flasks with filter lids, using 
medium 4. The medium was changed after overnight incubation and at twice-weekly 
intervals thereafter. Huh7 cells were passaged weekly, to provide cells at 80-95% 
confluence for experiments where required. To provide overnight control cultures 
after transfection experiments, approximately 1x 105 cells/cm2 were seeded into 
75 cm2 flasks and the media changes carried out as above. 
2.2.2.2. Proliferating the Huh7 cell line 
The culture medium was removed and 5 ml of pre-warmed trypsin-EDTA solution 
was added. The flask was re-incubated at 37°C for 2-3 minutes, until signs of cell 
detachment were visible. The flask was tapped to loosen adherent cells; then 10 ml 
of pre-warmed medium 4 was added and washed repeatedly over the culture surface 
of the flask to detach and separate the cells. The resulting cell suspension was then 
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centrifuged for 5 minutes at 150g, the supernatant discarded and the cell pellet re- 
suspended in medium 4 before adding to the required ongoing cultures. 
2.2.2.3. Cryopreservation and thawing of Huh7 cell line 
A cell suspension was obtained by the same procedure as for passaging, above. The 
cells were counted using a haemocytometer. The Huh7s were then centrifuged again 
under the same conditions and resuspended in a 9: 1 mixture of medium 4 and 
dimethyl sulfoxide (DMSO) for cryoprotection. Sufficient medium was added to 
produce a cell concentration of 106/ml, and the suspension was sealed into 
cryostorage vials, in 1 ml aliquots. Working quickly, and on ice, the vials were filled 
and removed to a freezer at 
-80°C. After overnight freezing, one vial was removed 
and re-cultured to check that viability and cell numbers had been maintained; the 
remaining aliquots were transferred to liquid nitrogen cryostorage. 
2.3. Statistical methods 
Numerical data were tabulated in the spreadsheet package Microsoft Office Excel 
2007 and standard equations within the software were used to obtain values for the 
mean, standard deviation(SD), and standard deviation relative to the mean (RSD) 
where applicable. Comparisons of group data were perfomed using the online 
calculators available at http: //www. Rrai)hi)ad. com/guickcalcs/index. cfm. A 
probability of s5% (p 5 0.05) that the null hypothesis was incorrectly rejected was 
chosen to indicate statistical significance, by scientific convention. Unpaired, 2-tailed 
student's T-tests were used to obtain p-values and confidence intervals for 
differences in continuous data values, unless otherwise stated in the text. Graphical 
representations of data were produced using Microsoft Office Excel 2007. 
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3. ISOLATION AND CULTURE OF PRIMARY HUMAN HEPATOCYTES 
3.1. Introduction 
3.1.1. Challenges encountered when isolating human, rather than rat, 
hepatocytes 
Rat primary hepatocytes are widely used in many areas of research. Methods for the 
isolation of rat hepatocytes have been refined since the first protocols were 
developed in the 1960s and have been comprehensively described [65,661 Although 
they require experience and extreme care in their execution, these methods can 
generally be relied upon to produce predictable quantities of viable hepatocytes and 
other liver cells. In contrast, the isolation of primary hepatocytes from human liver 
tissue is much less widely practised or reported. There are a number of important 
differences between rat and human hepatocyte isolation, and some specific 
difficulties in obtaining suitable human tissue for cell isolation. 
The most obvious difference between the rat liver and a human liver is that of size. 
There are also significant dissimilarities in the number of lobes and their disposition. 
On a microscopic level, the lobular architecture is relatively similar between the 
species, however the human capsule is significantly thicker and more difficult to 
disrupt. 
Another significant difference involves the physical practicality of working with liver 
tissue of the two species. Starting with a complete rat liver, the worker can perfuse 
several whole, encapsulated lobes. In contrast, human liver tissue is most commonly 
obtained as a by-product of partial hepatectomy or liver resection operations. For 
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this reason only one or two segments of a lobe are most commonly removed, rather 
than a complete, intact lobe. The human tissue therefore frequently has a disrupted 
capsule and may have inadequate intact vasculature for perfusion of the whole tissue 
segment. 
The quality and quantity of hepatocytes obtained from any species is affected by the 
underlying health and vasculature of the liver tissue, the composition of buffer 
solutions and media, the time (and any mechanical force) used for digestion and 
variations of buffer solution temperature during perfusion. However, other factors, 
which are avoided when using laboratory animals, affect the viability and 
functionality of human cells obtained as a by-product of surgical procedures, such as 
the underlying operative indication, age of the donor, the presence of liver disease 
and the warm ischaemic time. These issues are discussed further below. 
3.1.2. Sourcing human liver tissue 
Advances in medical care, and growing numbers of patients with complex co- 
morbidities, are driving increasing needs for the development of bioartificial liver 
devices and model systems for the assessment of drug toxicity, and for further in 
vitro research into the processes underlying liver tissue regeneration. There is 
therefore an essential requirement for primary human cells to use in these 
applications. Human liver cells can be sourced from cadaver tissue which has been 
rejected, or resized, for use in transplantation. However, the reasons for rejection 
may also influence the subsequent function of the isolated cells in culture; 
additionally, tissue is rarely available from such sources. More commonly therefore, 
cells are harvested from the tissue discarded during surgical liver resections. 
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The most common reason for liver resection in the UK is removal of metastases of 
colonic carcinoma, although, due to the source of its blood supply, the liver is 
susceptible to tumour metastasis from most sites in the gut. Primary hepatocellular 
carcinomas (HCC) and certain benign tumours may also be resectable. Depending on 
the location of the tumour(s) within the resected lobe, surrounding healthy tissue 
may not always be needed for histological confirmation that sufficient tumour 
margins have been excised. This tissue may thus be used to obtain cells for research, 
if the patient consents. 
Colorectal cancer is the second commonest cause of cancer-related death in the UK. 
Around 32000 cases are diagnosed each year and more than half of these patients 
will have liver metastases, either at the time of diagnosis or in the years following 
removal of their primary colonic tumour. This currently equates to around 18000 
cases per year in the UK. Once detected, and without treatment for this secondary 
disease, median survival is only 8 months and 5-year survival rates are extremely low. 
In contrast, the 5-year survival rate after liver resection is reportedly up to 44%tß41. 
Operative mortality ranges from 0-7%, depending on a variety of pre- and intra- 
operative factors. However, due to pre-existing morbidities and the individual 
characteristics (and spread) of their liver metastases, only approximately 3600 
patients per year will be considered suitable for liver resection surgeryt841. At 
Nottingham University Hospitals NHS Trust, around 50-100 patients are listed for this 
operation each year. 
Open surgical resection, to remove the affected part of the liver, has been the 
standard treatment for patients with localised colorectal liver metastases and HCC. 
Benign liver tumours are usually treated only if they are causing symptoms. The 
so 
standard resection procedure is performed through a large incision across the 
abdomen and is a major operation, usually taking several hours. 
However, a number of alternative or additional treatments are now available, which 
may increase the likelihood of a successful outcome and/or reduce post-operative 
morbidity. Most notably, laparoscopic ("keyhole") surgery may sometimes be 
possible. In this procedure, a number of small incisions are made in the abdominal 
wall, to provide access for the laparoscope and surgical instruments. The resected 
liver is enclosed in a bag and removed through another relatively small incision. The 
National Institute for Clinical Excellence (NICE) reports that post-operative hospital 
stay is generally significantly shorter after laparoscopic liver resection (mean stay 
ranged from 4 to 15 days) than after open liver resection (mean stay ranged from 8 
to 22 days)1851; but not all metastases are sufficiently isolated to be amenable to this 
technique. Other possible treatments include direct ablation of the tumour (using 
thermal, radiowave or microwave energy). Pre-operative procedures, to shrink the 
tumour(s) using chemotherapy or embolization of the portal vein branches, may also 
be of benefit. Whilst beneficial for the patient, these procedures now reduce the 
likelihood that resected liver tissue will be available, or suitable, for the preparation 
of hepatocytes for in vitro culture. 
3.1.3. Ethical issues and consent 
Patients scheduled to undergo hepatic resection may be requested to donate, for 
research purposes, those parts of the resected tissue which are not required for 
diagnostic tests. The use of such specimens poses relatively few ethical problems, 
since the research work does not affect the patient's care in any way. However, in 
general this patient group has been rapidly progressed to face major surgery 
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following a, perhaps unexpected, diagnosis of malignancy and consequently the 
patient must be approached with sensitivity and respect, to ensure that proper 
informed consent is obtained. Furthermore, it is important that the surgical 
procedure and its outcome are not altered by participation in the study. 
3.1.4. Inherent problems in obtaining suitable human liver tissue 
There are many practical and ethical constraints and obstacles to obtaining suitable 
human liver tissue for successful hepatocyte isolation. 
The opportunities for obtaining resected hepatic tissue are necessarily limited by the 
number of operations carried out. Further, a significant number of resection 
procedures are unfortunately delayed, or cancelled, due to lack of availability of 
intensive care beds for post-operative care. Alternatively, operations may be 
curtailed due to inoperability; usually because of peritoneal spread. In addition, 
there may be tissue-specific factors (including cirrhosis, steatosis and the location of 
metastases) which may cause the liver material to be unsuitable or unavailable for 
research purposes. All of the above hurdles make obtaining suitable human liver 
tissue highly unpredictable. For projects requiring primary cells which, generally, do 
not replicate in vitro these logistical problems may cause major and unavoidable 
delays. 
Primary human hepatocytes are optimally isolated from fresh, healthy post-mortem 
or ex-vivo liver tissue. Cells obtained from fatty or steatotic livers are difficult to 
purify, due to their variable and unpredictable density and even greater than usual 
fragility, usually resulting in a lower yield. There is also a significant inverse 
correlation between donor age and the viability of isolated hepatocytes164'861 Other 
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researchers report that cirrhosis, cholestasis and increased intra-operative clamping 
(Pringle) time negatively affect the yield [64,86,87): the last of these factors presumably 
depressing yield due to both warm ischaemia and blood coagulation in the capillary 
beds. 
Warm ischaemia is defined as the interruption of blood supply to tissue which 
remains at body, or room, temperature. The temperature at which ischaemia occurs 
is vitally important as it determines the overall metabolic status of the cells and 
therefore the scale of detrimental effects. Warm ischaemia is probably the main 
factor adversely affecting the viability of hepatocytes obtained from resected tissue 
but is, at certain stages, unavoidable during resections. Intra-operative interruption 
of the blood supply by clamping is frequently employed and, even after anatomical 
separation of the resected portion, there is usually some delay before the liver tissue 
is removed from the abdominal cavity. Unfortunately, during laparoscopic resections 
(which are favoured where possible due to faster recovery times), the warm 
ischaemic time of the resected tissue is generally increased by the additional time 
required for this technically demanding procedure. Post-operatively, liver cells 
deteriorate rapidly, so that samples must be processed without delay. Cold 
ischaemic time has also been found to affect the viability and yield of liver cells but in 
a less predictable manner [64,861 
Due to ethical issues and the limited routes by which it may be obtained, human liver 
tissue for research purposes is not readily available to most workers. For this reason, 
relatively few methods for the extraction of human liver cells have been published, 
and none of them can be considered well established, compared with the techniques 
available for extracting the liver cell populations from rodents. Some researchers 
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using human liver cells in vitro purchase their cells from commercial companies, 
whose methods of extraction are considered commercially confidential. However, a 
few workers have described methods for cell extraction, from which protocols may 
be derived. 
3.1.5. Overview of primary human hepatocyte isolation techniques 
Donated tissue is collected in the operating theatre and processing should start 
without delay, which can create logistical problems if the tissue becomes available at 
or beyond the end of a normal working day. If the tissue must be stored or 
transported before perfusion it should be maintained on ice or in an ice-cold 
preservation solutiont88-911. It is also important to flush the tissue with a buffer or 
preservation solution before storage, to remove blood from the capillary vasculature 
before coagulation (and blockage) occurst92'931. Where processing can begin within 
one hour of obtaining the tissue segment, published methods suggest simply 
transporting the sample to the laboratory in ice-cold saline or preservation solution, 
'91 
as quickly as possible'9aý 
Once the sample is in the laboratory, perfusion can be started, as the first step in the 
process of separating the cells. Tissue weights of between 50 g and 100 g yield the 
optimum numbers of cells per gramt91l. Smaller tissue fragments may lack suitable 
blood vessels for sufficient perfusion, whereas larger specimens will be exposed to 
proportionately less collagenase activity during the perfusion time and will not be 
optimally digested. Ideally, the tissue segment should have only one cut edge and be 
otherwise encapsulated by Glisson's capsule, so that the perfusion fluid is relatively 
well contained. Most workers seal unused cut blood vessels on the tissue edge with 
16a either glue or sutures'91ý 
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A modified two-stage perfusion is usually performed. The perfusion buffers used 
vary (88'89'94'951 but are almost always pre-warmed to 37°C. The first stage is to flush 
the blood from the vasculature before coagulation and blockage occurs. The 
perfusion buffer used may contain a calcium-chelating agent, to disrupt the tight 
junctions between cells. The second stage involves a pre-warmed buffer containing 
collagenase or similar enzymes, to disrupt and digest the extracellular matrix. In 
some cases, an additional perfusion step has been performed between stages one 
and two, in order to remove chelating agent from the vasculature before introducing 
the (calcium-dependent) collagenase enzyme [941 
The buffer composition, buffer volumes, perfusion rate, duration of perfusion, and 
temperature of the first buffer have varied between reporting 
laboratories [64,89,92,94,951 The type and concentration of digestion enzymes is also far 
from standardised, with some researchers having recirculated the second stage 
buffer and others not having done so. Furthermore, as collagenase is a mixture of 
proteolytic enzymes derived from bacteria, its efficiency and toxicity varies according 
to the source, and also over time, making its effects unpredictable(64). In the absence 
of universally adopted automated equipment, all laboratories which prepare primary 
cells from liver tissue are likely to have differing perfusion circuits, through which the 
buffers are circulated, and the circuit structure, capacity and temperature are rarely 
described by authors. The optimal conditions for human liver tissue digestion are 
therefore unknown. 
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The period of time allowed for tissue digestion is, like any enzymatic reaction, 
affected by several factors: 
0 concentration (and location) of the enzyme 
" concentration (and location) of the substrate 
0 environmental conditions (for example pH, temperature, presence of ions 
and other co-factors or inhibitors) 
A process of continuous perfusion of liver samples facilitates maintenance of the 
correct temperature and provides a constant presence of fresh enzyme mix. 
However, the amount of substrate (the extra-cellular matrix, ECM) and its 
distribution relative to the route of enzyme delivery (the liver vasculature) is widely 
variable and unpredictable in the sample obtained. If the second stage of perfusion 
is too short, there will be insufficient exposure to the enzymes and consequently less 
digestion of the tissue. Any extra mechanical force which is then required to harvest 
the cells from an insufficiently loosened ECM will increase physical damage to, and 
breakage of, the isolated cells. On the other hand, the proteases used for digesting 
the liver's extra-cellular matrix will also damage the parenchymal cells, if present for 
too long or at too high a concentration. Furthermore, as mentioned previously, the 
warm ischaemia necessitated by the digestion period also leads to hepatocyte 
damage and death. 
Following tissue digestion, the capsule surrounding the lobe is incised or broken 
using sterile instruments, at which point any dissociated cells are released. Some 
workers suggest that the tissue should be minced at this stage and subjected to a 
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further incubation in a collagenase solution to release the hepatocytes from the 
extra-cellular matrix1951. The liberated hepatocytes are separated from the resultant 
suspension of mixed cells by low-speed centrifugation, with or without use of a 
density-gradient centrifugation step to purify the viable hepatocyte fraction16a, 9oý 
The non-parenchymal fraction remains within the supernatant and can be subjected 
to further, higher speed centrifugation to enrich the hepatic stellate cell fraction. 
Mean hepatocyte viabilities achieved by various authors ranged from 70 
- 
83%(6486,901 
Mean yields, per gram of digested tissue, ranged from 0.12 - 83 million viable 
hepatocytes(90,93,96] The average human adult liver, in vivo, is thought to contain 
approximately 108 hepatocytes per gram of tissue [971. 
The remainder of this chapter presents the rationale for, and results obtained during, 
refinement of a method for the isolation of human primary hepatocytes from locally- 
obtained resected liver tissue. By this method, viable human hepatocytes could be 
reliably obtained for the first time in the University of Nottingham laboratory and 
made available for ongoing experiments. 
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3.2. Outline of the procedure for transporting and processing human liver tissue 
to obtain primary hepatocytes 
In brief, the steps required to obtain hepatocytes from resected liver tissue were as 
follows. 
o Planned resections were reviewed, to identify patients with the potential to 
provide suitable tissue, and patients were interviewed to obtain informed 
consent. 
oA perfusion circuit was constructed in the laboratory and readied for 
processing samples. 
o The resected liver segment(s) was taken from the donor's body cavity in the 
operating theatre and a distal piece was removed for hepatocyte isolation. 
o The donated tissue was prepared for transport and conveyed to the research 
laboratory. 
o The liver tissue was established on the perfusion circuit and perfused with 
buffers and enzymes to digest the liver structure. 
oA crude suspension of liver cells was liberated from the tissue and filtered to 
obtain a single-cell suspension. 
o The cell suspension was washed and centrifuged to obtain a hepatocyte-rich 
fraction. 
3.3. Materials and methods 
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3.3.1. Materials 
Marshall's hypertonic citrate solution (marketed as Soltran Kidney Perfusion solution) 
was obtained from Baxter Healthcare, UK. GibcoTM Liver Perfusion Medium and 
GibcoTM Liver Digest Medium were purchased from InvitrogenTM. Other materials 
were obtained and prepared as described in chapter 2. 
3.3.2. Obtaining liver tissue samples 
3.3.2.1. Evaluation of patients and obtaining informed consent 
Approval to enrol patients in the current study was sought and gained from the Local 
Research Ethics Committee (LREC) and from the local Trust's Research and 
Development Department. Patients who were due to undergo some form of surgical 
liver resection were seen for medical review at the surgical pre-assessment, around 
1-2 weeks prior to the scheduled operation date. At this time, those who were 
expected to have an open (rather than a laparoscopic) procedure, and who were not 
known to have generalised liver disease or damage, were given information about 
the study and asked whether they would consent to donate their resected tissue to 
the research team. Patients had the opportunity to ask further questions and signed 
a written consent form if they agreed to participate. It was a condition of the study 
that no patient data were collected and that the sources of specimens were 
anonymous to the research team (other than the consenting doctor). 
During the period September 2004 to September 2006, hepatic resections were 
scheduled for operation approximately once every two weeks in the local centre 
(Nottingham University Hospitals NHS Trust). Over this period, a total of 109 patients 
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attended the Surgical Pre-assessment Clinic around 1-2 weeks prior to their 
operation date, for a baseline medical assessment and anaesthetic review, and their 
cases were assessed for potential inclusion in the present study. During these 
appointments, a total of 39 patients were approached for consent to donate 
resected liver tissue to the study. Patients were not included in the study if they 
were known to have hepatic fibrosis, fatty liver disease, extensive metastases or 
were planned to have tissue removed by laparoscopic or radio-ablative means. The 
study protocol and its aims were well accepted by the majority of patients 
approached for the study and, of the 39 patients approached, 38 consented to 
donate resected hepatic tissue for the research. The patient information sheet and 
consent form are contained in Appendix 8.1. 
3.3.2.2. Co-ordination and logistics for sampling 
On the day of operation, the theatre sister and/or consultant surgeon were 
contacted at the time the operation was expected to start, to ascertain whether the 
procedure would be carried out as planned. Unfortunately, about half of the 38 
planned resections, in which patients had consented to donate tissue, were cancelled 
or postponed due to patient factors or the unavailability of post-operative care 
facilities. Once verbal confirmation was received that an operation would go ahead, 
it was then essential to maintain good communication and co-ordination with 
operating theatre staff, to optimise the potential for acquiring good quality samples 
and to ensure that resected tissue specimens were not inadvertently discarded, 
damaged, or subjected to undue bacterial contamination. Therefore, once surgery 
was underway in the remaining cases, contact with the theatre staff was maintained 
by telephone and pager until the final stage of resection was started (usually around 
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3-5 hours after the patient entered theatre). From this point on it was necessary to 
be present in the theatre, as the tissue could be made available at any time (although 
tissue procurement could take up to a further 3 hours, depending on intra-operative 
factors). 
3.3.2.3. Sampling 
Liver tissue was removed from the donor patient's abdominal cavity as soon as 
possible after its separation from the remaining in vivo liver, in order to minimise the 
warm ischaemic time. Following dissection of the resected tissue to identify the 
diseased segment(s), the lead surgeon then removed an apparently healthy portion 
of the resected tissue for use in hepatocyte isolation (Figure 3.1). However, due to 
the varying location(s) of tumours or cysts within the resected tissue, samples for 
hepatocyte isolation were sometimes unavailable, smaller than required or poorly 
encapsulated. From the 38 potential sources of samples, a total of only 27 samples 
suitable for use in the present study were obtained. Where possible, this was an 
encapsulated end wedge of tissue distal to the tumour site. The median weight of 
the tissue samples was 70 g, although individual sample weights were highly variable 
(range =8- 251 g). Taking into account the rather high failure rate, due to factors 
beyond the control of the study, an average of approximately 5 hours intensive work 
was required to obtain each of the samples considered suitable for further 
processing, using currently available technology. Future improvements in operative 
and patient treatment technologies may decrease the frequency with which samples, 
of the size and status required for the present study, can be obtained. 
61 
PATENTS LIVER 
operative resection margin 
cut liver surface 
showing blood vassals 
STUDY SPECIMEN 
Figure 3.1: Example diagram showing the anatomical source of a well perfused 
and encapsulated liver tissue specimen for in vitro isolation of 
hepatocytes. 
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3.3.2.4. Preparing and transporting the liver tissue sample from the operating 
theatre to the laboratory 
Two methods for preparing and transporting the liver tissue to the laboratory were 
assessed. It was necessary to balance the need to clear the tissue of coagulating 
blood against the need to minimise both the warm ischaemic time and the overall 
ischaemic time. The aim was therefore to clear blood from the vasculature of the 
liver wedge directly after its removal from the body cavity. This was achieved by 
perfusing the tissue vasculature with ice-cold Marshall's hypertonic citrate organ 
preservation solution (Soltran), prior to immersing it in more of this ice-cold fluid and 
transporting the sample, on ice, to the processing laboratory. Two main approaches 
were assessed: 
a. "slow IV-style perfusion" 
b. "rapid syringed perfusion" 
A total of 4 samples were treated using the first method (a). An intravenous fluid 
giving set and cannula was attached to a pre-refrigerated bag of Soltran solution 
(mounted on a drip-stand) and each visible vessel on the cut surface(s) of the tissue 
was manually perfused in turn, until no further blood flowed from the tissue. 
However, even if an inflatable cuff was used around the solution bag to increase the 
pressure and hence the rate of flow, this process was found to take up to half an 
hour and usually resulted in only incomplete clearance of blood. Moreover, due to 
conditions and facilities in the operating theatre, the specimen and fluid could not be 
kept optimally chilled during this procedure. 
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In a total of 23 subsequent experiments, tissue specimens were cleared of blood and 
simultaneously chilled by the following, alternative method (b). A 50 ml Luer-lock 
syringe was filled with pre-chilled Soltran solution and the nozzle applied directly to 
accessible vessels in the sample. The tissue was rapidly perfused by firmly depressing 
the plunger and the process repeated for each vessel until no further blood flowed 
from the tissue. The second method (b) was adopted for two reasons. Firstly, the 
tissue reached the laboratory (and hence the start of the isolation procedure) more 
quickly and ischaemic time was therefore minimised. Secondly, both the Soltran 
solution and the cooled tissue sample were subject to less environmental warming in 
the operating theatre. 
Following either method of perfusion, the tissue sample was placed in a sterile 1L 
plastic screw-capped pot containing a known amount of pre-chilled Soltran solution 
and placed on ice in an insulated box for transport to the laboratory. Some further 
blood was generally passively washed from the sample during carriage; the 
remainder was rapidly cleared from the sample during the initial phase of perfusion 
with chelating buffer (as described further below). 
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3.3.3. Constructing and preparing liver tissue perfusion circuits 
The requirements of a perfusion circuit for the digestion of human liver tissue are 
broadly as follows: 
a. The perfusion buffers must be retained at around 37°C. Although this 
creates a period of warm ischaemic time for the hepatocytes, this 
temperature is required for the optimal activity of collagenase or other 
enzymes used to digest the tissue. Two pumps are thus required: one to 
circulate the buffer fluids through the tissue and another to circulate warm 
water around the circuit and bottles of buffer fluid in order to keep them at 
37 ± 1°C. 
b. There should be the facility to switch between running the perfused fluid to 
waste or to recirculate it back through the tissue. Whilst chelating buffer 
becomes quickly contaminated with blood, and therefore must be discarded, 
it may be desirable to recycle digestion buffers (to minimise costs). 
The perfusion circuitry used for these experiments was mainly determined by the 
availability of existing hardware. Two pumped circuits were created, as shown in 
figure 3.2. 
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fiver segment heat exchanger 
perfusion chamber 
with 
perforated platform 
water bath 
: rist&tic 
pumps 
Figure 3.2: Schematic diagram of the perfusion circuit used to perfuse liver 
tissue specimens obtained during the present work. 
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One circuit (shown in red in figure 3.2 and hereafter referred to as the heating 
circuit) was used to circulate pre-heated water from a water bath through the outer 
chambers of a glass, coiled tube, heat exchanger and a glass perfusion vessel. The 
second circuit (shown in blue and purple in figure 3.2 and hereafter referred to as the 
buffer circuit) used a second peristaltic pump to circulate perfusion buffers through 
the heat exchanger and into the cannulated liver tissue, which was suspended in the 
perfusion vessel on a perforated glass platform. Buffer was then allowed to drain 
from the tissue through the perforated glass platform into the perfusion buffer 
chamber and was either run to waste or collected for recirculation. 
The heating circuit circulated pre-heated water at around 1 I/minute. In the initial 
experiments, this water was heated to 37°C, as this is the optimum temperature for 
tissue digestion enzyme activity. Subsequently, it was found that a higher 
temperature, around 40°C, was required in the water bath in order for the buffers to 
reach and perfuse the tissue at a temperature of 37°C (as determined by measuring 
the buffer temperature at the cannula outlet). 
The buffer circuit was used to pump the perfusion buffers through the heat 
exchanger and into the liver tissue segment. After passage through the heat 
exchanger, a horizontal Y-connector split the flow equally to allow the tissue to be 
perfused through two blood vessels simultaneously. It was found that a flow rate of 
21 ml/min per cannula was normally required to ensure a constant forward flow of 
buffer through the tissue samples without causing any perceptible damage to the 
tissue (other than the intended digestion) or undue buffer loss. The buffer circuit 
was rinsed with fresh, sterile phosphate-buffered saline immediately prior to use, as 
shown in figure 3.3, below. 
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3.3.4. Preparing and perfusing the liver tissue in the laboratory 
On arrival at the laboratory the pot containing the tissue specimen was weighed, so 
that the pre-perfusion tissue weight could be calculated. Working in a class 2 safety 
cabinet, the liver tissue specimen was then removed from the pot, which was also 
weighed, and processed as described below. 
3.3.4.1. Securing vascular access to the liver tissue specimen 
In a total of 8 initial experiments, plastic IV cannulae (Venflon 18G-22G) were used to 
introduce the perfusion buffers into the liver tissue. These soft plastic cannulae 
could be cut to length depending on the vasculature of each tissue specimen and 
were glued in place using quick-drying hardware glue ("superglue"). The glue was 
also used to seal any unused vessels from which perfusion buffer leaked during 
processing. 
Experience showed that this approach presented a number of disadvantages. Firstly, 
an exact match of cannula diameter and blood vessel width was very difficult to 
achieve, and often the vessels were too large for even the largest cannula grades. 
Secondly, use of the glue to seal vessel gaps (in both cannulated and uncannulated 
vessels), although advocated by a number of workers in this field191"981, was of 
unpredictable efficacy and also created substantial delay before and during the initial 
stages of tissue perfusion, thereby increasing the warm ischaemic time. 
For subsequent experiments the IV cannulas were replaced with sterile plastic 
pipette tips (20-200 pi capacity), as shown in figure 3.4. 
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I 
Figure 3.4: Photograph showing the cannulation of blood vessels on the cut sides of 
a liver tissue specimen, using sterile plastic pipette tips. Glisson's capsule 
is visible on the left hand surface of the specimen. 
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These pipette tips had the advantage of being rigid and therefore were not prone to 
kinking in the tissue vasculature. Most importantly, however, their tapering form 
allowed them to be cut to fit the tissue's blood vessels exactly. This improved fit had 
the added advantage of removing the need to glue the cannula in place and 
therefore reducing warm ischaemic time and increasing hepatocyte viability. 
Once reliable access to the vasculature had been secured (using either method), a 
two-stage perfusion procedure was performed. Commercially available buffers 
(Gibco'M Liver Perfusion Solution and Gibco'M Liver Digestion Solution) were used, 
having been chosen on the basis of favourable reports of their use in the 
literature 186,91,991. Appropriate values for several other variables were not recorded in 
the published literature and had to be determined, as described below. 
3.3.4.2. First (chelating) stage of the two-stage liver perfusion procedure 
A review of the available published literature showed that the reported optimum 
duration of the first stage, during which blood is flushed from the capillary beds and 
the cell junctions begin to dissociate as a result of calcium being removed by the 
chelating agent, ranged from 10-30 minutes, depending on the tissue size and 
buffer compositionl86"89"911. The procedure adopted for the first stage in the present 
work was essentially adapted from the rodent liver perfusion protocol (described in 
chapter 2), following the review of available literature. Bottles of Liver Perfusion 
Medium were pre-warmed to 40°C and connected to the perfusion circuit, as shown 
in figure 3.2. The peristaltic pump was activated and medium allowed to flow 
through the circuit (before cannulation of the liver tissue) until no visible air bubbles 
remained, whereupon the pump was halted. After cannulation of the tissue, as 
described above, the pump was restarted and flow of medium was allowed to 
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proceed for 20 minutes (using a maximum of 11 of Liver Perfusion Medium, 
irrespective of sample size and the number of cannulae). 
3.3.4.3. Second (digesting) stage of the two-stage liver perfusion procedure 
For liver tissue to be optimally digested, tissue throughout the sample must be 
exposed to sufficient digestive enzyme at optimum temperature and for sufficient 
time. The activities of collagenases and other digestive enzymes in the Liver Digest 
Medium were not disclosed by the manufacturer but were stated to have been 
batch-adjusted for consistency. The optimum working temperature for all batches 
was stated to be 37°C. 
Both stages of the two-stage liver perfusion technique expose the liver tissue to a 
further period of warm ischaemia. Furthermore, exposure to collagenases and other 
digestive enzymes, together with concurrent loss of the supportive extra-cellular 
matrix, is damaging to hepatocytes. The time allowed for tissue digestion is 
therefore critical, not only for the release of optimum numbers of cells, but also for 
the viability of those cells. Since the rate of flow and concentration of perfusion 
solution was pre-determined in this experiment (as described above), the mass of 
tissue to be treated was the main measurable variable affecting the time required for 
digestion. More specifically, the optimum time for perfusion was expected to be 
proportional to the perfused vascular area of the tissue wedge. For all practical 
purposes however (i. e. while retaining maximum numbers of viable hepatocytes), the 
vascular area and volume of tissue being satisfactorily perfused cannot be quantified 
prior to digestion. 
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Published reports of the time allowed for digestion of human liver range from 10-30 
minutes, where statedl91,95,991, although many workers either used in-house 
preparations of digestion medium or whole lobes of liver tissue. In the present work, 
it was noted in a total of 13 preliminary experiments that a digestion time of 20-30 
minutes sometimes resulted in very little tissue digestion and low hepatocyte yield 
(see Table 3.1). It was, however, hypothesised that the damaging effects of a longer 
digestion period would be mitigated if cold ischaemia was induced immediately after 
the second stage of perfusion (as in section 3.3.5.2), and consequently should 
produce higher total yields of intact hepatocytes. Subsequently, therefore, the 
digestion stage was allowed to proceed for 40-50 minutes, depending on total tissue 
weight and a visual estimate of the perfused volume, in order to test the following 
hypothesis: 
Hypothesis 1: that prolonging circulation of the Liver Digest Medium, and 
reducing the duration of post-digestion warm ischaemia, could 
increase hepatocyte yield without causing an overall reduction in 
hepatocyte viability. 
Following advice from other workers in the field (see Acknowledge ments), 11 of Liver 
Digest Medium was perfused, with recirculation of the second 500 ml, over this 
period. Recirculation in this way avoided consumption of up to an additional 1I of 
this reagent, helping to limit the costs involved and apparently without 
compromising the yield and activity of the hepatocytes obtained. 
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3.3.5. Post-perfusion tissue disaggregation and hepatocyte isolation 
The intra- and post-operative warm ischaemic time is inversely proportional to the 
viability of hepatocytes and the advantages of inducing cold ischaemia in liver tissue 
before and during transport to the laboratory are well documented[86, s8,9ýý 
Unfortunately, warm ischaemia is unavoidable during tissue perfusion, due to the 
temperatures required for enzyme activity. However, it was hypothesized that the 
re-induction of cold ischaemia during post-digestion processing (i. e. while harvesting 
the cell suspension and isolating the hepatocyte-rich fraction) would reduce the rate 
of hepatocyte deterioration and death during this part of the isolation procedure. A 
subset of experiments was therefore performed to assess whether hepatocyte 
viability could be improved by re-inducing cold ischaemia directly after tissue 
perfusion was completed and maintaining the cells at, or below, 4°C until placed into 
culture conditions. 
In a total of 13 initial experiments the hepatocyte fraction was isolated as described 
3.3.5.1. Harvesting the liver suspension and isolating the hepatocyte-rich 
fraction 
Once the tissue matrix was judged, by appearance and feel, to have been adequately 
digested, the flow of buffer was stopped. Working quickly, the cannulae were 
removed and the liver tissue was carefully lifted from the perfusion platform and 
placed into a fresh sterile 1I beaker containing 150 ml of medium 5, pre-warmed to 
37°C. The capsule, and any superficial undigested liver tissue, was incised with sterile 
scissors. The tissue was gently agitated by hand to encourage the cell suspension to 
flow into the surrounding medium. Undigested lumps of material were then 
removed from the beaker using sterile forceps and weighed to assess the amount of 
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tissue digested. The remaining mixture was filtered into a sterile, 750 ml measuring 
cylinder via a polyester gauze mesh with 64 gm square apertures (as described in 
section 2.2.1.1) to produce a suspension of single cells. 
Working quickly, the liver cell suspension was made up to approximately 200 ml with 
further pre-warmed medium 5 and then decanted into 4x 50 ml Falcon tubes. After 
centrifugation at room temperature (5 minutes at 50 g with slow acceleration and 
braking), the supernatant (containing the non-parenchymal cell fraction) was 
removed and the cell pellets were carefully re-suspended in further medium 1. Two 
further, identical centrifugation-resuspension cycles were performed to wash the 
parenchymal cell fraction. After the final centrifugation, the hepatocyte-rich cell 
pellets were resuspended and combined in medium 5, giving a total volume of 25 ml. 
This hepatocyte-rich suspension was gently added to 25 ml of Percoll working 
solution and mixed by slow inversion and rotation of the tube. Finally, the cell 
suspension was centrifuged for 5 minutes at 100 g and room temperature to obtain a 
cell pellet enriched in intact hepatocytes. The pellet was then resuspended in cell 
culture medium as determined by subsequent experimental plans. The total number 
of hepatocytes obtained was calculated from the cell numbers counted, manually, by 
light microscopy using an improved Neubauer haemocytometric chamber. The 
percentage of viable hepatocytes present was determined by the Trypan Blue 
exclusion method (as described in Chapter 2) and viable cell numbers isolated per 
gram of sample tissue were calculated. 
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In a further 14 experiments this protocol was adjusted, as described in section 
3.3.5.2, in order to test the following hypothesis: 
Hypothesis 2: that post-digestion cooling of the liver cell suspension from 37°C to 
between 0 and 4°C would increase hepatocyte viability. 
3.3.5.2. Induction and maintenance of cold ischaemia in the isolated liver 
cells 
In a total of 14 experiments, the final two steps of the liver cell isolation method 
were adjusted as follows: 
Following removal of the cannulae (or pipette tips) at the end of the two-stage 
perfusion procedure, the tissue was placed into a fresh sterile beaker containing 
200 ml of ice-cold medium S. The cell suspension was liberated and undigested 
material was removed, as in 3.3.5.1. The remaining mixture was diluted with further 
ice-cold medium 5 and, using a procedure that was otherwise similar to that in 
3.3.5.1, it was filtered into a pre-cooled sterile, 750 ml measuring cylinder. 
The cell suspension thus obtained was equally divided between 4 pre-cooled 50 ml 
Falcon tubes which were placed into a beaker of melting ice between subsequent 
centrifugation cycles. Centrifugation purification steps were carried out as in 3.3.5.1 
but the centrifuge chamber was refrigerated to 4°C before and during use. 
The final number and viability of hepatocytes was, again, assessed by counting and 
the Trypan Blue dye exclusion test. 
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3.4. Results 
The effects of two variables in the human hepatocyte isolation method, digestion 
time and post-isolation temperature (as outlined in sections 3.3.4.3 and 3.3.5.2, 
respectively), were the main subjects of experiments to optimise the numbers and 
viability of hepatocytes obtained. Results from 13 experiments involving digestion 
periods of 20 or 30 minutes coupled with post-digestion procedures conducted at 
room temperature are presented in table 3.1. Results from 14 subsequent 
experiments, which combined longer periods of tissue digestion with re-induction of 
cold ischaemia after digestion, are shown in table 3.2. 
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3.4.1. Effect of digestion time on the proportion of tissue digested 
Figure 3.5 shows the effect of digestion time on the proportions of tissue digested, 
for samples where pre- and post-digestion sample weights were recorded. The 
proportion of tissue digested cannot have been influenced by differences in the post- 
digestion experimental conditions and therefore the data are not differentiated on 
the basis of this criterion. 
3.4.2. Viability of the harvested hepatocyte populations 
Figure 3.6 shows the effect of post-digestion processing temperature on hepatocyte 
viability. 
Hepatocyte cell populations isolated (post-perfusion/digestion) at, or below, 4°C had 
a mean viability of 88.2% (95% confidence interval 83.2-93.2 %), compared with 
54.7% (95% confidence interval = 39.7-69.7%) for cells isolated at room temperature. 
Failure to maintain the isolated hepatocytes at or below 4°C was therefore 
associated with a very significantly lower heptocyte viability (P = 0.0002 by unpaired 
t-test) as shown in Figure 3.6. 
3.4.3. Total and relative yields of viable hepatocytes 
The weight of original tissue sample, and remaining undigested tissue weight 
following perfusion, was measured and recorded in a total of 19 experiments. The 
recording of these parameters allowed calculation of the digested tissue weight and, 
thence, the yield of viable hepatocytes per gram of digested tissue, as shown in 
tables 3.1 and 3.2. 
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Somewhat surprisingly, little or no correlation was observed between sample weight 
and the yield of viable hepatocytes, whether the yield was expressed as numbers per 
whole sample weight (Figure 3.7), as numbers per gram of sample tissue (Figure 3.8), 
or as numbers per gram of digested tissue (Figure 3.9). The lack of correlation 
remained if the data for room temperature and chilled post-digestion processing 
were plotted separately. 
However, some correlation was evident between digestion time and hepatocyte yield 
and, in particular, the correlation differed according to the post-digestion isolation 
protocol used. When post-digestion processing of hepatocytes was carried out at 
room temperature, there was a trend towards lower total yields of viable 
hepatocytes as second perfusion stage (digestion) time was increased from 20 to 30 
minutes. In contrast, when post-digestion processing was carried out at 0-4°C, the 
viable cell yield tended to increase as digestion time from 30 to 40 or 50 minutes, as 
shown in figure 3.10. 
The mean tissue weight for samples processed at room temperature, post-digestion, 
was 125 g (range 41-251 g), with a mean viable hepatocyte yield of 1.69 x 106/g of 
whole sample weight or 10.04 x 106/g of digested tissue weight. The mean tissue 
weight for samples processed at 0-4°C, post-digestion, was 54 g (range 8- 140 g), 
with a mean viable hepatocyte yield of 3.15 x 106/g of whole sample weight or 
14.81x 106/g of digested tissue weight. The increases in yield produced by isolation 
under chilled conditions (whole sample average 
-100% higher and digested tissue 
average 
-50% higher than was achieved by isolation at room temperature) (figure 
3.11) were not statistically significant however (P = 0.629 and 0.320 respectively). 
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Figure 3.5: No correlation was observed between the digestion time and the 
proportion of tissue sample digested. 
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Figure 3.6: Viability of isolated hepatocytes is significantly increased by re- 
induction of cold ischaemia during post-digestion processing, both 
before and after enrichment of the viable hepatocytes fraction by 
centrifugation through Percoll (showing standard error bars; P =a 004 
and 0.0002 respectively) 
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Figure 3.7: Relationship between human liver sample weight and the total yield of 
viable hepatocytes obtained, showing essentially no correlation. 
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Figure 3.8: Relationship between human liver sample weight and the yield of 
viable hepatocytes per gram of sample tissue, showing poor 
correlation (R2 = 0.400). 
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Figure 3.9: Relationship between human liver sample weight and the yield of viable 
hepatocytes per gram of digested tissue, showing essentially no 
correlation. 
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3.10: Samples which were processed at room temperature post-digestion 
showed a trend to yield fewer viable hepatocytes, in total, if the 
digestion period was allowed to proceed for more than 20 minutes 
(M; trend-line shown in red). Chilling the cell suspension to 0-4°C 
during post-digestion processing tended to allow a higher proportion 
of viable hepatocytes to be obtained without compromising overall 
viable hepatocyte numbers ("; trend line shown in blue). 
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Figure 3.11: Use of a prolonged digestion time with post-digestion chilling to 
between 0-4°C showed a trend to increase the yield of viable cells as a 
proportion of the digested tissue weight. However, this difference did 
not reach significance (p = 0.320). 
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3.5. Discussion 
The isolation of human primary hepatocytes is subject to a number of unavoidable 
and uncontrollable factors which create difficulty when trying to obtain robust, 
reproducible results. The main problem is commonly perceived to be the lack of 
homogeneity of the human tissue samples from which the cells are to be isolated, 
whether in comparison to hepatocyte cell lines or to primary hepatocytes obtained 
from laboratory animals. In contrast to these alternative sources of hepatocytes 
and/or liver tissue, the investigator lacks control over numerous variables (the health 
and age of the source patient, the size and conformation of the sample, the intra- 
operative ischaemic period etc. ), all of which may impact upon the subsequent 
success of the hepatocyte isolation process. 
The unpredictable timing and frequency of specimen availability can also cause 
immense difficulty when attempting to plan either the hepatocyte isolation 
procedure or the most judicious use of the resulting cells, particularly in the context 
of shared laboratory resources and facilities. In ideal circumstances, a dedicated 
tissue perfusion and cell isolation facility would be maintained, in order to make 
maximum and optimal use of whatever tissue specimens become available, even 
when liver resection operations are planned and executed at relatively short notice. 
A number of such facilities now exist in the UK. The potential advantages of such 
laboratories (and the skilled staff who must use them), are tempered by the 
geographical, temporal, and financial factors encountered when distributing the 
resulting hepatocytes, as there is still no published protocol for cryostorage of these 
cells which does not result in significant loss of viability. However, as the NHS 
becomes increasingly structured to form fewer, but larger, Centres of Excellence for 
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complex procedures such as partial hepatectomy, it may become increasingly 
unusual for individual researcher in the UK to have either the need or the 
opportunity to isolate their own primary cells from human liver tissue. In the 
meantime, several further challenges confront those researchers who are able to 
source human liver tissue for hepatocyte isolation. 
In the experiments described above, sample size and anatomy were found to be 
highly variable. In particular, the numbers, and distribution, of intact and sufficiently 
sized blood vessels were frequently sub-optimal. The extent to which each specimen 
remained encapsulated by Glisson's capsule was also extremely variable. At least 
half of the tissue specimens obtained during these experiments had more than one 
cut surface. This commonly gave rise to two problems affecting tissue perfusion. 
Firstly, many of the blood vessels on one surface might pass almost directly through 
to the second surface without any significant supply to the capillary beds in between, 
and therefore it could be difficult to find sufficient vascular access for perfusion. 
Secondly, the increase in unencapsulated surface area probably allowed more 
perfusion fluid to leak out of the tissue during perfusion, thereby reducing the 
internal vascular pressure (and hence the extent of distribution of the perfusion fluid 
through the sinusoidal beds). 
The above factors frequently made it impossible to achieve extensive parenchymal 
distribution of the perfusion fluids, thereby significantly limiting the potential yield of 
hepatocytes. Due to the relative infrequency of sample availability, hepatocyte 
isolation was attempted from all samples of relatively healthy tissue that were 
obtained. However, particular challenges were encountered with the samples which 
were under 30g in weight, as most were thin strips of tissue which had a 
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proportionately larger cut surface from which leakage could occur. Despite these 
difficulties, the lack of an obvious correlation between sample weight and 
hepatocyte yields (as described and shown in section 3.4.1.2) indicates that a flexible 
approach to cannulation and perfusion of low-weight specimens could produce 
acceptable (if perhaps sub-maximal) yields of viable hepatocytes. 
Securing good vascular access to the tissue, in order to achieve widespread perfusion 
with minimal unwanted leakage of perfusion fluid, presented an unpredictable 
challenge for each individual specimen. The precise methods and materials used for 
tissue cannulation were determined, during preliminary experiments, to be highly 
influential on the ultimate success of the hepatocyte isolation procedure. The 
optimal technique derived from the experiments described above had a number of 
advantages. Firstly, matching pipette tip diameter to the vasculature aperture, for 
successful cannulation, was simply and rapidly achieved by visual inspection and 
cutting the tip with a pair of sterile scissors. Furthermore, the rigid nature of the 
pipette tips was useful both to stabilise the tissue specimen on the perfusion 
platform and to ensure un-occluded flow of the perfusion fluids. Lastly, as the 
pipette tips were cut to fit each blood vessel in a multiply-cannulated piece of tissue, 
the perfusion volume passing through each would have been approximately in 
proportion to the size of the blood vessel in question. As the blood vessel diameter is 
itself likely to be proportionate to the volume of tissue it perfuses (assuming that the 
tissue is homogeneous, healthy and uninterrupted, which was unfortunately not 
always the case), the sample might therefore have been more uniformly perfused 
than if the tip outlet size was the same (i. e. uncut) in each blood vessel. 
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Gluing of large, obviously leaking, unused blood vessels was found to be helpful on 
occasion and was performed when necessary. However, gluing of the whole cut 
surface, in order to contain the perfusion fluids within the tissue sample, was found 
to be difficult and time-consuming. An over-the-counter coagulation spray, sold for 
use on superficial wounds, was more simple to apply, but did not result in a good seal 
to the surface and appeared to cause excessive hepatocyte mortality during 
subsequent tissue disaggregation and post-digestion processing of the cell 
suspension. 
Perhaps the most significant challenge, present during the above experiments, was 
the maintenance of hepatocyte viability. If viability was not a concern of the 
researcher, it would have been possible to collect the sample from the operating 
theatre without particular urgency and with no special transport conditions, store it 
until a convenient time, and then perhaps apply a combination of mechanical 
mincing and crude collagenase digestion until 100% of the parenchymal matter had 
been liberated into suspension, thus obtaining a very high yield indeed. However, 
this is a physiologically unrealistic scenario for working with hepatocytes and many 
precautions must be followed to minimise the proportion cells dying before, during, 
and after isolation of the hepatocytes from the tissue matrix. In other words, 
increasing the number of hepatocytes liberated by digestion for longer periods is 
only worthwhile if their viability is maintained, otherwise the increase in liberated 
cell numbers is outweighed by their increased loss of viability. 
As described in section 3.1.5, the advantage of chilling the ischaemic tissue as soon 
as practicable following its removal from the patient's body cavity (i. e. pre-digestion) 
has been widely reported. Swift induction, and strict maintenance, of a temperature 
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between 0 and 4°C is required, and the materials utilised for this procedure may 
need to be maintained chilled for several hours in the (usually very warm) operating 
theatre prior to use. Here, again, good communication with the more experienced 
members of theatre staff is required, in order to avoid prematurely setting up (and 
increasing the warming of) the materials to receive the tissue specimen. Rapid 
transport of the sample to the laboratory from the hospital was, fortunately, aided 
by the adjacent locations of these facilities in the present study. 
The re-induction of cold ischaemia, immediately after digestion of the liver tissue 
samples, was associated with a significant increase in the proportion of viable 
hepatocytes obtained following processing of the liver cell suspension. Maintenance 
of the low temperature required strict adherence to the regime at all steps of the 
post-digestion procedure in order to achieve success. All plastic-ware and solutions 
had to be pre-cooled at 
-20°C and 4°C, respectively, and then contained in or on 
melting ice during use to maintain a temperature of 0-4°C. However, it was 
important not to allow the hepatocytes to settle into contact with the cooled sides of 
their containers for any prolonged period of time, in order to avoid direct thermal 
damage to the cells. 
In the above experiments, the mean hepatocyte viability of 88%, achieved when 
using the adjusted isolation method with prolonged digestion time and induction of 
cold ischaemia after digestion, was high in comparison with the results published by 
other workers. In contrast, the low percentage viability (mean 55%) which was 
obtained prior to alteration of the main method precluded the use of the resulting 
hepatocytes in downstream experiments due to the high, and detrimental, 
percentage of dead and/or dying cells. Such cells cause unwanted clumping due to 
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the release of DNA and may induce damage in co-existing viable cells, due to 
apoptotic signalling and cell breakdown. Due to the relative lack of proliferative 
capacity of primary hepatocytes, they are commonly only used in cell culture 
applications if the population viability is at least 75%. Thus the ability, using a 
modified isolation protocol, to reduce the dead hepatocyte fraction to only 5-15% of 
the total was not only statistically significant but also presented an ongoing 
advantage when using the cells in subsequent experiments. 
Perhaps even more importantly, processing at room temperature produced much 
more variable results (viability RSD = 49%) in contrast to the more predictable results 
obtained when using chilled processing (viability RSD = 11%). This conferred another 
extremely important advantage to the modified protocol, particularly in view of the 
infrequent nature with which human liver tissue samples could be obtained. 
The mean yields of viable hepatocytes, per gram of digested tissue, were within the 
ranges published by other researchers, as detailed in section 3.1.5. As the absolute 
hepatocyte numbers obtained from these human liver specimens were relatively 
high with respect to the quantities that are typically required for many in vitro 
applications, the yield was usually sufficient for any subsequent experiments. 
However, unlike the percentage viability of the cell population, which was rendered 
much more predictable through use of the modified protocol, the overall yield of 
viable cells remained extremely variable, even after accounting for differences in 
tissue sample sizes. 
Therefore, there was a statistically significant increase in the proportion, but not the 
yield (however yield is expressed), of viable hepatocytes when cold ischaemia was re- 
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induced post-digestion. It thus appears that using a longer digestion period followed 
by re-induction of cold ischaemia enabled the number of (contaminating) non-viable 
hepatocytes to be decreased significantly, though it did not increase the overall 
number of viable hepatocytes sufficiently to be statistically significant. This is a 
surprising and somewhat counter-intuitive result. 
It seems likely that prolonging the perfusion process essentially prolongs warm 
ischaemia (in both digested and undigested areas of the tissue), thereby reducing the 
overall proportion of viable hepatocytes in the harvested cell suspension, but 
increasing the overall numbers of liberated cells. The proportion of the tissue sample 
which is digested might be expected to increase. However, the rate of perfusion, and 
total volume, of digestion fluids remained unchanged and, thus, a proportionate 
increase in the volume of tissue digested cannot reasonably be expected. Upon 
further consideration, it is also logical that the area (or volume) of distribution of 
perfusion fluids is influenced mainly by the anatomy of the vasculature and that a 
longer period of digestion merely increases the extent of physical dissociation of the 
parenchyma within that same area or volume. This would result in fewer or weaker 
remaining associations with the ECM, in regions exposed to the perfusion fluid, on 
completion of the digestion period and thereby easier physical separation of 
hepatocytes within those regions when the tissue was incised and manipulated at the 
end of the perfusion procedure. So it might be hypothesised that the proportion of 
cells, within the liberated population, which had suffered fatal mechanical trauma 
was decreased. Whatever the correct explanation, it is possible that chilled 
processing was the main beneficial factor and acted by preserving the viability of cells 
immediately following digestion, whereas processing at room temperature led to the 
continued degradation and death of cells during and after the centrifugation stages. 
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Centrifugation through an iso-dense solution of Percoll and cell culture medium 
proved to be an effective means of enriching the intact hepatocyte fraction. Percoll 
is a 23% w/w suspension of colloidal silica particles coated with polyvinylpyrrolidone. 
The suspension is non-toxic to cells when used in an iso-tonic solution, and has a low 
viscosity, thus reducing shear forces during centrifugation. Cell fragments or 
damaged cells which have lost intra-cellular contents are less dense than viable cells 
and do not sediment through the Percoll column. This procedure is not affected by 
differences in the antecedent parts of the protocol and can be performed either at 
room temperature or at 4°C. The density of the liquid phase the Percoll suspension 
would have been higher at 4°C than at room temperature and there would have 
been a higher rate of interaction with the particulate matter. Both factors might 
contribute to a reduction in the proportion of damaged cells precipitated during 
centrifugation, but these effects are likely to have been minimal, since the 
hepatocytes themselves would also have increased in density. Regardless of 
temperature of processing, it was found that hepatocyte populations with a very low 
initial proportion of viability did not achieve a sufficiently high viability for 
subsequent experimental use, even after Percoll centrifugation. This may reflect 
either an overloading effect of the column by high numbers of dead cells or higher 
numbers of apoptotic cells, which would be expected to possess a higher density 
than viable cells (following cell shrinkage) and therefore precipitate through the 
column without separation. 
Some outlying results of hepatocyte yield were amenable to rational explanation. An 
early experiment (1) yielded a cell suspension containing extremely high numbers of 
contaminating red blood cells, which obscured much of the field in the 
haemocytometer and therefore prevented accurate quantification of hepatocyte 
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yield. This is thought to have resulted from poor initial flushing of blood from the 
tissue sample using the IV giving-set method. In three experiments (6,11 and 22) 
which resulted in relatively poor yields of viable hepatocytes, the cells obtained 
following digestion of the tissue samples were observed, by light microscopy, to 
contain large, clear intra-cellular inclusions and the cell suspensions exhibited a thick, 
pale, creamy froth above the media layer following centrifugation. It was inferred 
that the hepatocytes of these specimens were steatotic and thus more than usually 
susceptible to fragmentation, resulting in a high level of attrition during processing. 
Due to their high fat content, remaining cells were also likely to be of lower than 
usual density, and therefore precipitated with less efficiency by the Percoll 
centrifugation step. Both factors help to account for the very low hepatocyte yields 
from these experiments. 
Undoubtedly, one of the main variables affecting post-digestion processing was the 
innate heterogeneity of the human primary hepatocyte population, with relation to 
both cell size and cell density. This heterogeneity results from differences in 
anatomical distribution, functional differentiation, and the numbers (and types) of 
storage granules and organelles contained in these large, complex cells. The effect of 
this heterogeneity was most obvious when processing visibly steatotic cells, as 
described above. However, such factors are applicable to all primary hepatocyte 
populations and their variability makes it difficult, if not impossible, for the 
researcher to counteract their effects. 
To conclude, human primary hepatocytes with high percentages of viability were 
obtained from surgically resected human liver tissue. A protocol for two-stage 
perfusion was developed from previously published methods and from locally- 
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established methods for rodent hepatocyte isolation. Several physical issues relating 
to tissue perfusion were explored and optimised. A modified protocol, utilising a 
longer period of liver tissue digestion in combination with re-induction of cold 
ischaemia to preserve the cells after digestion, was found to be associated with 
significantly higher levels of hepatocyte viability. Unavoidable delays, enormous 
inter-sample variation and lengthy experimental procedures created complex 
conditions in which it was not possible to obtain reliable and predictable results or 
conventional standardisation of experimental parameters. Despite the challenges, 
the aim of the experiment series 
- 
to optimise experimental condition for isolating 
highly viable suspensions of hepatocytes from human liver tissue 
- 
was achieved. 
The cells thus obtained facilitated many of the subsequent experiments described in 
this thesis. 
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4. TRANSFECTION STRATEGIES FOR PRIMARY HEPATOCYTES 
4.1. Introduction 
4.1.1. General overview of transfection 
Transfection is a process by which non-native genetic material is inserted into target 
prokaryotic or eukaryotic cells to enable them to express foreign proteins. This is an 
essential technique for investigating the roles of individual genes and their products 
in the pathogenesis of disease or as targets for its treatment. There are a number of 
different methods existing for transfection: the best choice in each instance largely 
depends upon the cell type to be targeted and the effect or product to be generated 
and/or measured. A number of different virus types are commonly used for 
transfection; making use of their natural ability to enter cells and use the host cell 
machinery to generate the corresponding proteins/polypeptides from the genes they 
are carrying, including any incorporated foreign genes. There are also various non- 
viral methods for transfection. 
There are two main types of transfection: transient transfection and stable 
transfection. In transient transfection, the foreign DNA or RNA carries its own 
promoter sequence(s) and therefore may be rapidly translated. The gene, or genes, 
of interest is/are commonly encoded in a carrier plasmid or recombinant virus, 
referred to as a vector. Viruses, such as adeno-associated viruses and Semliki Forest 
virus, are commonly used to achieve high-level transient transfection of host cells'100 
1021 Many copies of the vector may enter each cell so that a high level of translation 
(the process by which mRNA is processed by host cell ribosomes to produce the 
protein it encodes) may be achieved. However, expression of the transfected vector 
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sequence generally declines after a few days, as the foreign DNA or RNA is lost from 
the host cell population, due to active elimination or cell turnovertlo31 
During stable transfection, which can be performed only using DNA, the vector 
sequence is permanently incorporated into the host cell's genetic material. The 
transfected gene or genes may be integrated into the host's genome by splicing, or 
may persist as a nuclear episome. Retroviral vectors are useful for stable 
transfection, as they naturally integrate genetic material into the host 
chromosome(s)11021. As only one or two copies of the sequence are likely to be 
integrated per cell, amounts of the foreign protein expressed by each cell are usually 
lower than with transient transfection (at least initially). However, depending on the 
vector and cell line used, the expression may be maintained indefinitely and the 
incorporation of additional genes which conferring a drug resistance can enable a 
homogenous cell population to be selected in culture, i. e. where, finally, all the cells 
in the in vitro culture carry the inserted genes. Unfortunately, because cell 
proliferation is required, both for the DNA integration and subsequent selection 
phases, stable transfection has little utility in non-proliferating cells (including 
primary hepatocytes)11041 
Optimal transfection methods for any given cell type result in a high level of gene 
expression (efficacy) and confer a low level of host cell toxicity. A number of 
different methods have been developed for the transfection of eukaryotic cells. 
These methods are commonly categorised as viral transfection (also known as 
transduction) and non-viral transfection. 
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Viruses possess natural mechanisms by which they can bind to, then release genetic 
material into, target cells (see figure 4.1). In many cases, proteins on the surface of 
the virion act as ligands for naturally occurring host cell receptors and then trigger 
endocytosis. If a virus has been genetically modified, through recombination, to 
carry additional genes (as shown in figure 4.1), the foreign genes will also be carried 
into the infected cells. The virus's own (and usually highly efficient) mechanisms for 
directing transcription and/or translation of its genome usually results in a high level 
of expression of the foreign gene of interest. 
Generally, non-viral transfection relies either on causing nucleic acid-containing 
particles to associate with, or pass through, cell membranes prior to releasing their 
contents into the cell or on the creation of pores in the membranes of target cells 
(generally using an electric current by a process known as electroporation). In the 
same way as viral transfection, non-viral transfection can produce either transient or 
stable transfection, depending on the cell type, transfected genes and selection 
pressures applied (if any). 
Positively-charged substances, such as diethylaminoethyl (DEAE)-dextran, were first 
used for transfection in 1965110s) DEAE-dextran is cationic under acidic conditions, in 
common with many other non-viral transfectants, and therefore binds to the 
negatively-charged (acidic) phosphate groups on DNA. The resulting complex salts, 
which may be extremely large molecules, can interact with the hydrophilic moieties 
of lipid membranes of target cell and subsequently can be endocytosed. 
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Figure 4.1: Introduction of DNA into eukaryotic cells by viral transfection. Positive- 
sense RNA viruses are directly translated in the endoplasmic reticulum. 
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Cationic lipids are now among the most commonly used reagents for non-viral 
transfection. These lipid molecules are comprised of two (hydrophobic) fatty acid 
chains, a linker sequence, and a hydrophilic amino group[1061 and they can bind to 
DNA or RNA to form transfection complexes. These complexes may take the form of 
liposomes (spherical structures in which a lipid bilayer encapsulates the nucleic acids) 
or of micelles (smaller spheres in which nucleic acids organise around a spherical 
monolayer of amphiphilic lipid molecules) as shown in figure 4.2. 
Either the lipid then merges with the host cell membrane (resulting in release of the 
DNA into the cytoplasm) or the entire particles are internalised by endocytosis (see 
Figure 4.3). Newer lipid-based preparations may also bear specific ligands, which 
bind the complexes to receptors on the cell surface. 
Solutions of these DNA-containing complexes must usually be in contact with a 
cultured adherent cell layer for several hours to allow adsorption and cellular 
endocytosis to occur. Transfection then requires the host cell's normal intra-cellular 
trafficking processes to transport the DNA to the nucleus11071. The efficiency of non- 
viral transfection tends to vary between different cell types and species and, in 
addition, the formulation of the complexes, incubation time, cell density and medium 
composition all need to be optimised accordingly. 
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nucleic acids 
R iLI~ 
Liposome 
Figure 4.2: Schematic diagram showing the monolayer nature of a micelle, in 
contrast to the bilayer structure of a liposome, when formed in the 
presence (right) or absence (left) of DNA or RNA. Hydrophilic 'heads' of 
the molecules organise to the exterior when formed in aqueous solutions 
and associate with the nucleic acids (shown in green). (Adapted from 
Villarrealnlosj) 
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Figure 4.3: Introduction of DNA or RNA into eukaryotic cells by cationic lipid 
transfection (adapted from Lee et al. 11091) 
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Electroporation is a procedure in which one or more short, high-voltage pulses of 
electricity is passed through a specially designed cuvette containing a carefully 
selected electrolyte solution, in which the target cells have been suspended, and in 
which the nucleic acid to be transfected is also present11101. This disrupts the 
normally stable potential difference across the cell membranes and small, temporary 
pores develop in them. Naked DNA or RNA, present in the buffer solution, is thought 
to enter cells mainly by electrophoretic transfer' following association with the cell 
membrane adjacent to these pores (as shown in figure 4.4)hlll, l1Z1 
Photochemical internalisation is a further mechanism of transfection which uses the 
application of light and photosensitising chemicals to cause endocytosis and then 
cytosolic release of the macromolecules of interest (in this case DNA or RNA). Micro- 
injection and biolistic bombardment are two other physical means of transfection. 
Micro-injection uses a fine needle to inject unmodified genetic material directly into 
cell nuclei. It may be performed manually, or by automated machine: either method 
requires highly specialised equipment. Biolistics refers to the technique of inserting 
particles into target cells using compressed air. This technology is also described as a 
"gene gun". The "bullets" comprise microscopic particles of metal coated with 
plasmid DNA[1031 
A non-active transfer process, driven by the potential difference existing between the 
inside and outside of the cell (as the result of active ion-transfer processes). For simplicity, 
this "unintentionally-aided" process is referred to as passive transfer in this thesis. 
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Figure 4.4: Introduction of genetic material into eukaryotic cells by electroporation. 
DNA sequences enter the nucleus by non-active transfer mechanisms to 
undergo transcription, whereas single stranded RNA sequences which 
contain a suitable ribosome entry site can be directly translated in the 
endoplasmic reticulum. 
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4.1.2. A comparison of methods for viral transduction with those for non-viral 
transfection, with reference to the advantages and disadvantages of each. 
Viral transduction commonly has high levels of efficacy (i. e. a high proportion of 
target cells express the protein(s) of interest) and overall efficiency (i. e. the amount 
of genetic material required for transfection is low, relative to the transfection 
efficacy achieved). One reason for this is that the genes of interest are actively 
transported to the nucleus by viral mechanisms; another is that the virus may contain 
its own RNA polymerases to enable high levels of transcription [1021. However, the 
main disadvantage of viral transduction is that of cellular toxicity, due to the effects 
of synchronously expressed viral proteins. A consequential reduction in host cell 
function may also have damaging effects. Transient transfection using viral vectors is 
therefore often limited to very short-term studies of gene expression. 
Viruses which stably transfect cells by integrating their genetic material are generally 
unsuitable for use with non-dividing cells, as previously mentioned. Baculoviruses, 
which offer good efficiency in producing correctly folded and functional target 
proteins, are generally unsuitable for the transfection of mammalian cells as they can 
only express protein in insect cells, although recent advances have permitted the 
transfection of some mammalian cell lines 1113,1141 Recombinant adeno-associated 
viruses or vaccinia viruses can achieve tremendously high levels of target gene 
expression and are useful for over-expressing proteins within a cell1101,1021 However, 
the translation level of both viral and foreign genes may be so high that it has a 
detrimental effect on the host cells, which usually die after 1-2 days. Furthermore, 
the expression and presence of vector virus proteins may be a confounding factor in 
interpreting the results of experiments which examine cell function and interactions. 
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Non-viral methods of transfection are least damaging to the target cells but also tend 
to be the least effective. Most such methods lack any means of active transfer to the 
nucleus and this can substantially limit transcription (when using DNA) and therefore 
the effectiveness of transfection. However, if the target cells are to be subsequently 
examined individually, or if the successfully transfected cells can be selected in some 
way, these may still be suitable techniques to use for achieving a sufficient level of 
foreign protein expression. Non-viral carriers can be usually be used to introduce 
larger genetic fragments than viral vectors, which may be advantageous in some 
circumstances. 
The oldest method of non-viral transfection, diethylaminoethyl (DEAE)-dextran, is 
simple to use and gives reliable results, but is frequently disadvantaged by 
consequential cytotoxicity. The cytotoxicity may be exacerbated by the need to 
remove, or reduce the concentration of, any serum component of the cell culture 
medium, to avoid interference with the transfection mixture during incubation. A 
number of cell types are also non-permissive to (DEAE)-dextran11031. As one of the 
other non-viral transfection procedures, calcium phosphate-DNA complexes are 
relatively cheap to produce and easy to apply. A solution of DNA in a phosphate 
buffer is mixed with a solution of calcium chloride to form the complexes. However, 
the efficiencies achieved are often unpredictable because it can be difficult, 
reproducibly, to obtain optimally- and homogenously-sized complexes[1151. Many 
primary cell types are also resistant to calcium-phosphate transfection11051 Synthetic 
cationic polymers, such as polyethyleneimine (commonly referred to as PEI), can also 
be complexed with the anionic phosphate groups of nucleic acids. This technique 
offers a higher efficiency than older methods in some cell types and, because these 
chemicals lack strongly hydrophobic moieties, they are not sequestered by 
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interaction with the serum in the cell culture medium. However, the 
macromolecular complexes formed are likely to present many uncomplexed ionic 
sites and may cause toxicity through unintended interactions with cellular 
membranes and other components1161 
. 
There are also several lipid-based transfection reagents commercially available, 
which may offer improved efficiency and reproducibility of transfection as compared 
with the DEAE-dextran or calcium-phosphate methods. However, the amphiphilic 
character of any excess (uncomplexed) reagent may cause direct cytotoxicity by 
disruption of the cells' membranes 1161. A further disadvantage of lipid-mediated 
endocytosis is that phospholipids and other fats within serum, if present within the 
cell culture medium, may associate with the hydrophobic sites of the complexes 
formed and inhibit their interaction with plasma cell membranes, thereby reducing 
transfection efficiency. On the other hand, reducing the level of serum in the cell 
culture medium, as when using DEAE-dextran, may increase the risk of cytotoxicity 
from the transfection complexes or the genes carried in them1losI 
Electroporation techniques are fast, simple and among the most efficacious methods 
of non-viral transfection but these advantages generally come at the expense of 
irreversible damage to a proportion of the target cells. The electric pulse (or pulses) 
used causes disruption to the cells' membranes so that, in addition to molecules 
within the buffer solution being able to diffuse passively into the cell cytoplasm and 
nucleus (see figure 4.4), intra-cellular contents can also diffuse out, adversely 
affecting viability of the cells [1121 
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Recovery of the cells' membranes from this trauma is highly dependent upon the cell 
type and robustness and also on the buffer, cell handling and duration and amplitude 
of the pulse. A high proportion of cell death (50-7O%h1051) may occur, although this 
drawback may be of less concern if using a rapidly proliferating cell line. However, 
there is no restriction on the use of serum in the culture medium and its presence 
may help to minimise some of the damaging effects. 
Photochemical internalisation has the potential for very broad applicability, and 
enables multiple samples to be processed at once, but the potentially many 
photochemical reactions induced can result in significant and permanent cell toxicity. 
Micro-injection and biolistic bombardment both have limited applicability due to 
issues of complexity, high cost and very restricted scale. 
4.1.3. Transfection using cationic polymeric polyethylenimines 
4.1.3.1. Principle of cationic polymer-mediated transfection 
Polyethylenimines (PEIs) were first developed for use by soap manufacturing and 
water purification industries (1171. Their suitability as transfection reagents was first 
described in 1996(1161. PEIs have been found to condense DNA extremely efficiently, 
tlo71 to form small polyplexes which may be more readily endocytosed than lipoplexes 
They are very stable, water-soluble polymers that can be synthesised in two forms, 
branched chain and linear (as shown in figure 4.5). Branched PEIs are made by 
polymerising aziridine monomers, whereas the linear forms of PEI are made by 
polymerising 2-substituted 2-oxazoline monomers. 
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Figure 4.5: Diagram showing the chemical structure of the (a) linear and (b) 
branched forms of polyethylenimine. Multiple amine groups accept 
protons at physiological pH. (Adapted from Godbey et al. (1171) 
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As shown in figure 4.5, both branched and linear PEI possess numerous proton- 
accepting amino groups (potentially more than 1000, depending on the polymer's 
molecular weighttlln), conferring excellent buffering capacity in relation to the 
polymers' size. Branched chain PEI possesses primary, secondary and tertiary amine 
groups, with their pKa ranging from 5.5 to 9.0. The high residual buffering capacity of 
the PEI component allows the polyplexes to resist lysosomal degradation following 
endocytosis, by reducing the acidification of the endolysosome that would otherwise 
normally occur following endocytosistlls1. Acidification causes destabilisation, 
swelling and degradation of the endolysosome and permits escape of the intact 
polypiexes once the endolysosome breaks downt1191 
When mixed with an aqueous solution of plasmid DNA, PEI surrounds, and causes 
condensation of, the DNA. In this context, condensation describes the process by 
which double-stranded DNA collapses into a compact toroid-shaped particle. This 
process occurs if more than 90% of the DNA's charge is neutralised by the presence 
of cations and the electrostatic charge which usually maintains its open coil structure 
is therefore removed. The small, polyplexed particles of PEI and DNA may each 
contain several plasmids. The diameter of these particles can range between 
20-130 nm[117,1201, and is influenced by the ionic strength of the solution in which the 
reaction is performed, the ratio of nitrogen atoms in the polymer to phosphorus 
atoms in the DNA (N: P ratio) in the whole mixture, and the type and molecular 
weight of the PEI used 11201. Different configurations of complexes are inevitably 
created in the same mixture, and are probably influenced by physical mixing 
techniques (1171. When PEI: DNA polyplexes are overlaid onto adherent cell cultures, 
they associate with the plasma membranes of cellst1201. The main interaction is 
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thought to occur with negatively-charged sulfated proteoglycan molecules[1171. A 
proportion of the complexes are subsequently endocytosed. 
Generally, smaller particles are more easily endocytosed by cells and denser 
complexes of PEI may protect the DNA from degradation'"''. The influence of 
particle size and surface charge on uptake into cells, intra-cellular trafficking, and 
DNA expression appears to be complex11261 
4.1.3.2. Considerations when using cationic polymer-mediated transfection 
The choice between branched chain and linear PEI is not straightforward. Branched 
chain PEI (around 25 kDa) was initially found to give better general transfection 
success11171. However, it also seems that very low molecular weight linear PEI 
(around 5 kDa) can result in good transfection efficiencies and may also result in 
lower toxicity to the transfected cells. The relationships between PEI form or 
molecular weight and transfection efficiency are likely to be influenced by the size 
and density of polyplexes formed which, as described above, may vary between (and 
even within) batches of polyplex made with the same polymert119I. Whichever form 
of PEI is chosen, it is therefore necessary to spend some time optimising the N: P ratio 
as well as carefully regulating the chemical, physical and mechanical conditions under 
which the complexes are formed. 
Proteins can bind to, and effectively inactivate, PEI: DNA complexes ["'1, although this 
adverse effect may be minimised by altering the N: P ratio of the complexes and/or 
washing serum from the target cell layer prior to overlaying the PEI: DNA mixture. 
Lastly, uncomplexed PEI increases the permeability of cell membranes and is 
therefore toxic if present at too high a concentration. 
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4.1.4. Transfection by electroporation 
4.1.4.1. Principle of electroporation 
Electroporation, also known as electropermeabilisation or electrotransfer, is a 
technique which uses voltage pulses to disrupt the plasma membranes of target cells, 
thereby allowing naked DNA or RNA to diffuse into the cell and its nucleus. Target 
cells, either in suspension or in monolayer culture in specially adapted culture 
vessels, are placed between two conductive metal plates and a very short pulse of 
electricity is applied (typically, for mammalian cells, around 260V11101). Genetic 
material, in solution surrounding the cells, diffuses passively into the cells through 
the pores transiently created in their plasma and nuclear membranes by the 
electrical pulse, as shown in figure 4.4. These pores are naturally resolved within a 
short time and the transfected sequences are usually rapidly transcribed and/or 
translated, following recovery of the host cell. 
4.1.4.2. Considerations when using electroporation 
As there is no targeted or active transport into the cell, a relatively high external 
concentration of DNA or RNA is required for effective transfection. However, overall 
efficiency tends to be high due to the high proportion of cells that are likely to be 
permeabilized by this technique. Rapid translocation of the transfected genes usually 
allows production of the protein of interest to begin very quickly, in contrast to many 
other transfection techniques. This advantage may however be lost if the 
unprotected DNA or RNA is ejected from, or destroyed by, the host cell. The use of 
ý121" super-coiled DNA, or capped RNA, may be necessary to mitigate this degradation 
1231 
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The number and size of the membrane pores created depends upon the voltage, 
capacitance, the duration of the pulse, the composition of the cell suspension 
medium, and the cell type. The same factors will also influence the directly damaging 
effects of the method: creating too much permeability will kill the target cell. Most 
small membrane pores will resolve quickly but a proportion of cells will be more 
liable than the average to irreversible membrane damage and will die for this reason. 
There is therefore a need for careful optimisation of the cell concentration, ionic 
composition of buffers and electrical parameters used for each cell type. 
In principle, cells might be electroporated in any standard physiological buffer or 
medium. However, the ionic composition of the culture medium or cell buffer will 
affect both the transmission of the pulse and its effect on the cells' membranes, so in 
some methods a specialised (sometimes proprietary) solution may be used to create 
the cell suspension. This is the case for nucleofection, a method of electroporation 
using a commercial electroporation machine (Nucleofector®; Amaxa® AG, Germany) 
with proprietary buffers. Nucleofection has been widely reported to confer the high 
efficiency of electroporation with lower levels of cell damage and death 1124,1251 The 
contents of its cell suspension buffers and the parameters of its pre-coded 
programmes of electrophoretic pulsing are not disclosed by Amaxa® and therefore 
unable to be openly assessed. 
During the initial phases of the present experimental work, the ultimate intention 
had been to transfect primary hepatocytes with single gene constructs from the 
hepatitis C virus and to examine the effects on lipid metabolism. Immuno- 
histochemical techniques would have enabled the examination of individual 
transfected cells, thereby obviating the need to successfully transfect a high 
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proportion of the hepatocyte population. The development and availability of the 
HCV JFH1 clone and subgenomic replicon (described further in Chapter 5) offered 
numerous additional opportunities and potential advantages in a primary hepatocyte 
culture model and therefore investigation of the replication of JFH1 in primary cells 
became the main aim of the project. However, investigation of its capacity for 
replication would be problematic unless a high proportion of transfected cells could 
be achieved, as the chief methods to measure replication involve the (usually 
indirect) quantification of marker protein production from an entire population of 
cells, rather than a cell-by cell immunocytochemical analysis. As has already been 
mentioned, differentiated primary hepatocytes do not proliferate freely in culture, 
thus the selection and expansion of successfully transfected cell populations was not 
feasible. In hepatocytes, expression of a potentially cytotoxic set of genes from the 
hepatitis C virus would offer temporal limitation to the utility of this approach, in any 
case. Re-suspension and selection of cells expressing the replicon after an initial 
culture period, using fluorescence-assisted cell sorting (FACS), would be physically 
intolerable to live hepatocytes and thus similarly unfeasible. 
There are few publications containing details of techniques for non-viral transfection 
of primary hepatocytes and fewer still which consider transfection methods for 
human primary hepatocytes. Calcium phosphate transfection has been described in 
a number of studies of rat primary hepatocytes, achieving efficacies of 20-25%h126.12'ß 
However, a later study suggested increased toxicity and only low levels of efficiency 
* Preliminary studies (not presented in this thesis), using rat hepatocytes, found that chemical 
and / or mechanical removal of these fragile cells from the culture surface, and the shear 
forces of the sheath fluid during subsequent FACS analysis, caused almost universal cell 
fragmentation and death. 
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in comparison to newer methodologies (128). Cationic lipid-mediated transfection of 
rat hepatocytes has also been described, using a number of commercially available 
reagents. Efficacies of 5-22% were described in one study, which used GFP as a 
reporter gene in rat hepatocytest1291. In a similar study which used a luciferase 
reporter, the level of transgene expression was found to decline after only 24-31 
hours 11301. Cationic lipid transfection methods have been reported to produce varying 
levels of cell toxicity and reduced duration of viability in subsequent culture, and may 
be inhibited by serum in the culture medium1131"133. There is some evidence that 
optimum transfection levels are achieved by prolonging the post-isolation/pre- 
transfection periodtl3a. 13s1; unfortunately, this may be disadvantageous for the 
examination of any downstream effects of transgene expression, as there may be 
greater relative de-differentiation of the hepatocyte phenotype prior to transfection. 
Chemin et a1.11361 described the use of both linear and branched chain PEI to 
successfully transfect primary hepatocytes from ducks and tree shrews. They were 
able to achieve efficacies of up to 10% and 50%, respectively. The optimum N: P ratio 
range was found to be 10: 1. In some contrast to these high levels, another study 
comparing various types of PEI to transfect reporter genes into rat hepatocytes 
reported maximum average efficacies of 0.56% to 14.7%, depending on the plasmid 
used (but not the amount of DNA, type of PEI, or incubation time)11371. Efficacy did 
not increase beyond 24 hours. A further study demonstrated transfection of both 
human and rat primary hepatocytes using a PEI-mellitin conjugate, but did not 
provide data for efficacy or effciency'1381 
A limited number of studies have now reported the successful use of nucleofection to 
transfect primary hepatocytes. Rat hepatocytes were reported to be successfully 
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transfected by Ishihara et aL11241, although efficacy was not reported, and porcine 
hepatocytes were transfected with 40-50% efficacy by Chen et a1. h1391. 
In the remainder of this chapter, work to optimise two methods for the transient 
transfection of primary hepatocytes is described. The most effective DNA 
concentration and N: P ratio for PEI: DNA transfection was determined, using 
adherent cultures of rat hepatocytes approximately 18 hours after isolation. The 
optimal DNA concentration and Nucleofector® programme for nucleofection was 
determined using freshly isolated rat and human hepatocytes in suspension. The 
results obtained from both methods are presented and the efficacy, advantages and 
disadvantages of the two methods are then compared and summarised. 
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4.2. Materials and methods 
4.2.1. Cationic polymer-mediated transfection 
4.2.1.1. Materials for cationic polymer-mediated transfection 
The gWizGFP plasmid, (5757bp; MW 3800 kD), was obtained from Aldevron [see 
appendix 8.2 for vector gene map]. Linear PEI (25kDa, Polysciences) was obtained 
from Park Scientific Ltd. 
Standard hepatocyte culture media were prepared as described in chapter 2; 
additional media were prepared as follows. 
Medium 7 comprised William's Medium E (Gibco®) (500 ml), 2 mM L-glutamine 
(Gibco°), 5 mM nicotinamide and 10 µg/ml bovine pancreas insulin (final 
concentrations of supplements indicated in each case). 
Medium 8 comprised William's Medium E (Gibco°) (500 ml), 2 mM L-glutamine 
(Gibco°), 5 mM nicotinamide, 10 µg/ml bovine pancreas insulin and 1.5%v/v 
dimethylsulfoxide (DMSO) (final concentrations of supplements indicated in each 
case). 
Medium 9 comprised William's Medium E (Gibcoo) (500 ml), supplemented by the 
addition of 50 ml fetal calf serum (PAA Laboratories°), 2 mM L-glutamine (Gibco°), 
5 mM nicotinamide and 10 µg/ml bovine pancreas insulin (final concentrations of 
supplements indicated in each case). 
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4.2.1.2. Methods for cationic polymer-mediated transfection 
4.2.1.2.1. Preparation of cell cultures 
Freshly isolated primary rat hepatocytes (prepared as described in Chapter 2), were 
cultured in a monolayer applied at 105 CM -2 to 6-well collagen-coated plates in 
medium 1. The hepatocyte cell cultures were incubated at 37°C in a humidified 5% 
CO2 atmosphere. After an initial 2-hour period of incubation, non-adherent 
hepatocytes were removed from the monolayer culture by aspiration of the culture 
medium and by washing the monolayer with PBS (pre-warmed to 37°C), after which 
the cultures were re-incubated overnight with medium 2. Following overnight 
incubation, and just prior to addition of the transfection complexes, the medium was 
aspirated and 400 d fresh medium 2 was applied to each well. 
Some disruption to the hepatocyte layers was visible following PEI transfection 
during preliminary experiments. Subsequent to this observation, medium 7 was used 
during overnight culture of the monolayers prior to transfection, as many 
manufacturers of transfection agents suggest that certain antibiotic solutions may 
cause cellular toxicity if present during transfection, due to increased cellular 
permeabilization. Also, medium 7 was replaced with medium 8, containing DMSO as 
a cell protectant, immediately before addition of the transfection complexes (instead 
of medium 2)11361. These two modifications resulted in improved retention of the cell 
monolayers and were then adopted for all subsequent experiments. 
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4.2.1.2.2. Preparation of DNA 
Working stocks of the gWiz plasmid were obtained by transformation of competent 
E. coli. For these experiments the unmodified plasmid was used. After lysis of the 
bacterial cultures and ultra-centrifugation to obtain the DNA, the plasmid DNA was 
purified by ultra-centrifugation, using a caesium chloride gradient, and then 
extracted by needle aspiration. The plasmid was precipitated using ethanol and re- 
dissolved in RNase- and DNase-free water. The DNA concentration was then 
measured, and adjusted to 5 µg/µ1, using a NanodropTM ND1000 UV 
spectrophotometer. Plasmid DNA stocks were stored at 
-20°C prior to use. 
4.2.1.2.3. Preparation and application of PEI: DNA transfection complexes 
A 10 mM stock solution of PEI was prepared in de-ionised and autoclaved water. The 
pH was adjusted to 7.0 with HCI and the final solution was filter-sterilised and stored 
at 4°C. The stock PEI and DNA solutions were diluted to various working 
concentrations (as shown in table 4.1), being made up to 200 µl, using PBS and 
vortexed briefly to mix. The working-strength PEI solution was added drop-wise to 
the working-strength DNA solution, with intermittent manual shaking. The resultant 
PEI: DNA mixture was then vortexed briefly and incubated at room temperature for 
15 minutes to allow the complexes to form. 
Initial experiments showed some toxicity to the monolayered hepatocytes at higher 
concentrations of the complexes and thereafter PBS containing 5% sucrose w/v was 
used as a diluent (as shown in table 4.1(136) 
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Table 4.1: Amounts of DNA and PEI used to prepare PEI: DNA complexes for the 
transfection of rat primary hepatocytes. Each of the calculated volumes 
was made up to 200µl using 5% sucrose PBS diluent (except where 
otherwise indicated) prior to mixing. 
DNA PEI 
N: P ratio Mass (µg) Volume (µl) Phosphate (nmol) Nitrogen (nmol) Volume (µl) 
0.5 0.1 1.5 6 0.6 
1.0 0.2 3.0 12 1.2 
4 
2.0 0.4 6.0 24 2.4 
4.0 0.8 12.0 48 4.8 
0.5 0.1 1.5 15 1.5 
1.0 0.2 3.0 30 3.0 
2.0 0.4 6.0 60 6.0 
4.0 0.8 12.0 120 12.0 
10 
6.0 1.2 18.0 180 18.0 
8.0 1.6 24.0 240 24.0 
10.0 2.0 30.0 300 30.0 
12.0 2.4 36.0 360 36.0 
6.0 1.2 18.0 225 22.5 
8.0 1.6 24.0 300 30.0 
12.5 
10.0 2.0 30.0 375 37.5 
12.0 2.4 36.0 450 45.0 
6.0 1.2 18.0 270 27.0 
8.0 1.6 24.0 360 36.0 
15 
10.0 2.0 30.0 450 45.0 
12.0 2.4 36.0 540 54.0 
6.0 1.2 18.0 360 36.0 
8.0 1.6 24.0 480 48.0 
20 
10.0 2.0 30.0 600 60.0 
12.0 2.4 36.0 720 72.0 
The experiments using these parameters were carried out using PBS as diluent for the 
PEI: DNA complexes. 
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The first three experiments, which examined N: P ratios of 4: 1 and 10: 1 as 
recommended in previously published studies, failed to achieve any observable 
transgene expression using a ratio of 4: 1. Therefore, only ratios of around 10: 1 were 
tested during the remaining experiments. 
The PEI: DNA complexes (400 µI per culture well) were then added by pipette to the 
culture wells (prepared as in 4.2.1.2.1 and containing the medium already overlaying 
the hepatocyte monolayer) and the cultures were re-incubated. Control cell cultures 
were also prepared for each batch and comprised: 
a. hepatocyte preparation control, one culture well prepared and maintained 
using standard media (as described in Chapter 2); 
b. untransfected media and buffer control, one culture well prepared and 
maintained using modified transfection medium 7 and 8 (as described above) 
and with the addition of 400 µI of 5% sucrose PBS. 
After 4 hours, the transfected hepatocytes cultures were examined by light 
microscopy, in order to observe visible signs of toxicity relative to untransfected 
control cultures, such as cell detachment, dysmorphology and increased granularity 
or vacuolation. Also at 4 hours post-transfection, 1 ml of medium 9 was added to 
each well, without prior aspiration of the existing contents. The transfection solution 
was allowed to remain in contact with the cell cultures for 24 hours in total. The 
hepatocyte cultures were examined for evidence of transgene expression at 20 hours 
after application of the transfection complexes. 
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4.2.2. Electroporation-mediated transfection using nucleofection 
4.2.2.1. Materials for electroporation by nucleofection 
Nucleofection kits for rat primary hepatocyte transfection were purchased from 
Amaxa®. A limited number of nucleofection kits for human primary hepatocyte 
transfection were a kind gift from Amaxa®, as they were under development and not 
commercially available at the time of these experiments. Both kit types contained 
sterile Nucleofector® cuvettes and pipettes, rat- or human-specific Nucleofector® 
solution, Nucleofector® solution supplement and plasmid pMaxGFPTM (MW 2303 kDa; 
0.5 µg/. I in 10 mM tris pH 8.0). Before use, the entire volume of Nucleofector® 
solution supplement was added to the Nucleofector® solution and thoroughly mixed 
by inversion to produce the working solution. This solution was brought to room 
temperature before use. 
4.2.2.2. Methods for electroporation of rat hepatocytes by nucleofection 
4.2.2.2.1. Preparation of rat primary hepatocyte cell suspensions 
The required number of freshly isolated rat hepatocytes in suspension (prepared as 
described in chapter 2) was placed into a 50 ml Falcon tube and sedimented by 
centrifugation (5 minutes; 50g; 4°C). Working quickly, the supernatant was discarded 
and the hepatocyte pellet was resuspended in Nucleofector® working solution, to 
produce a suspension with a measured concentration of 106 cells per 100 µl. 
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4.2.2.2.2. Nucleofection techniques for rat primary hepatocytes 
The cell mixture (100 µl) and varying amounts of gWiz DNA (as shown in Table 4.2), 
diluted to 0.5 gg/gl, were added to each cuvette, avoiding air bubbles. The cuvette 
was immediately capped and placed into the machine for nucleofection, in order to 
avoid sedimentation or unnecessary warm ischaemia of the hepatocytes. Following 
nucleofection (whereby the machine was discharged using programme Q25 as 
recommended for rat primary hepatocytes by the manufacturer), the cuvette was 
removed. 
Control cell cultures were also prepared for each batch as follows. 
a. Hepatocyte preparation control. One well of non-nucleofected hepatocytes 
prepared and maintained using standard media (as described in Chapter 2). 
b. DNA controL One well of non-nucleofected hepatocytes plus DNA, prepared 
as nucleofected cells, with 10 µg DNA added to the cuvette but NOT 
electroporated; rested for 15 minutes and cultured and maintained in the 
same way as nucleofected cells. 
c. Nucleofector® buffer control. One well of non-nucleofected hepatocytes, 
prepared as nucleofected cells up to and including suspension in 
Nucleofector® buffer; added to the culture wells at 100 µI per well and 
maintained in the same way as nucleofected cells. 
d. untransfected electroporation control. One well of DNA-free Nucleofected 
hepatocytes, prepared as nucleofected cells but with no gWiz DNA added to 
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the cuvette; nucleofected and maintained in the same way as standard 
nucleofected cells. 
e. untransfected electroporation control for viability. One well of DNA-free 
nucleofected hepatocytes, prepared as nucleofected cells but with no DNA 
added to the cuvette; nucleofected and used immediately to assess post- 
nucleofection viability by Trypan Blue assay (as described in Chapter 2). 
4.2.2.2.3. Post-nucleofection procedures for rat primary hepatocytes 
Pre-warmed Medium 1 (500 µl) was added to the Nucleofector® cuvette, following a 
15 minute "rest" period at room temperature. The entire cell suspension was gently 
aspirated by pipette and transferred to a collagen-coated cell culture well containing 
1.5 ml Medium 1, which had been pre-warmed to 37°C. The culture plate was gently 
agitated by planar reciprocating motion, to distribute the hepatocytes evenly, and 
incubated at 37°C in a humidified 5% CO2 atmosphere. 
After 4 hours, non-adherent hepatocytes were removed from the monolayer culture 
by aspiration of the culture medium and washing the layer with PBS (pre-warmed to 
37°C), after which the cultures were re-incubated with medium 2 (2 ml per well). The 
hepatocyte cultures were examined for evidence of transgene expression at 20 hours 
after nucleofection. 
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Table 4.2: Amounts of DNA used during nucleofection of primary rat or human 
hepatocyte suspensions, and the resulting, relative concentrations of 
cells and/or DNA. Note that, although the total reaction volumes are 
altered depending on the amount of DNA used, the relative 
concentrations of cells to DNA remain proportional to the mass of DNA 
added. 110 pg of DNA was used for the transfection of rat hepatocytes 
only. 
DNA Total 
i 
Final concentrations 
mass (µg) volume (µl) 
suspens on 
volume (µl) hepatocytes (cells/µl) 
DNA 
(n8/0) 
Hepatocytes 
(cells/ng DNA) 
2 4 104 9615 19.2 501 
4 8 108 9259 37.0 250 
6 12 112 8929 53.6 167 
8 16 116 8621 69.0 125 
101 20 120 8333 83.3 100 
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4.2.2.3. Methods for electroporation of human hepatocytes by nucleofection 
4.2.2.3.1. Preparation of human primary hepatocyte cell suspensions 
The required number of freshly isolated human hepatocytes in suspension (prepared 
as described in Chapter 3 and suspended in medium 5) was placed into a 50 ml 
Falcon tube and sedimented by centrifugation (5 minutes; 50g; 4°C). Working 
quickly, the supernatant was discarded and the hepatocyte pellet was resuspended 
in Nucleofector® working buffer solution to produce a suspension with a measured 
concentration of 106 cells per 100 pl. 
4.2.2.3.2. Nucleofection techniques for human primary hepatocytes 
An optimised protocol for nucleofection of human primary hepatocytes was not 
available. Following advice from the manufacturer, the effects of a number of 
different variables affecting the procedure were explored. For each reaction, 100 µI 
of the cell mixture (106 cells), and varying amounts of pMaxGFPTM DNA at 0.5 µg/ml 
(as shown in Table 4.2), were added to each cuvette, avoiding the creation of air 
bubbles. The cuvette was immediately capped and placed into the machine for 
nucleofection, in order to avoid sedimentation or unnecessary warm ischaemia of 
the hepatocytes. Following nucleofection (whereby the machine was discharged 
under various proprietary pre-programmed settings as suggested by the 
manufacturer and detailed in section 4.3.3), the cuvette was removed. 
Control cell cultures were also prepared for each batch, although limited by 
availability of reagents, and comprised the following. 
129 
a. Hepatocyte preparation control. One well of non-nucleofected hepatocytes, 
prepared and maintained using standard media (as described in Chapter 2). 
b. untransfected electroporation control. One well of DNA-free nucleofected 
hepatocytes, prepared as nucleofected cells but with no pMaxGFPTM DNA 
added to the cuvette; nucleofected and maintained in the same way as 
standard nucleofected cells. 
4.2.2.3.3. Post-nucleofection procedures for human primary hepatocytes 
The manufacturer reported that expression of the transfected gene may be 
increased, in certain cell types, by allowing the suspension of electroporated cells 
and DNA to remain undisturbed, and undiluted by the addition of cell culture media, 
for a period of 15 minutes following discharge of the machine. No data were 
available to indicate the effect of this "rest" period when nucleofecting human 
hepatocytes. Pre-warmed Medium 5 (500 VI) was therefore added to the 
Nucleofector® cuvette, either immediately or following a 15-minute "rest" period at 
room temperature. Working quickly, the entire cell suspension was then gently 
aspirated by pipette and transferred to a collagen-coated cell culture well containing 
1.5 ml Medium 5 which had been pre-warmed to 37°C. The culture plate was gently 
agitated by planar reciprocating motion, to distribute the hepatocytes evenly, and 
incubated at 37°C in a humidified 5% CO2 atmosphere. 
After overnight incubation, non-adherent hepatocytes were removed from the 
monolayer culture by aspiration of the culture medium and washing the layer with 
PBS (pre-warmed to 37°C), after which the cultures were incubated with medium 6. 
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The hepatocyte cultures were examined for evidence of transgene expression at 
20 hours after nucleofection. 
4.2.4. Determination of transfection efficacies 
The GFP protein, encoded by both plasmids, is fluorescent when exposed to ultra- 
violet light, therefore the cell cultures were examined using a Leica DM IRB 
microscope fitted with a mercury lamp UV light source and a standard fluorescein 
530/25 filter cube set. 
Total cell numbers, and the numbers of cells displaying visible green fluorescence, 
were counted at 100x magnification in three fields per cell culture well, to allow 
calculation of the mean proportion of cells expressing the GFP transgene under each 
combination of conditions. All cell cultures were examined at 20 hours after 
transfection, and at 48 hours if no evidence of transgene expression was visible at 
20 hours. 
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4.3. Results 
4.3.1. Transfection efficacy and efficiency achieved by PEI transfection of rat 
primary hepatocytes 
As shown in table 4.3, transfection complexes formed using 0.1-4.0 µg DNA and an 
N: P ratio of 4: 1 failed to produce any detectable expression of GFP at either 20 or 48 
hours. Using the same amounts of DNA and an N: P ratio of 10: 1, a few cells per well 
were seen to exhibit GFP fluorescence only where the maximum of 4 µg DNA was 
used. 
Further experiments therefore examined the efficacies achieved with at least 6 pg 
DNA and N: P ratios of at least 10: 1. The results obtained are shown in table 4.4. The 
level of expression was highly variable, as indicated by the high relative standard 
deviation (RSD) values, but generally low for all combinations of DNA and N: P ratios. 
At an N: P ratio of 20: 1, sporadic cellular dysmorphology and reduced confluence of 
the monolayer was observed. On the basis of this apparent toxicity, higher N: P ratios 
were not examined. 
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Table 4.3: Results of preliminary experiments to transfect rat primary hepatocytes 
with PEI: DNA complexes containing the GFP-encoding plasmid gW& 
Hepatocytes expressing GFP 
Mean 
N: P ratio DNA (µg) Cell batch 
Total cells 
viewed (10) 
transfection 
efficacy (%) 
Prelim 1 Prelim 2 
0.5 0 0 3.60 <0.027 
4 1 
1.0 0 0 3.53 <0.028 
: 
2.0 0 0 3.84 <0.026 
4.0 0 0 4.01 <0.025 
0.5 0 0 3.31 <0.030 
1 10 
1.0 0 0 3.60 <0.027 
: 
2.0 0 0 3.96 <0.025 
4.0 3 12 3.89 0.386 
1 PEI = polyethylimine; N: P = nitrogen: phosphate; GFP = green fluorescent protein 
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A graphical comparison of average efficacies obtained from PEI-mediated 
transfection of rat primary hepatocytes is shown in figure 4.6. Overall, there was no 
correlation between efficacy and DNA µg (correlation coefficient = 
-0.02) and only a 
weak negative correlation between efficacy and N: P ratio (correlation 
coefficient = 
-0.23). On average, the highest proportion of rat hepatocytes 
expressing the GFP transgene (i. e. highest efficacy) was obtained using an N: P ratio of 
10: 1 and 10 µg gWiz plasmid DNA, although the differences observed were not 
statistically significant and therefore any apparent trend in figure 4.6 should be 
interpreted cautiously. 
A comparison of average transfection efficiencies obtained under the same range of 
conditions is shown in figure 4.7. The highest proportion of rat hepatocytes 
expressing the GFP transgene, when expressed per gram of DNA (i. e. highest 
efficiency) was found using an N: P ratio of 20: 1 and 6 µg gWiz plasmid DNA. 
Although the differences were not statistically significant, and there appeared to be 
no correlation when the results from replicates were considered separately 
(correlation coefficient = 
-0.04), the mean values for efficiency (as shown in figure 
4.7) reveal some negative correlation with the amount of plasmid DNA (correlation 
coefficient = 
-0.47). The lack of a clear correlation between efficacy and either DNA 
amount or N: P ratio is, perhaps, not unexpected, given that there must be a 
concentration of DNA which effectively saturates the potential for membrane 
penetration by the PEI-DNA complex, and that there must be an N: P ratio above 
which additional ("free") PEI either cannot enhance the uptake of PEI-DNA complex 
or may even interfere with it. A representative image of PEI-transfected rat 
hepatocytes, using 10 µg plasmid DNA at an N: P ratio of 10: 1, is shown in figure 4.8. 
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The data in table 4.4 indicate that the most important variable affecting transfection 
efficacy was the batch of cells (A, B, C or D) used in the experiments, which may have 
contributed considerably to the difficulty in distinguishing between the effects of N: P 
ratio and DNA quantity. Although batch efficacies were very variable (RSD = 40 to 
75%), with the exception of batches A and D, the differences between the batch 
means are significant (P : 50.02). Thus some unidentified (and hence unquantified) 
characteristic of the hepatocyte and/or complex populations had a major influence 
on transfection efficacy. Given that the rats were of a single laboratory strain, of 
similar age and same sex, and that every effort was made to achieve uniformity in 
the isolation of the hepatocytes, it may be that the between-batch differences in 
efficacy arose from inherent differences in the behaviour of hepatocytes from 
different individual rats towards PEI-DNA complexes. This difference has not been 
reported by other workers. An alternative explanation may be that small, 
unnoticeable differences in the physical preparation of the PEI: DNA complexes (such 
as the style and efficacy of mixing) resulted in variable populations of complex size 
and charge distribution, thus altering the entire batch efficacy. 
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Figure 4.6: Transfection efficacies obtained by PEI transfection of rat primary 
hepatocyte monocultures. Legend indicates N: P ratios. 
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Figure 4.7: Transfection efficiencies obtained by PEI transfection of rat primary 
hepatocyte monocultures. Legend indicates N: P ratios. 
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Figure 4.8: Rat primary hepatocytes, visualised using ultra-violet fluorescence 
microscopy, with those visible having expressed the fluorescent protein 
GFP, 20 hours after PEI-mediated transfection of the gWiz plasmid. 
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4.3.2. Transfection efficacy and efficiency achieved by nucleofection of rat 
primary hepatocytes 
The proportions of cells which were found to express the GFP transgene following 
nucleofection using varying amounts of plasmid DNA are shown in table 4.5. 
The viability of control e was, on average, 20.9% lower at 15 minutes post- 
nucleofection, compared to the initial, post-isolation (pre-nucleofection) viability of 
the hepatocyte batch. Thus roughly 80% of rat hepatocytes survived nucleofection. 
This effect was evidenced by a visible reduction in the confluence of the hepatocyte 
monolayer of control d, when examined at 20 hours post-nucleofection, compared to 
non-nucleofected cells (controls a, b and c). 
There were no visible signs of cell toxicity due to DNA (control b) or Nucleofector® 
buffer (control c) alone. 
No expression of GFP was seen in any of the control wells (a-d). 
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Table 4.5: Expression of GFP in rat primary hepatocytes at 20 hours post- 
transfection using nucleofection1. 
Proportion of cells expressing GFP at 20 
hours post transfection (%) 
DNA (µg) Experimental hepatocyte batch' Mean efficacy (%) 
Standard 
deviation 
C E F G 
2 21.81 1.50 10.68 12.88 11.718 5.859 
4 NT 9.03 19.89 28.21 19.043 4.761 
6 26.42 16.64 21.63 24.09 22.195 3.699 
8 NT 20.51 23.32 36.80 26.877 3.360 
10 55.96 NT2 51.91 54.64 54.170 5.417 
Batch mean 34.7 11.9 25.5 31.3 
Batch RSD % 53 71 61 50 
Viability drop % NT 18.5 23.5 20.7 20.90 2.51 
1 GFP = green fluorescent protein; RSD = relative standard deviation; NT = not tested. 
2 Each batch contained cells from a single liver isolation procedure. 
This sample was incorrectly tested and did not yield a valid result. 
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in contrast with PEI-mediated transfection, there was much less evidence of batch- 
to-batch variation in efficacy. Batches C, F and G produced very similar levels and 
ranges of efficacy and, although batch E produced the lowest average efficacy, the 
differences were only borderline for statistical significance (p = 0.04,0.08 and 0.03, 
for batches C, F and G, respectively). Most of the hepatocyte batches were different 
from those used for PEI-mediated transfection and it is possible that the lesser 
between-batch variation observed with nucleofection arose by chance but it may 
also be that electroporation, at least in the form of nucleofection, is less prone to 
variations in efficacy resulting from differences between the livers of individual rats. 
Also in contrast with PEI-mediated transfection, nucleofection showed a clear 
positive correlation between DNA amount and the efficacy achieved in transfection 
(figure 4.9) (correlation coefficients 0.87 to 0.99 for individual batches). This is 
logical, given that a higher concentration of plasmids around a membrane pore 
should increase the numbers entering the cell and, presumably, the nucleus. 
Figure 4.10 shows the efficacy of transfection of rat hepatocytes by nucleofection, as 
compared with the PEI-mediated transfection at N: P ratio of 10: 1. The highest 
proportion of cells expressing the GFP transgene was obtained by nucleofection using 
10 µg DNA (54.17%; range 51.91-55.96). The mean difference between the 
maximum efficacy following nucleofection and the maximum efficacy following PEI- 
mediated transfection was 51.16%. This difference was highly statistically significant 
(p <0.0001). 
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Maximum efficiency of nucleofection was observed using 2 µg DNA, as shown in 
figure 4.11. However, the difference in efficiency between 2 and 10 µg DNA was not 
significant (p = 0.865). Furthermore, although there was an apparent nadir of 
efficiency at 6-8 µg DNA, the high variability of batch efficacies obtained using 2 µg 
DNA mean that the comparatively lower efficiencies at 4,6 or 8 µg were not 
statistically significant. However, the increase in efficiency achieved by changing 
from 6 or 8 µg DNA to 10 µg DNA was significant (p = 0.033 and <0.001 respectively). 
Nucleofection with 10 µg DNA was very significantly more efficient than PEI 
transfection using the same amount (p = <0.0001). 
A representative image of nucleofected rat hepatocytes, using 10 µg plasmid DNA, is 
shown in figure 4.12. The brightness of fluorescence per cell, although variable, was 
noticeably higher than following PEI-mediated transfection, suggesting the presence 
of higher levels of the protein within each cell. This may be due to a higher rate of 
translation (perhaps due to higher copy numbers of the plasmid per cell) or may 
simply reflect earlier initiation of translation (due to the rapid, and transport- 
independent, nature of plasmid entry during any form of electroporation) and, 
consequently, a higher level of GFP at the time of analysis. 
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Figure 4.9: Graph showing the influence of plasmid DNA, ug, on the efficacy of 
transfection by nucleofection. Legend shows batch codes. 
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Figure 4.10: The gWiz plasmid is more effectively expressed in rat primary 
hepatocytes following nucleofection of freshly isolated cells ("; mean 
values as shown in table 4.5), in comparison with PEI mediated 
transfection of 2 hours-old monocultures at an N: P ratio of 10: 1 ( ; as 
shown in tables 4.3 and 4.4). 
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Figure 4.11: The gWiz plasmid is more efficiently expressed in rat primary 
hepotocytes following nucleofection of freshly isolated cells ("), in 
comparison with PEI-mediated transfection of 2-hour-old monocultures 
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Figure 4.12: Rat primary hepatocytes expressing the fluorescent protein GFP, 20 
hours after nucleofection of the gWiz plasmid. The cell monolayer had 
been washed to ensure that all visible cells were adherent and 
therefore equidistant from the lens. Note the varied, but generally 
high, level of fluorescence per cell. 
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4.3.3. Transfection efficacy and efficiency achieved by nucleofection of 
human primary hepatocytes 
Electroporation, in the form of nucleofection, having proven to give much higher 
transfection efficacy with rat hepatocytes than PEI-mediated transfection, was 
therefore used for subsequent experiments with the human hepatocytes that had 
been isolated. 
4.3.3.1. Effect of a post-nucleofection rest period prior to addition of cell 
culture media 
Table 4.6 and figure 4.13 show the results obtained by nucleofection of human 
primary hepatocytes from a single hepatocyte batch (15), using various amounts of 
the pMaxGFPTM plasmid, with or without the addition of a 15-minute post- 
electroporation rest period. Four discharge programmes were used for this 
assessment, as advised by the kit manufacturer (A24, M23, P20, T28). The addition 
of the rest period was associated with a significant increase in transfection efficacy 
(p <0.035 for all DNA values). Efficacy was strongly correlated with DNA amount, 
without or with the rest period (correlation coefficient 0.98 and 0.91, respectively). 
Further experiments, to determine the optimum Nucleofector® programme and DNA 
quantity for expression of the transgene, were all performed with the addition of a 
15-minute post-nucleofection rest period, as indicated by the above results. 
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Table 4.6: Expression of GFP in human primary hepatocytes at 20 hours post- 
transfection using nucleofection, either with or without a 15-minute 
rest period post-electroporationl. 
Proportion of cells expressing GFP at 20 hours post-transfection (%) C oE 
DNA M Plated immediately Plated after 15-minute rest (µ g) u ö ü 
Z 
Results Mean SD Results Mean SD 
A24 0.66 1.11 
M23 0.63 3.29 
2 0.55 0.35 2.47 1.25 
P20 0.85 3.75 
T28 0.05 1.74 
A24 1.65 3.25 
M23 3.44 10.68 
4 1.81 1.13 6.34 3.12 
P20 1.00 5.51 
T28 1.13 5.92 
A24 5.00 23.04 
M23 4.18 24.80 
53 6 3.90 1.04 19.18 5. 
P20 3.92 15.06 
T28 2.50 13.80 
1 GFP = green fluorescent protein; SD = standard deviation 
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Figure 4.13: Transfection efficacy of nucleofection of freshly isolated human 
hepatocytes is significantly increased by allowing a 15-minute 
incubation period at room temperature after nucleofection and prior to 
plating (showing standard error bars).   cells plated immediately 
following nucleofection; 
  cells plated following a 15-minute 
undisturbed rest period after nucleofection (n = 41. 
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4.3.3.2. Use of various, manufacturer-recommended nucleofection 
programmes for transfecting human primary hepatocytes 
Using the nucleofection programmes detailed above, larger proportions of cells 
appeared dysmorphic or dead after using programmes A24, P20 and T28, compared 
with M23. Following discussion with the manufacturer, who had also received 
feedback from other users, two further programmes were also trialled (U14 and X09) 
and compared with M23. 
Table 4.7 shows the proportions of human primary hepatocytes, from each of three 
different batches (15-17), which expressed the GFP gene following electroporation 
using three Nucleofector® programmes. The hepatocytes were generally observed to 
be less dysmorphic and more confluent following overnight incubation when using 
programme U14, compared with M23 and X09. No significant difference was 
observed between the transfection efficacies of programmes U14 and X09, with 4 or 
6 µg DNA, or M23 with 6 µg DNA. However, M23 with 4 µg DNA showed significantly 
lower efficacy (p = 0.001) than the other combinations, confirming (with different 
batches of hepatocytes) the observation in table 4.6 that programme M23 showed a 
correlation between efficacy and DNA amount, over this narrow range. The absence 
of a similar correlation when using programmes U14 and X09 might have indicated 
either that transfection efficacy was already maximal using 4 µg DNA in combination 
with U14 and X09 or that the apparent differences and similarities between all three 
programmes were actually due to the different hepatocyte batches used for each 
programme. Nonetheless, on the basis that programme U14 produced the lowest 
proportion of dead/dysmorphic cells, it was selected for use in the final experiments 
to optimise the quantity of DNA required. 
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Table 4.7: Expression of GFP in human primary hepatocytes at 20 hours post- 
transfection and with a 15-minute rest period post-transfection, using 
three different nucleofection programmes'. 
Proportion of cells expressing GFP at 20 hours post-transfection (%) 
DNA Programme M23 Programme U14 Programme X09 
Results Mean SD Results Mean SD Results Mean SD 
10.68 16.72 10.64 
4 11.56 10.74 0.80 29.96 21.90 7.07 29.97 21.10 9.76 
9.97 19.03 22.70 
24.80 19.51 13.03 
6 27.94 25.00 2.85 24.82 22.33 2.67 28.02 20.41 7.50 
22.26 22.68 20.18 
1 GFP = green fluorescent protein; SD = standard deviation. 
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4.3.3.3. Transfection efficacy and efficiency achieved by nucleofection of 
human primary hepatocytes using a range of DNA quantities 
The proportions of cells from each of 3 further batches of hepatocytes (23-25), which 
were found to express the GFP transgene following nucleofection using programme 
U14 and varying amounts of pMaxGFPTM plasmid DNA, are shown in table 4.8. 
These three batches of hepatocytes showed clear correlations between transfection 
efficacy and DNA amount (correlation coefficients = 0.90 to 0.97), using programme 
U14. Taking into account the results presented in tables 4.6 and 4.7, this indicates 
that the presence or absence of such a correlation is at least partly dependent upon 
the particular batch of hepatocytes. 
Maximum efficacy was obtained using 8 µg DNA (the range of DNA values was not 
extended, in order to conserve reagents) with hepatocyte batches 23,24 and 25. 
Using 2 µg DNA was associated with significantly lower efficacy than when using 4,6 
or 8 µg DNA (p <0.02). Maximum efficiency of transfection was obtained using 4 µg 
DNA. Using 2 µg DNA was associated with significantly lower efficiency than when 
using 4,6 or 8 µg DNA (p <0.04). As shown in figure 4.14, the efficacy of the batches 
was consistently in the order 24>23>25, underlining the fact that efficacy was also 
batch-dependent, in addition to being dependent on the amount of plasmid DNA 
used in these three batches. Transfection efficiency showed a similar pattern of 
batch-dependency. Figures 4.15, and 4.16, show the average efficacy and efficiency, 
respectively, of nucleofection in batches 23,24 and 25 of human primary 
hepatocytes. Figure 4.17 shows human primary hepatocytes that expressed GFP 
following nucleofection with 8 99 pMaxGFPTM DNA using programme U14. 
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Table 4.8: Expression of GFP in human primary hepatocytes at 20 hours post- 
transfection using nucleofectionl. 
Proportion of cells expressing GFP at 20 hours 
post transfection (%) 
DNA (g) Experimental hepatocyte batch Mean efficacy (%) 
Standard 
deviation 
23 24 25 
2 3.29 3.75 1.43 2.823 1.228 
4 17.30 22.45 10.68 16.78 5.896 
6 19.95 25.13 18.77 21.28 3.383 
8 22.14 29.10 20.82 24.02 4.449 
1 GFP = green fluorescent protein 
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Figure 4.14: Influence of human hepatocyte batch on the efficacy achieved using 
nucleofection and varying amounts of the pMoxGFPTM plasmid DNA. 
Legend shows human hepatocyte batch number. 
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Figure 4.15: Transfection efficacies (average of batches 23,24 and 25) obtained 
using nucleofection of the pMaxGFPTM plasmid in freshly isolated 
human primary hepatocytes. 
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Figure 4.16: Transfection efficiencies (average of batches 23,24 and 25) obtained 
using nucleofection of the pMaxGFPTM plasmid in freshly isolated 
human primary hepatocytes. 
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Figure 4.17: Human primary hepatocytes containing the fluorescent protein GFP, 20 
hours after nucleofection of the pMaxGFP'M plasmid. The cell 
monolayer had been washed to ensure that all visible cells were 
adherent and therefore equidistant from the lens. A variable, but 
generally high, level of fluorescence is seen per cell. 
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4.4. Discussion 
The selection and optimisation of a method to transfect heterogeneous populations 
of fragile, non-proliferating cells (isolated from a single piece of liver tissue) requires 
solutions for various potential problems, the number of which is increased if there is 
a need, or preference, for more than just a low level of transgene expression. During 
the experiments described above, two non-viral transfection methods, based on very 
different principles, were optimised for rat and human primary hepatocytes. Each 
method had advantages and disadvantages which impacted upon its overall utility 
and which are discussed further below. 
4.4.1. PEI-mediated transfection of rat primary hepatocytes 
As expected, PEI-mediated transfection of rat primary hepatocytes was found to be 
affected by numerous factors; including the N: P charge ratio, amount of DNA applied, 
composition of the PEI: DNA diluents and composition of the cell culture media. 
Despite controlled changes in these variables, only low proportions of cells could be 
induced to express the transgene. Furthermore, most of the transfected cells were 
only weakly fluorescent under ultra-violet light, suggesting either that few copies of 
the transgene entered each cell, or that the rate of translation was low (perhaps 
hampered by any continuing association with PEI). 
In the above experiments on rat hepatocytes, maximum efficacy was observed when 
using an N: P ratio of 10: 1, although this conclusion was not statistically proven. It 
has been shown that polyplexes formed at N: P ratios of >4 generally contain fully 
condensed DNA and tend towards smaller size as the N: P ratio increasest1201. In these 
experiments, no expression was seen with N: P ratios of <4, suggesting that 
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condensation (and perhaps smaller size) is important for successful transfection. 
Smaller polyplex size has, with some cell and polyplex types, been associated with 
higher rates of plasmid transfer to the nucleus, and thus transgene expression 11201 
No demonstrable changes in the confluence of the hepatocyte monolayers were 
observed following exposure to the PEI polyplex solution, other than at the highest 
N: P or DNA values (section 4.3.1), thus toxicity during transfection was not 
considered to have influenced the results at lower levels. Further experiments, to 
assess the viability or hepatocyte-specific function of hepatocytes following PEI 
transfection at a range of N: P ratios and DNA amounts, were not performed to 
confirm this observation. This would have been an obvious subject for experimental 
trial, had an acceptable level of efficacy been achieved with PEI-mediated 
transfection. 
The efficacy of PEI-mediated transfection appears to be highly variable depending on 
hepatocyte source species but, in primary hepatocytes derived from tree shrews and 
ducks, it has been found to induce expression of a transgene in 10 and 50%, 
respectively, of observed cellsI1361. These levels are higher than the maximum 
average (3%) found in these experiments on rat primary hepatocytes. There was also 
a marked variation in the range of efficacies found, under different conditions, using 
different batches of rat hepatocytes. Each batch was prepared from a different rat, 
but the animals were of identical strains, kept under identical conditions of 
husbandry, and the hepatocyte preparations were all of very similar, high viability. 
The reasons for the high level of between-batch variation in PEI-mediated 
transfection efficacy are uncertain. Some variation between the cell populations was 
inevitable, both as a result of differences in the in vivo physiology of the hepatocytes 
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(perhaps due to slight variations in animal age) and due to anatomical variation 
affecting the liver perfusion procedure. Both of these unavoidable factors would 
have had some impact on the relative physiological similarity of the resultant 
hepatocytes in vitro. Small, unrecorded variations in the hepatocyte isolation 
procedure may have caused some level of non-fatal cell damage, thus affecting the 
subsequent response of the cells to the transfection procedure. Despite very careful 
preparation, the size, charge distribution and numbers of PEI: DNA complexes applied 
to the cells presumably also varied, both within and between batches (although 
these parameters were not quantified during the above experiments). For example, 
manual mixing would probably produce heterogeneous populations of complexes, 
and short, unavoidable delays in the application of complexes are thought to result in 
increased complex size [1201, although the exact impact of these variables remains 
unclear and unpredictable. Nonetheless, as these parameters are thought to be 
important in optimising the efficacy of PEI-mediated transfection, they could have led 
to the variations in results seen in the above experiments. Whatever the cause of 
between-batch variations in PEI transfections, its occurrence is undesirable and 
creates problems in the interpretation of data from subsequent experiments. 
The low efficacy and apparent low level of cellular transgene expression in rat 
primary hepatocytes resulting from PEI transfection was disappointing and would 
have created problems in the conduct of later experiments to investigate the 
replication of JFH1, if the electroporation technique had not been available as an 
alternative. 
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4.4.2. Issues affecting the comparison of PEI-mediated transfection and 
nucleofection 
Nucleofection, which has been reported to produce high transfection efficacy and 
lower levels of cell damage than are commonly associated with electroporation, 
seemed to offer a possible alternative to PEI-mediated transfection. The relative 
efficacy and efficiency of PEI and nucleofection in the transfection of rat primary 
hepatocytes, was therefore studied. However, there are important differences 
between PEI-mediated and electroporation-mediated (nucleofection) transfection 
which make it difficult to compare their efficacies directly. Perhaps the most obvious 
of these stem from the differing physical requirements of each procedure. 
The nucleofection method, in common with most platforms for electroporating 
mammalian cells, requires the target cells to be suspended in a defined solution of 
electrolytes and enclosed within a cuvette containing metal contacts for conductance 
of an electrical pulse or pulses. This requirement for use of a cell suspension 
essentially restricts the use of electroporation to freshly-isolated cells (unless 
specialised equipment is available), due to the physical intolerance of primary 
hepatocytes to disturbance, or passage, once established in adherent culture. In 
contrast, the long duration needed for polyplex contact, together with the numerous 
wash procedures involved in PEI-mediated transfection, require adherent culture of 
hepatocytes to have been established before using this procedure. This unavoidable 
difference in the cells used for transfection gives rise to a number of confounding 
factors when attempting to compare the outcomes of these methods. 
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Firstly, differences in the length of time between hepatocyte isolation and 
transfection can be expected to result in the transgene being transported, 
transcribed and translated in cells with very different levels of environmental 
(particularly cell-to-cell) stimuli. Hence, such cells are likely to experience both 
qualitative and quantitative differences in intra- and inter-cellular signalling, which 
will subsequently affect many aspects of differentiated cell functions, gene activation 
and cell cycle control. 
Secondly, a relatively high level of cell attrition occurred following nucleofection. The 
viability of rat hepatocytes was, on average, 20.9% lower at 15 minutes post- 
nucleofection than before nucleofection. However, due to the nature of 
electroporation, these measurements are unlikely to afford an accurate 
representation of cell viability, because the pores created by electroporation would 
be expected to resolve in many cells once placed into supportive culture conditions. 
Thus cell viability may have been under-estimated due to penetration of the dye 
through the induced pores in cells which could have recovered. Furthermore, dead, 
non-adherent cells were removed by gentle flushing of media over the cell 
monolayer, following overnight incubation after transfection. The efficacy, as 
measured by expression of the transgene after overnight incubation, is expressed as 
a proportion of the remaining, viable cell population; the proportions recorded are 
thus both statistically, and practically, enriched. PEI-mediated transfection was not 
observed to produce any excess cell death. 
Further variables, which affect any comparative assessment of primary cells, are 
those which stem from the fact that each batch is derived from a different patient or 
animal, and may therefore possess different (and unpredictable) levels of nutrition, 
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function and robustness. Any pre-existing differences will be further complicated by 
cellular variation arising from the hepatocyte isolation procedure (as presented and 
discussed in Chapter 3). Therefore, not only is there heterogeneity within 
hepatocyte populations but also between them, with between-population variability 
being unavoidable even if the two populations are derived from the same animal (or 
patient). In any case, due to the limited availability of cells and (in the case of 
nucleofection) reagents at any one time, it was not possible to perform synchronous 
comparative experiments on all occasions. This inevitably leads to some uncertainty 
when drawing conclusions, which could only ever be partially mitigated by increasing 
the experimental numbers. 
There are advantages arising from a transfection protocol which can be applied 
immediately after isolation of a hepatocyte suspension from the liver tissue. 
Principal among these is the ability to place the transfected cell population into any 
culture conditions (and with any other cell types) required for subsequent 
experiments, whether that might be sandwich mono- or co-culture, free-floating 
spheroid co-culture, or bio-reactive scaffold culture. Furthermore, it is advantageous 
to be able to introduce the cells into these systems as soon as possible following 
isolation, in order to allow maximal retention of hepatocyte-specific cell functions. 
4.4.3. Nucleofection of rat primary hepatocytes 
Rat hepatocytes displayed visibly higher amounts of fluorescence after nucleofection 
than after PEI-mediated transfection, suggesting that higher copy numbers of the 
transgene had been transferred into the nuclei and/or higher rates of transcription 
and translation had occurred due to the differing ages of the cells (as discussed 
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above). However, the freshly isolated cells used for nucleofection were unlikely to 
have been as functional or responsive as the newly-cultured cells used in PEI- 
mediated transfection, due to the recent mechanical and physiological trauma they 
had received, and therefore the observed higher levels of GFP protein in 
nucleofection could have stemmed from its higher efficacy of transfection. However, 
it must be borne in mind that expression of the GFP gene in both of the plasmid 
constructs used is driven by the cytomegalovirus intermediate-early (CMV-IE) 
promoter sequence, which is a common, and highly effective promoter sequence 
used in many experimental plasmids. Derived from a highly infectious virus, the 
sequence might enable preferential translation of its associated genes without 
requiring the host cell to be fully functionally intact and differentiated. Changes in 
the intensity of fluorescence, following either PEI- or Nucleofector®-mediated 
transfection, did not occur for up to 3 days post-transfection, which implies that the 
level of GFP expression in individual cells was influenced, in this case, more by the 
number of gene copies which reached the nucleus, than by differences in the age 
and/or differentiation of the host cells (i. e. than the rates of expression). It is 
unknown whether GFP synthesis ceased, due perhaps to loss of the transfected 
material, or simply reached a balanced level between synthesis and degradation, and 
therefore it is not possible to deduce whether there were any differences in these 
mechanisms between PEI-transfected or nucleofected cells. 
In the experiments described in this chapter, nucleofection was found to provide 
superior efficacy and efficiency of expression of the GFP transgene in rat primary 
hepatocytes, in comparison with PEI-mediated transfection. Nucleofection produced 
a maximum efficiency at 10 µg DNA, which was approximately 14-fold higher than 
that obtained using PEI. The highest nucleofection efficiency required only about 
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2.3 x 106 plasmids per hepatocyte to effect the transfection of approximately 50% of 
cells. Thus, nucleofection resulted in the GFP gene being expressed in approximately 
40,000 hepatocytes per gg of DNA. Despite the attrition rate of around 21%, this was 
therefore a very effective means of transfection. Killed cells were largely removed by 
washing the monolayer established after overnight incubation following 
nucleofection. However, if transfected cells were to be used in any form of 
suspension or aggregate culture following transfection, it would probably be 
necessary to insert a sedimentation step (with or without the addition of a density 
gradient), in order to remove dead cells before proceeding. 
4.4.4. Nucleofection of human primary hepatocytes 
The good results obtained by nucleofection of rat hepatocytes in these experiments, 
and favourable reports of the technique in the literature, supported the trial of 
nucleofection for the transfection of human primary hepatocytes. At the time these 
experiments were performed, the manufacturer (Amaxa®), did not offer a 
commercial protocol for transfection of human primary hepatocytes, but was able to 
provide some buffer solutions (presumably similar to those already marketed for rat 
and mouse hepatocytes) for experimental testing. Limited availability of these 
solutions, and of human hepatocytes (for the reasons detailed in the chapter on 
hepatocyte isolation), unfortunately restricted the scope of experiments performed. 
For these reasons, experimental numbers were sub-optimal, and the effects of 
nucleofection on human hepatocyte cell numbers and viability could not be fully 
assessed, in contrast to the measurements performed during the rat hepatocyte 
nucleofection experiments. This was partly due to the restricted amount of cuvettes 
and buffer available (allowance could not be made for the additional controls 
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required), but also partly because it was not possible for one person to perform all of 
the procedures and tests required without compromising the overall speed of the 
experiment (and therefore adversely affecting hepatocyte viability). 
As with rat hepatocytes, the nucleofection procedure was found to be rapid and 
relatively simple for use with human hepatocytes. The ability to include fetal calf 
serum in the cell culture medium, without affecting the success of the transfection 
procedure, was particularly useful for human hepatocytes, as the isolation procedure 
is invariably longer and thus physiologically more traumatic to the cells than for rat 
hepatocytes, and serum seems to be important in cell recovery, post-isolation. Using 
a proprietary technology is very restrictive in terms of the extent to which variables 
(notably the code-named electroporation programmes and cell suspension buffer) 
can be tested, and their effects understood, during the optimisation of a method. 
However, the efficacy and reliability of the method compensated, in part, for this 
disadvantage. 
Nucleofection of human primary hepatocytes resulted in relatively high proportions 
of cells expressing the GFP transgene. In the same manner as with rat primary 
hepatocytes, nucleofection appeared to cause the death of a substantial proportion 
of cells which were, however, easily removed by gentle flushing of media over the 
cell monolayer, following overnight incubation after transfection. Both the measured 
efficacy and the measured efficiency were proportionately increased by this removal 
of dead cells (and therefore reducing the magnitude of the denominator). The 
creation of a high proportion of transfected cells was a key requirement for the 
subsequent experiments and, together with the high hepatocyte cell numbers 
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obtained by optimising the liver perfusion protocol, this enrichment of the 
transfected cell fraction was extremely beneficial. 
In summary, two protocols for the non-viral transfection of primary hepatocytes 
were optimised. PEI-mediated transfection resulted in low efficacy and efficiency of 
transgene expression in rat primary hepatocytes and required undesirable 
modifications to be made to the culture protocol. Furthermore, this method was 
only applicable to adherent cell layers and therefore imposed limitations on the 
ongoing usage of the transfected cells. In contrast, nucleofection proved to be a 
simple and rapid method of transfection which yielded much higher levels of efficacy 
and efficiency. The ability to apply this method to a suspension of hepatocytes 
facilitates a wider range of down-stream experimental formats and also permits the 
removal of damaged cells by a number of methods. Nucleofection was therefore 
considered to be most suitable method for the transfection of human primary 
hepatocytes in the experiments presented in Chapter 5. 
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S. INVESTIGATION OF THE REPLICATIVE CAPACITY OF THE JFH1 CLONE OF THE 
HEPATITIS C VIRUS WITHIN HUMAN PRIMARY HEPATOCYTES 
5.1. Introduction 
The in vitro expression, replication and propagation of viral pathogens offers the 
opportunity for researchers to understand the ways in which they infect, and affect, 
the host cell(s) and, thence, to conceive and develop targeted drug treatments. 
Although some conclusions can be drawn simply by comparing a viral genome to 
those of its phylogenetically-related family members, this information tends to be of 
more limited scope and value than that derived from specific investigation of the 
virus in question. The genomic analysis of hepatitis C virus (HCV), which proved so 
uniquely valuable in its discovery (as described in chapter 1), revealed a relatively 
simple 9,600 nucleotide sequence of RNA. Patterns of sequence motifs in the HCV 
genome were found to be similar to those of the Flaviviridae and, as a consequence 
of these genomic similarities, HCV was assigned to this family. Through comparison 
to other Flaviviridae, the genome map and the approximate function of many of the 
HCV genes was deduced. However, HCV is the only known virus with human 
infectivity within a separate genus of the Flaviviridae family (the other member of 
the genus being the marmoset virus GB virus B) 
. 
Thus, there are no closer relatives 
from which more precise aspects of its pathogenesis could be deduced. For further 
insights, and thus progress towards targeted therapeutics, specific investigation of 
HCV itself was required. 
Other Flaviviridae are able to infect many different types of human (and animal) cells, 
so therefore the first question to be answered was: which cells are naturally infected 
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by HCV? In vivo studies of cells and tissue from infected patients demonstrated that 
HCV proteins and/or whole virus are associated with hepatocytes and peripheral 
blood mononuclear cells (PBMCs). Subsequent in vitro studies found that some T- 
and B- cell lines could indeed be infected by wild type HCV, but the infection was 
usually transient and only occurred at a low level [1401. Similar results were found in 
studies of human biliary epithelial cells1lal1 Most studies of the pathogenesis of HCV 
performed to date have therefore investigated the effects of expression of its gene(s) 
in hepatocytes of some form, as outlined in figure 5.1. 
Both in vivo animal and in vitro cell culture models can be useful for furthering the 
understanding of viral pathogenesis. The former can provide an excellent means for 
studying host-pathogen interactions over a longer time period and across a range of 
physiological systems, rather than being restricted to the target organ (i. e. the liver). 
Animal hosts also provide an intermediate model, between molecular and/or cellular 
systems and humans, for the trial of therapeutic agents. However, unless the animal 
model is particularly easy (and cheap) to obtain and maintain, detailed study at the 
cellular level may be costly and impractical. Furthermore, animal models are usually 
subject to some uncertainty surrounding their physiological similarity (and, by 
deduction, relevance) to a human host. There may also be ethical constraints on this 
type of research. In contrast, in vitro cell culture models are an obvious choice where 
detailed cellular analysis is required, often being both cheap and readily available. 
However, the complex cell-cell interactions of the in vivo environment are usually 
lost and, even if the cultured cells are human, the cell types used may function very 
differently to human primary cells in vivo. Both animal and cell culture models may 
therefore show less relevance to the in vivo, clinical situation than is ideal. 
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The only known natural reservoir for HCV is man. Two other species have been 
found to be permissive for infection under laboratory conditions: the chimpanzee 
(Pan troglodytes) and a subspecies of tree shrew (Tupaia belangeri chinensis). 
Neither animal exhibits a typically anthropoid clinical course following 
infection 1142'1431, but both have still contributed, enormously, to laboratory studies of 
HCV. 
The chimpanzee model has been used to validate many significant discoveries, such 
as the infectiousness of laboratory isolates and replicons, treatment strategies, and 
even the original identification of the wild-type virus11421. However, there have been 
shown to be key differences in the efficiency of the chimpanzee immune response to 
infection, and there is a much lower-than-expected rate of chronic infection in these 
animals. Cirrhosis and hepatocellular carcinoma, which are significant long-term 
sequelae of HCV infection in man, have not been found to occur in either 
anima lt142,143) Persistent infection is more readily established in tree shrews, 
although only low levels of viraemia develop. Unfortunately, the main limitation to 
the widespread use of this particular model is that the animals are difficult to breed, 
and to work with, in captivity1laz1 
An artificial animal model for viral infection has been also been used to examine the 
effects of HCV genome expression and replication. Chimeric mouse models are 
essentially designed to support human cells (hepatocytes, for example) within an in 
vivo (murine) environment. Mice with severe combined immunodeficiency (SCID) 
are bred with transgenic mice which carry the urokinase plasminogen activator gene 
with an albumin promoter (alb-uPa). Expression of the uPa gene, which is targeted 
towards hepatocytes due to its albumin promoter, causes over-expression of 
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urokinase, hypofibrinogenaemia and accelerated cell death. Human hepatocytes, 
harvested from an uninfected adult donor, are implanted intra-hepatically and 
experience a survival advantage as the pre-existing murine hepatocytes are depleted 
by their expression of the uPa gene [1441. The engrafted human hepatocytes can then 
support in vivo infection with HCV. 
Early work in this field demonstrated the ability of the chimeric mouse model to 
support, and to some extent sustain, productive infection of wild-type HCV following 
injection of serum from HCV-infected human patients"44'. Later studies have 
demonstrated infection of a similar model with infectious HCV clones(las] 
Naturally, the immune system of the animals must be severely deficient, in order to 
allow persistence of the foreign cells11441, and therefore those aspects of pathogenesis 
which derive from the host's immune response are unlikely to be replicated. At least 
21 human-specific proteins are produced by this model, but unusual patterns of 
glycogen storage are seen in the hepatocytestl461. It is possible that normal 
regulatory cell-cell signalling is inhibited by the species differences and, if so, this has 
further implications for the study of disease pathogenesis. Furthermore, the 
mechanism of chimera creation means that significant numbers of hepatic progenitor 
cells are present in the liver and many cells are actively proliferating [1461. This 
undoubtedly results in a liver phenotype which is very different from the usual in vivo 
situation. 
An alternative previous approach has involved taking adult, primary hepatocytes 
from human patients already naturally infected with HCV, to allow them to be 
cultured and characterised in Vitro [1471. Further studies have examined the novel 
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infection, with wild-type HCV from patient sera, of human primary hepatocytes from 
uninfected donors'74'801. Such studies seem to offer valuable similarities for 
comparison with natural, in vivo, HCV infection. Unfortunately, the level of 
replication of serum-derived HCV in primary hepatocytes has been found to be highly 
variable and generally very low[1481. Furthermore, there are at least three potential 
drawbacks to this approach. Firstly, the presence of HCV quasi-species within 
infected patients means that both the viruses and the infected cells will be 
heterogeneous and difficult or impossible to characterise or reproduce. Secondly, 
the distribution and amount of viral genetic material will be unpredictable and 
difficult to identify accurately. Thirdly, when using naturally-infected hepatocytes, 
the low numbers of cells (either derived from biopsy specimens or from end-stage 
cirrhotic livers removed for transplantation) and their short durability of 
differentiated function in culture tend to limit the scope of investigations. 
Adult human hepatocytes can be immortalised, in vitro, by transformation (whether 
spontaneous or due to the transfection of a gene such as SV-40 T-ag). 
Immortalisation is usually accompanied by manifestation of a proliferative (and even 
neoplastic) phenotype which prolongs the available experimental period. 
Unfortunately, this loss of hepatocyte senescence is also associated with loss of 
differentiated function during prolonged culture. Furthermore, the level of 
permissivity for wild-type HCV replication in immortalised human hepatocytes 
11481 
appears to be just as low as that of primary cells. 
Studies of the mechanisms of binding, and entry into host cells, of HCV have been 
greatly facilitated by the use of two successful model systems: HCV pseudoparticles 
(HCVpp; formed by expressing the HCV envelope glycoproteins that are normally 
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present on the surface of HIV virions(1491) and virus-like particles (HCV-LP; formed by 
recombination of baculoviruses to express the envelope and core protein of HCV1791). 
Both types of construct have been used, in hepatic and non-hepatic cells in vitro, to 
explore the mechanisms of attachment and cell entry of HCV. However, these 
systems are of little utility for studying the intracellular pathogenesis of the virus and 
will not be discussed further in this review. 
Until recently, the majority of studies of HCV pathogenesis have been performed 
using permanent cell culture lines in vitro in the study of single genes or viral 
replicons (either subgenomic or full-length), to examine particular aspects of the viral 
life cycle. By definition, such studies have made use of relatively homogeneous 
laboratory clones of the virus, rather than wild-type heterogeneous virus 
populations, in order to improve the specificity and reproducibility of results by 
working with a defined viral sequence. Inevitably, this reduces somewhat the 
physiological relevance of these experiments. In fact, it is the heterogeneity of HCV, 
derived from the mutability of its RNA genome during replication, which has created 
most problems for HCV researchers. 
On the other hand, just occasionally, the heterogeneity of HCV has also helped 
towards achieving certain solutions. The highly important JFH1 genome was 
characterised from the dominant strain of an HCV population found in just one 
infected patient in Japan"501 Its serendipitous isolation, and the subsequent 
discovery that it is able, uniquely, to infect common in vitro cell lines, is an example 
of just such a solution. 
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5.1.1. Viral requirements for HCV expression and replication in vitro 
Consensus sequences, and thence clones, of numerous different viral strains have 
now been derived from all of the major genotypes of HCV. HCV replicons, created 
from these consensus sequence clones of wild-type viruses, have been constructed 
using the non-structural genes of genotypes la (e. g. H77), lb (e. g. cons) and 
2a (e. g. JFH1). Some schematic examples of HCV replicons are shown in figure 5.2. 
These constructs, which are described as either sub-genomic or full length, have 
recently been widely used with in vitro cell cultures to study the viral and cellular 
requirements for HCV replication. 
Studies, using these replicons to investigate the pathogenesis of HCV, began with a 
focus on the non-structural proteins, which effect viral processing and packaging 
inside the host cell. Subgenomic replicons generally comprise the NS3 
- 
NS5B genes 
of the HCV genome in question, flanked by its 5' and 3' non-translated regions 
(NTRs). The NS2 sequence has been found not to be required for in vitro replication 
and its in vivo function remains uncleartlsll 
Originally, all such replicons were dicistronic: containing the HCV 5' internal ribosome 
entry site (IRES); an inserted gene followed by a second IRES; and either the non- 
structural or both structural and non-structural genes from the HCV consensus 
sequence, together with its 3' repeat region. The 5' NTR contains the HCV IRES, and 
the 3' NTR is thought to conserve and protect the RNA from intra-cellular 
degradation. It is therefore desirable to retain both NTRs in any derived construct. 
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Figure 5.2: Some examples of HCV replicons: (A) subgenomic dicistronic replicon 
carrying a resistance gene (e. g. neo) for selection and the EMCV IRES; 
(B) subgenomic dicistronic replicon carrying the firefly luciferase gene 
for quantification of replicon translation; (C) selectable subgenomic 
dicistronic replicon carrying the green fluorescent protein (GFP) gene 
for detection of translation in individual cells; (D) monocistronic full 
length infectious replicon/wild type virus structure; (E) dicistronic full 
length infectious replicon with selectable resistance gene; (F) dicistronic 
full-length infectious replicon with selectable resistance and luciferase 
marker of translation; (G) monocistronic full-length infectious replicon 
chimera, with structural proteins of one clone (shown in yellow) and 
non-structural, replication efficient, genes of a second clone. 
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In order to select for cells harbouring a replicating sequence, a second cistron is also 
created by the insertion of a selectable resistance gene (such as the neomycin 
phosphotransferase gene) following the HCV 5' NTR, plus an external IRES (such as 
the encephalomyocarditis (EMCV) IRES), to ensure continued association with the 
host cell ribosome and translation of the following HCV non-structural genes (see 
figure 5.2A). The subsequent modification of successful subgenomic replicons, to 
express a reporter gene (such as luciferase) instead of the resistance gene, allows the 
relative effects of mutations to be assessed as a function of the replicative capacity of 
the replicon in question (see figure 5.2B). Naturally infectious replicons, which do 
not require cell-culture adaptation, may be monocistronic in the same way as wild- 
type HCV. 
In the absence of an ideal, in vivo-like cell line or other cell culture model, these 
constructs were transfected into Huh-7 cell clones for examination of their replicative 
ability[a9,1ao, 1sz1 Most produced no, or very little, evidence of expression or 
replication. However, those replicons which did replicate successfully were 
frequently found to have developed cell-culture adaptive mutations, as described 
below. The sites, and extent of conservation, of these mutations provide useful 
insights into the function and importance of the peptides where they occur. 
Interestingly, however, there is some evidence that a high proportion of proteins and 
protein complexes derived from non-structural genes in infected cells do not 
contribute to the replication of HCV and the function of these "excess proteins" is not 
yet known (441 
Cell-culture adaptive mutations have been found to occur in all non-structural genes, 
whereas the NTRs remain highly conserved [491. Some mutations increase replicative 
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capacity only when occurring in synergistic clusters; others are independently 
functional. An early report from Blight et al. described clusters of mutations, in the 
NS5A gene, which mapped to a region associated with in vivo sensitivity to interferon 
treatment in wild-type virusest511. Many further mutations, associated with increased 
levels of genome replication, have been found to reduce the number of potential 
phosphorylation sites 1151-1531 
. 
It has since been found that a hyperphosphorylated 
form of the NS5A protein reduces replication of the genome and that, if the Huh? 
cells are treated with an inhibitor of cellular kinases to block this 
hyperphosphorylation, these adaptive mutations do not occur1lsa1 
The protein derived from the NS4B gene has been shown to associate with 
intracellular membranes, inducing a so-called "membranous web", and its gene is 
another site where adaptive mutations occur during in vitro cell culture. NS4B 
protein is thought to anchor the rest of the viral replication complex to cellular 
membranes and selected mutations are presumed to increase the affinity of this 
association in a non-natural host cell environment 1441 
Mutations, throughout the region of non-structural genes, tend to map to areas 
unrelated to the active sites of the resultant enzymes, thus the proteins' functions 
are commonly unaffected 1361. Furthermore, most viral mutations arising through cell 
culture are not found in wild-type HCV viruses and many are common to different 
genotypes. These cell-culture-adaptive mutations are therefore likely to act as 
specific adaptations to the Huh7, or other, cell line and to affect the interactions 
between cellular and viral proteins. Importantly, most highly adapted replicons 
which replicate successfully in cell cultures fail to infect, or to replicate efficiently, in 
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in vivo chimpanzee models1501 and therefore the findings obtained using these 
constructs must be interpreted with caution. 
Even the highly replication-competent JFH1 clone has been shown to develop cell- 
culture adaptive mutations under certain culture conditions. These particular 
mutations are associated with increased production of virions in cell culture, which 
retain infectivity for the uPa-SCID chimeric mouse model. However, it was found that 
these mutations are quickly lost in the new host and there is evidence that such 
mutations confer a reduction in in vivo fitness of HCV1531. It has been suggested that 
adaptive mutations shift viral function towards continuing replication and translation 
of viral RNA, and away from RNA release in mature viral particles but, again, the 
reasons for this remain uncleartlao1 
5.1.2. Host cell requirements for the expression and replication of HCV RNA 
The near-exclusive specificity of HCV for human cells has been a dominant factor in 
the development of cell culture models, as already mentioned. Although there is 
evidence for the infection of a number of non-hepatic cells in vivo (peripheral blood 
mononucleocytes, lymphocytes and dendritic cells), in vitro research has focused on 
the apparent main site of infection, and its consequences: i. e. the liver. The most 
permissive cell line identified is the Huh7 cell line, including several adapted sub-lines 
(such as Huh7.5 and Huh? Lunet cells). 
Permissivity for HCV infection of hepatocytes has been shown to be associated with a 
number of cell surface membrane proteins, namely CD81, SR-B1, claudin-1 and 
[40,77,155,1561 
. 
5,1 6 These proteins have been found to associate with the envelope 
glycoproteins of HCV prior to cell entry, using the HCVpp and HCV-LP models as 
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described in section 5.1. Other cell-surface molecules, notably the mannose-binding 
C-Iectins liver/lymph node-specific Intercellular adhesion molecule-3-grabbing 
nonintegrin (L-SIGN) and dendritic cell-specific Intercellular adhesion molecule-3- 
grabbing non-integrin (DC-SIGN), have also been demonstrated to bind the HCV 
envelope glycoproteins, but they are not present on hepatocytes and thus not 
directly involved in their infection1ls'1 
If RNA (either genomic or sub-genomic) is inserted into the target cells by 
transfection, a number of further cellular determinants affect the ability of the 
genome to be expressed and/or replicated. Lipid droplet formation and transport 
within the host cell appears to be key to the transport and interactions of viral 
proteins135j, as outlined in 1.1.2, and viral replication is inhibited by a reduction in the 
level of saturated or mono-unsaturated fatty acid synthesis1441. Thus it may be 
hypothesized that intra-cellular synthesis, transport and storage of lipids and 
lipoproteins is likely to be a key requirement of a highly successful in vitro cell culture 
model. Other work, using primary hepatocytes, has shown that creation of a 
(cytokine-induced) proliferative environment increases the rates of serum-derived 
HCV virus infection and replication [811. 
It has been shown that replicative capacity for HCV RNA varies between different 
stocks of Huh7 cells in different laboratories and also between batches of different 
passage number in the same laboratory149.1511 Furthermore, these studies have also 
shown that in a normal, unselected population of Huh7 cells, only a small proportion 
will show permissivity for HCV replication, suggesting that these cells are 
heterogeneous with regard to the (largely undetermined) properties which support 
HCV infection. Production of infectious HCV particles also decreases as cells are 
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serially passaged. The reasons for this gradual loss of permissivity are as yet 
unknown. 
In the case of a selected sub-clone of the Huh7 hepatocyte cell line known as Huh7.5, 
increased permissivity for HCV replication has been shown to be related to the loss of 
a cytoplasmic protein produced by retinoid-inducible gene 1 (RIG1). The RIG1 
protein functions by recognising structured RNA within the cell's cytoplasm and 
triggers the production of type 1 interferon via interferon regulatory factor 3 (IRF-3) 
and NF-KB, thereby suppressing infection. Huh 7.5 cells are derived from a clone of 
Huh-7 cells which possesses a mutated and inefficiently expressed RIG1 gene(lss' 
This clone was selected after being identified as harbouring HCV subgenomic 
replicons, and was subsequently "cured" by interferon, thereby offering the prospect 
of a known permissive environment for full-length HCV infection. 
Interestingly, it has also been shown that methamphetamine down-regulates IRF-5 
(and thus the innate interferon response), which results in increased replication of 
HCV in Huh7.5 cells11591. This finding not only underlines the importance of the innate 
immune response during HCV infection, but also correlates with the clinical 
observation that recreational abuse of methamphetamine has been found to be 
associated with chronic HCV infection'1591. A different study, of Huh7 cells expressing 
a genotype lb replicon, showed that exposure to ethanol increased replication and 
translation of HCV RNA and that this was associated with an oxidative stress pathway 
response, via the up-regulated expression of cyclo-oxygenase 2 (COX-2)t160] 
All of the above evidence therefore suggests that the level of in vitro HCV replication 
results from complex interplay between individual cells and specific replicon 
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sequences. This interaction may offer advantages and disadvantages to the 
researcher: on the one hand, it adds yet another source of variation and may render 
comparative interpretation of the results somewhat unreliable; on the other, if 
homogeneous clones of HCV can be selected, this variation may be explored to 
determine the exact requirements of infection. 
There is some evidence that HCV infectivity and replication is enhanced when the 
host cells exist in an organised, three-dimensional (3D) culture, rather than a 
monolayer. A study performed using immortalised hepatocytes showed some 
evidence that cells which maintained differentiated function and polarised cuboidal 
morphology were more susceptible to serum-derived HCV infectiont1611. In the same 
experimental model, down-regulation of the interferon response pathway increased 
the infectivity of HCV; underlining the importance of the innate immune response as 
a key factor in hepatocyte susceptibility to HCV infection. 
Interestingly, research using 3D cultures of an Huh7 sub-clone infected with a 
genotype lb infectious replicon showed that, although cell growth (and viral protein 
expression) occurred at a lower level than in 2D monolayer cultures, release of 
infectious particles was enhanced [1621. A further, short-term study also showed that, 
after 48 hours, expression and replication of a subgenomic replicon in Huh7 cells was 
significantly lower in 3D culture in comparison to 2D monolayers[1631. Unfortunately, 
longer-term studies have not been carried out to explore further the temporal profile 
of expression in 3D culture in Huh7s; most probably because these cells are a rapidly 
proliferating line which quickly require repeated passage in culture (which would 
disrupt or destroy any three-dimensional aggregates). However, the apparently 
altered profile of HCV expression in 3D cell cultures may begin to offer some 
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explanations for the general discrepancy between the susceptibility to infection 
found in vivo versus in vitro cells. 
Production of the JFH1 replicon from a genotype 2a virus proved to be a 
breakthrough against the previous background of replicon research. Uniquely, JFH1 
replicons are replicated efficiently in Huh7 cells without cell-culture adaptive 
mutations. Full length JFH1 replicons also produce virus which is infectious, both to 
cell cultures and to the chimpanzee model. Although the clinical presentation (of 
acute, fulminant hepatitis followed by clearance of infection) of the patient from 
whom JFH1 was derived does suggest that this is a somewhat unusual strain of 
HCV1571, it is unclear why this particular clone is capable of in vitro replication without 
mutations11641 
5.1.3. Expression systems permissive for JFH1 to date 
The JFH1 sub-genomic replicon has been investigated mainly in the Huh7 cell line or 
sub-clones, as discussed further in section 5.1.3.1. This has enabled findings to be 
compared and/or correlated with previous findings in these cell types using single 
gene transfection or other, cell-culture adapted, replicons. However, a number of 
additional human cell types have been shown to be permissive to replication, albeit 
at a lower level. HepG2 cells, which are a liver cancer cell line, and IMY-N9 cells, 
which are a cell line produced by fusion of primary hepatocytes with HepG2 cells, 
were both shown to be permissive for subgenomic replication of JFH111501 HeLa and 
293 cells, which originate from human cervical cancer and embryonic kidney tissue, 
respectively, are non-hepatocyte cell lines which also, nonetheless, have been shown 
to permit replication of JFH1 without requiring adaptive mutations [1651 In some ways 
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this raises questions as to the true equivalence of the JFH1 clone to "wild-type" 
viruses because, as far as is known, this behaviour is not representative of the 
normal, in vivo, infectivity of HCV. On the other hand, these results only reinforce 
evidence of the clone's high level of infectivity and replicative capacity, which is 
usually so difficult to reproduce by in vitro culture of the virus. 
5.1.3.1. Dynamics of JFH1 expression and replication in Huh7s 
As previously noted, the JFH1 replicon has been investigated, primarily, in the Huh? 
cell line. Elegant work, using a bi-cistronic subgenomic replicon containing the firefly 
luciferase gene Luc (see figure 5.2), has enabled relative quantification of the levels 
of the replicon's expression over time, following transfection of Huh7 cells with in 
vitro transcribed mRNAI'661 (see figure 5.3). By comparison with the levels of 
expression produced by a mutated, replication-deficient version of the replicon, used 
as a control, increases in luciferase activity were shown to result from replication of 
the replicon RNA, thus providing higher levels of the mRNA template. Luciferase 
expression was found to rise between 4 and 48 hours post-transfection and then 
plateau until 72 hours (further measurements were not reported); whereas 
replication-deficient mutants displayed levels which declined from 4 hours onwards. 
The rise in luciferase expression was correlated with measured increases in both 
replicon RNA and NS5a protein in transfected cells; whereas this protein became 
undetectable after 24 hours in cells which had been transfected with the replication- 
deficient mutant. Translation of both competent and mutated replicons could be 
inhibited by treating the cells with interferon-a11661. 
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Figure 5.3: Top: Replication of JFH1 
, 
in Huh7 cells; as indicated by production 
of the luciferase marker enzyme at 4,24,48 and 72 hours following 
transfection with in vitro transcribed RNA of the subgenomic JFH1 
replicon (solid line), as compared with a relication-deficient replicon 
containing a GND mutation in the NS58 gene (dashed line). 
RLU = relative light units. Bottom: Huh7 cells stained with an anti- 
NS5A antibody at time points corresponding to those in the graph 
11663 above (adapted from Targett-Adams et al. ) 
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5.1.3.2. JFH1 and other replicons in primary hepatocytes 
Very few published studies have been performed using human primary hepatocytes 
to investigate a defined clone or replicon of HCV and all such work is relatively recent 
(i. e. published after completion of the experimental work described here). 
Lazaro et a!. 1821 transfected a full-length genotype la infectious clone into non- 
transformed human fetal hepatocytes and produced high levels of infectious virus in 
cell culture supernatants for up to 64 days. The fetal cell population contained 
significant numbers of proliferating and/or undifferentiated hepatocytes and 
multipotent stem cells, which may confer advantages for viral replication and reduce 
the physiological relevance to adult hepatocytes. Nonetheless, these results are 
extremely encouraging. 
Molina et 01.1751 compared the infectivity of serum-derived wild-type virus (genotypes 
1-3) with that of JFH1 virus in adult human hepatocytes. They found that HCV- 
containing sera produced relatively low levels of replication of HCV RNA in primary 
hepatocytes (0.18 genome equivalents (Geq) per cell), compared with JFH1 virus 
(3.3- 9.7 Geq/cell). However, the latter values remained an order of magnitude 
lower than those generated by JFH1 infection of Huh7.5 cells. The same study 
produced data showing that entry of both JFH1 and serum-derived viruses into 
primary hepatocytes was associated with expression of the CD81 receptor but the 
authors noted that, although the use of anti-CD-81 monoclonal antibodies inhibited 
serum-derived HCV infectivity by 90%, JFH1 infection of primary hepatocytes was 
reduced by only 60%. These observations further suggest that the efficacy of HCV 
187 
infection is dependent on heterologous combinations of both viral and host cell 
factors. 
Another study, by Lan et a!. 11671, investigated infectious JFH1-derived virus in both 
primary hepatocytes and Huh7.5 cells, to examine its effects on apoptosis. They 
showed that apoptosis was increased by expression of the non-structural viral genes 
and that this increase was mediated by sensitization of the cells to the TNF-related 
apoptosis-inducing ligand (TRAIL)11671. Data on the dynamics, or relative efficacies, of 
infection were not presented. 
No published studies of the translational and/or replicative dynamics of HCV in 
primary human hepatocytes are available as of this date. Certainly, the results of 
such studies would be of the utmost interest, both for the novel data and insights 
they would provide and for the ability for comparisons to be made with the 
enormous amount of work already performed in Huh7 cell lines. There are 
undoubtedly many factors to be optimised in the individual laboratory before 
experimental studies using primary human hepatocytes can be performed 
satisfactorily and with confidence and these have been addressed (to some extent) in 
the preceding chapters of this thesis. The remainder of this chapter presents an 
outline of work performed to build on the established protocols for isolating and 
transfecting human primary hepatocytes by using the methods to investigate the 
replicative capacity, and dynamics, of the JFH1 clone in primary hepatocytes. 
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5.2. Materials and methods 
5.2.1. Materials 
Nile Red stain was obtained from Sigma and an aqueous stock solution was prepared 
at 0.5 mg/ml. 
Plasmids containing HCV replicons (SGR-Luc-JFH1 and SGR-Luc-GND-JFH1) were 
kindly provided by Dr Paul Targett-Adams (MRC Virology Unit, Glasgow) with the kind 
permission of Dr Takaji Wakita (National Institute of Infectious Diseases, Tokyo). The 
pMaxGFP plasmid DNA was obtained from Amaxa® GmbH, Germany. Midiprep kits 
were obtained from Qiagen°. 
Nucleofection® kits were obtained from Amaxa®, as described in chapter 4. The XBaI 
restriction enzyme kit (containing Buffer H and XBal enzyme) and mung bean 
nuclease enzyme kit were obtained from New England Biolabse. T7 Megascript kits 
and RNaseZap® were obtained from Ambion®. The luciferase assay kit (E1500) was 
obtained from Promegam. Water, pipette tips and Eppendorf tubes, used at all 
stages, were certified, and maintained, sterile and free of DNAse and RNAse. 
For gel electrophoresis, ethidium bromide solution (10 mg/ml), agarose powder and 
lOx tris-acetate-EDTA buffer were obtained from Sigma. Working-strength buffer (lx 
tris-acetate-EDTA) was obtained by dilution of the 10x stock solution with sterile, de- 
ionised and nuclease-free water. DNA and RNA concentrations were determined 
using a NanoDrop® ND-1000 UV-Vis spectrophotometer. 
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5.2.2. Demonstrating the presence of lipid in three-dimensional co-culture 
spheroids of human primary hepatocytes and rat hepatic stellate cells 
The production, transport and storage of lipid has been shown to be extremely 
important for the intracellular processing and replication of HCV, as described earlier 
and in 1.1.2, therefore it was desirable to ascertain whether or not lipid droplets 
were present in the hepatocytes of the chimeric human/rat spheroids prepared. As 
lipid is lost during alcohol- or aldehyde-based methods of fixation, the staining and 
microscopy for lipid droplet was performed on live, unfixed cells. A disadvantage of 
this is that cross-sections of the cell aggregates could not be made and only cells at 
the surface of the spheroids could be observed. 
Nile Red dye (9-diethylamino-5H-benzo[a]phenoxazine-5-one) is strongly fluorescent 
in a hydrophobic environment (such as intracellular lipid droplets) but is also soluble 
in aqueous solution and thus is suitable for use on live cellst1681. 
Intracellular lipid was stained using Nile Red as follows. Culture medium was 
aspirated from the cell culture well using a sterile 5 ml syringe fitted with a blunt- 
ended needle. PBS (2 ml), pre-warmed to 37°C and containing Nile Red stock 
solution at a dilution of 1: 5000 v/v, was added to the well and the mixture incubated 
for 10 minutes. The culture wells were then examined and the spheroids 
photographed using a Leica TCS confocal microscope (excitation 485 nm; emission 
525 nm). 
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5.2.3. Methods for expression of the subgenomic JFH1 replicon in Huh? 
cells and human primary hepatocytes 
5.2.3.1. Preparation and in vitro transcription of pSGR-Luc-JFH1 and 
pSGR-Luc-GND-JFH1 
Stocks of SGR-Luc-JFH1 and SGR-Luc-GND-JFH1 plasmid DNA were obtained by lysis 
of transformed, competent E. coli and purified using the Midiprep kit. The DNA was 
re-dissolved in water, to a measured concentration of 1 µg/µl, and stored at -20°C 
until required. 
In order to prepare mRNA for transfection, the plasmids were linearised using the 
restriction enzyme XBal kit, so that an in vitro transcription reaction could be 
performed. Twenty microlitres of 10x Buffer H, 10 µI XBaI enzyme and 70 µl water 
were added to 100 µl of plasmid DNA solution, to make a total volume of 200 µl, 
which was vortex mixed and then incubated for 4 hours at 37°C. 
The linearised DNA was then precipitated by the addition of approximately 1 ml 
100% ethanol, the mixture was centrifuged, the supernatant discarded and the pellet 
was re-suspended in 85 µI water. Mung bean nuclease was used to remove any 
single-stranded overhangs (so-called "sticky ends", which can reduce the efficacy of 
transcription). The DNA suspension was mixed with 10 µI mung bean nuclease buffer 
and 5µI mung bean nuclease and incubated at 30°C for 30 minutes. 
The linearised DNA was then further purified by precipitation, using the phenol- 
chloroform method, and stored at 
-20°C until further use. The integrity of the 
linearised DNA and completeness of linearisation were ascertained by ethidium 
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bromide gel electrophoresis, as described in 5.2.3.2. Only DNA which showed as a 
single, clear band and running slower than the original circular plasmid was used as a 
template for production of mRNA. 
RNaseZap® was wiped over working surfaces and equipment to minimise RNase 
contamination in the working environment. The T7 Megascript® kit was used to 
prepare an RNA transcription mixture according to the manufacturer's 
recommendations, which was added to the DNA templates as recommended. The 
transcription reactions were allowed to proceed for 2 hours at 37°C. 
Following the DNase step to remove the DNA template, the resultant RNA was 
examined for integrity using RNase-free ethidium bromide gel electrophoresis (as 
below) and quantified by Nanodropo, as before. Only RNA which showed as a single, 
clear and un-smeared band was used for cell transfections. RNA was then stored at 
- 
80°C until use. 
5.2.3.2. Visualising DNA or RNA by ethidium bromide gel electrophoresis 
To assess the quality of DNA and/or RNA, following plasmid or RNA preparation, 
these nucleic acid products were subjected to gel electrophoresis. All plastic-ware 
was cleaned with RNaseZap prior to use. 
A 1% agarose gel was made as follows. Briefly, 1g agarose powder was suspended in 
100 ml 1x tris-acetate-EDTA buffer and heated in a microwave oven until liquified. 
This solution was allowed to cool to approximately 40°C, ethidium bromide solution 
was added (final concentration 0.5 µg/ml) and the solution was mixed thoroughly by 
manual swirling motion. While still molten, the agarose-ethidium bromide gel was 
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poured into an 8 cm x 10 cm gel casting tray with gel comb and allowed to cool until 
set. 
Once set, the comb was removed and the gel placed into an electrophoresis tank 
containing further lx tris-acetate-EDTA buffer and ethidium bromide at 0.5 µg/ml. 
The nucleic acid solution of interest (2 µl) was mixed with 10 lal loading dye and 
pipetted into a well in the gel, alongside 5 µI of a molecular weight ladder (0.5-5 kb). 
The gel was then exposed to current at 90 V for 30 minutes, or 100 V for 45 minutes, 
for the separation of DNA or RNA respectively, following which it was examined 
under ultraviolet light for evidence of distinct band(s) of DNA or RNA. See figure 5.4 
for examples. 
5.2.3.3. Transfection of Huh7 cells with subgenomic JFH1 RNA 
Each prepared batch of SGR-Luc-JFH1 RNA and SGR-Luc-GND-JFH1 RNA was tested to 
confirm intact translational and/or replicative efficacy by electroporation into Huh? 
cells and assay of luciferase activity at 4,24 and 48 hours (as described below). After 
preparing and counting a single-cell suspension of Huh7 cells in PBS (as described in 
Chapter 2), the required number of cells was pelleted by centrifugation and 
resuspended at 1 million/100µI in PBS containing 5% sucrose. SGR-Luc-JFH1 RNA 
and SGR-Luc-GND-JFH1 RNA samples were allowed to defrost before use but 
maintained on melting ice. 
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Working quickly, 5 µg SGR-Luc-JFH1 RNA or SGR-Luc-GND-JFH1 RNA and 100 µI cell 
suspension was transferred to each Nucleofector® cuvette. Each cuvette was capped 
and the mixture was nucleofected immediately, using programme T14. The cell 
suspension was then immediately but gently added to pre-warmed 6-well cell culture 
plates containing 2 ml medium 4, using a fine-tipped pipette. Plates were gently 
agitated to distribute the cells evenly and incubated at 37°C in a humidified 5% CO2 
atmosphere. 
Control cell cultures were also prepared for each time point, as follows. 
a. Cell quality control. One well of non-nucleofected Huh7 cells, prepared and 
maintained using standard media (as described in Chapter 2). 
b. Negative control. One well of nucleofected Huh7 cells, prepared as above 
but with no RNA added to the cuvette; nucleofected and maintained as described for 
the test cultures. 
C. Positive DNA-transfected control. One well of nucleofected Huh7 cells, 
transfected with 2 µg pMaxGFP DNA (as suggested by the manufacturer) and 
maintained as described for the test cultures. 
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5.2.3.4. Transfection of human primary hepatocytes with subgenomic 
1FH1 RNA 
Human primary hepatocytes were prepared in suspension as described in Chapter 3 
and sedimented by centrifugation (5 minutes; 50 g; 4°C). Working quickly, the 
supernatant was discarded and the hepatocyte pellet was resuspended in 
Nucleofector® working buffer solution, to produce a suspension with a measured 
concentration of 106 cells per 100 µI. 
For each reaction, 5 µg SGR-Luc-JFH1 RNA or SGR-Luc-GND-JFH1 RNA and 100 µI cell 
suspension were transferred to each Nucleofector® cuvette. The cuvette was 
immediately capped and placed into the machine for nucleofection, in order to avoid 
sedimentation and unnecessary warm ischaemia of the hepatocytes. Following 
nucleofection, using program U14 as described in Chapter 4, the cuvette was 
removed and incubated at room temperature for 15 minutes before proceeding. 
5.2.3.5. Post-nucleofection procedures for transfected hepatocytes in 
monoculture 
Pre-warmed Medium 5 (500 VI) was then added to the Nucleofector® cuvette and, 
working quickly, the entire cell suspension was then gently aspirated by pipette and 
transferred to a collagen-coated cell culture well containing 1.5 ml Medium 5, which 
had been pre-warmed to 37°C. The culture plate was gently agitated by planar 
reciprocating motion, to distribute the hepatocytes evenly, and incubated at 37°C in 
a humidified 5% CO2 atmosphere. 
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Control cell cultures were also prepared for each time point, as follows. 
a. Cell quality control. One well of non-nucleofected hepatocytes, prepared and 
maintained using standard media (as described in Chapter 2). 
b. Negative control. One well of nucleofected hepatocytes, prepared as for the 
test nucleofected cells but with no RNA or DNA added to the cuvette; nucleofected 
and maintained as described for the test cultures. 
c. Positive DNA-transfected control. One well of nucleofected hepatocytes, 
transfected with 4 µg pMaxGFP DNA and maintained as described for the test 
cultures. 
Separate culture wells of were assayed for production of luciferase enzyme at 4,24 
and 48 hours after transfection. If measurement was to occur at or after 24 hours of 
incubation, non-adherent hepatocytes were removed from the monolayer culture 
following overnight incubation, by aspiration of the culture medium and washing of 
the layer with PBS (pre-warmed to 37°C), after which the cultures were incubated 
with medium 6 (prepared as described in chapter 2) until examined as described 
below. 
5.2.3.6. Measurement of SGR-Luc-JFH1 translation and replication in 
monocultured cells 
The luciferase assay kit was prepared according to the manufacturer's instructions. 
Cell culture medium was aspirated from the culture plate wells and the adherent cell 
layer was washed with PBS to remove non-adherent cells and cell debris. Then 
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100 µl of 1x luciferase assay lysis buffer was added and spread over the cell layer 
before pipetting the lysed cell mixture into a Microfuge® tube. Lysates were 
centrifuged at 13000 g for 1 minute and the relative luciferase activity of 40 µl 
supernatant was determined by mixing with 100 µI luciferase reagent in a 
scintillation vial (Hughes and Hughes®; 1116) and assaying immediately in a 
luminometer (Turner® TD-20e; delay 5 s, integration 10 s) to determine the amount 
of light produced. 
A vial containing a mixture of 100 µI luciferase reagent and 40 µI luciferase assay lysis 
buffer was used to calibrate zero response on the machine reading. The amount of 
light produced from, and recorded for, the test samples was assumed to be 
proportional to the amount of luciferase enzyme present in the cells which had been 
lysed. The results are presented in section 5.3. 
5.2.3.7. Post-nucleofection procedures for transfected hepatocytes in 
three-dimensional co-culture 
In order to examine the potential effects of cuboidal morphology and interaction 
with hepatic stellate cells on the expression and replication of the JFH1 HCV replicon, 
three-dimensional spheroid co-cultures were formed using freshly transfected 
human primary hepatocytes. These spheroids were formed as described by Thomas 
et a!. 1711, but with human, rather than rat, hepatocytes. 
Briefly, 106 freshly isolated human hepatocytes which had been electroporated in the 
presence of either SGR-Luc-JFH1 RNA or SGR-Luc-GND-JFH1 RNA, as described in 
5.2.3.3, were placed in a single low-adhesion coated culture well (prepared as 
described in chapter 2), containing 1.2 ml pre-warmed medium 6. A single-cell 
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suspension of 2-week old rat hepatic stellate cells (obtained and cultured as 
described in section 2.2.1) was prepared in medium 6 and adjusted to 1 million cells 
per ml. A volume of 0.3 ml of this suspension, containing 300,000 HSCs, was added 
to the hepatocyte-containing well. The cell solutions were gently mixed, with each 
other and the medium, by planar reciprocating motion and incubated at 37°C in a 
humidified 5% C02 atmosphere. The cell culture medium was not exchanged during 
the subsequent experimental period, as spheroids have been shown to require 
ý711. 
undisturbed physical conditions during the first 48 hours of culture 
5.2.3.8. Measurement of SGR-Luc-JFH1 translation and replication in 
three-dimensional co-culture spheroids of human primary 
hepatocytes and rat hepatic stellate cells 
To measure expression of the transfected replicon, the cell culture medium 
(containing spheroids and non-adherent cells) was aspirated from the culture plate 
wells and pelleted by centrifugation for 5 minutes at 50g. The supernatant was 
discarded and 100 µI of ix luciferase assay lysis buffer was added and mixed by 
pipetting to lyre the cells and cell aggregates. This lysate was then also spread over 
any remaining adherent cells in the culture well before pipetting the lysed cell 
mixture into a Microfuge® tube. Luciferase activity was then quantified as described 
in 5.2.3.6. The results are presented in section 5.3. 
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5.3. Results 
5.3.1. Visualisation of lipid in three-dimensional co-culture spheroids of 
human primary hepatocytes and rat hepatic stellate cells 
A representative image of a spheroid (not transfected with replicon) stained with Nile 
Red is shown in figure 5.5. Large numbers of red-stained lipid inclusions can be seen 
in a number of cells on the surface of, and around the edge of, the spheroid (note 
that Nile Red only fluoresces in a hydrophobic environment 11681 and thus it is not 
excited in either the aqueous cytoplasm or the serum-free, extracellular culture 
medium). Previous work at the University of Nottingham has shown that HSCs 
maintain an extremely slender morphology and activated cytochemical profile during 
spheroid co-culture [711, thus it seems clear that these rounded cells containing the 
lipid inclusions are indeed hepatocytes. 
This provides encouraging evidence that human primary hepatocytes in spheroid co- 
culture with hepatic stellate cells contain intracellular lipid droplets, thus apparently 
fulfilling one of the requirements for HCV infection as described in 1.1.2. and 5.1.2. 
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5.3.2 Transfection of Huh7 cells with subgenomicJFH1 RNA 
For each experiment, the untransfected control cultures showed no visible signs of 
toxicity or contamination, by light microscopy. GFP-protein was observed by UV- 
microscopy in all DNA-transfected controls after 20-24 hours, as described in 
chapter 4. No luciferase activity was detectable in the mock-transfected controls (b), 
thus there was no evidence of unintended contamination of cultures with RNA and 
spectrophotometric light emission was specific to luciferase-transfected test cultures. 
Table 5.1 and figure 5.6 show the results of experiments to transfect Huh7 cells with 
subgenomicJFH1 replicon. These findings essentially confirm the published results of 
other groups (see figure 5.311661) and demonstrate an increase in replicon translation 
for at least 48 hours following transfection with replication-competent mRNA, 
whereas translation of the replication-deficient mutant declined progressively from 4 
hours post-transfection onwards. Three batches of each RNA replicon were 
produced. Figures 5.7 and 5.8 shows that the change in average luciferase 
production, from the 3 batches of the two different types of RNA used, was more or 
less exponential over the 4 to 48 hour period (data for each separate batch showed 
similar curves with similar R2 values to those of the averages). Coincidentally, 
perhaps, the doubling- (t2) or halving-time (t0.5) for luciferase activity in JFH1- or GND 
mutant-transfected cells, respectively, occurred over a period of about 12 hours. 
The pattern of luciferase decrease observed in the GND mutant-transfected cells was 
broadly similar to that shown in figure 5.311661 (note: y-axis in figure 5.3 is 
exponential) but ta. 5 was only about 4h in that particular case. The decrease in 
luciferase activity in GND mutant-transfected cells was presumably due to enzyme 
202 
and/or RNA template loss by degradation during Huh7 cell proliferation. The longer 
to. s seen in the present study may reflect slower rates of cell proliferation and/or 
luciferase degradation, in the particular Huh7 cell batches used. 
The pattern of luciferase increase observed with the JFH1-transfected cells in the 
present study was also broadly similar to that shown in figure 5.3 11661 (note: y-axis in 
figure 5.3 is exponential), in which t2 = 14 h during the first 24 h, although in that 
earlier study a plateau in luciferase production was clearly reached at about 48 h (the 
cut-off time in the present study), possibly due to exhaustion of the nutrient supply. 
The net increase in luciferase (over losses incurred by enzyme and/or RNA template 
degradation) observed in the JFH1-transfected cells presumably reflected replication 
of the RNA template. 
Irrespective of the slight differences between the results of the two studies, the 
results of the present study indicated clearly that the RNA used in subsequent 
experiments was intact, functional and capable of replication as expected and that 
the methodology was working reliably. 
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5.3.3. Translation and replication of the subgenomic JFH1 replicon in 
human primary hepatocytes 
For each experiment, the untransfected control cultures showed no visible signs of 
toxicity or contamination, by light microscopy. GFP-protein was observed by UV- 
microscopy in all DNA-transfected controls after 20-24 hours, as described in 
chapter4. Thus the hepatocytes used appeared to be healthy and capable of 
expressing the foreign protein following electroporation. As expected, no luciferase 
activity was detectable in the mock-transfected monoculture controls (b). 
Table 5.2 and figure 5.9 show the results of experiments to transfect human primary 
hepatocytes with subgenomicJFH1 replicon. 
Overall, baseline (SGR-Luc-JFH1 4 hr average = 0.02 ALU, RSD 143%; GND mutant 4 hr 
average = 0.08 ALU, RSD 109%) and subsequent levels of luciferase expression were 
considerably lower than those obtained using Huh7 cells (SGR-Luc-JFH1 4 hr 
average = 29 ALU, RSD 34%; GND mutant 4 hr average = 21 ALU, RSD 55%). 
Such simplistic comparisons are not really valid, however, because of the numerous 
differences between the cell types. For example, the intra-cellular processes of cell 
lines tend to be subject to less regulation, whilst their proliferative phenotype is likely 
to allow faster recovery from the electroporation insult as well as subsequent 
increase in cell numbers, compared to primary cells. Due to the differences in 
functional phenotype, there is no defined mechanism by which the recovery of 
function of the Huh7 cells (which existed in optimum culture conditions up until 5-10 
minutes before electroporation) can be compared with recovery of function of 
primary hepatocytes (which may have been disrupted from optimum conditions in 
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vivo some 3-6 hours prior to electroporation). Measurement of DNA content, in 
order to quantify cell numbers and thereby determine the luciferase activity per cell, 
would have been problematic due to the multinucleated nature of some hepatocytes 
and was not performed due to the very limited availability of materials and 
experimental time. 
In the absence of these data, it is not clear how much of the difference in luciferase 
expression between the Huh7 cells and human primary hepatocytes was due to 
differing cell numbers (due to electroporation-associated cell death and/or 
subsequent proliferation of the Huh7 cells) and how much was due to a real 
difference in translational efficacy or permissivity between the two cell types. 
As shown in figure 5.9, there appeared to be a tendency for a higher level of baseline 
(4 h) translation of the GND mutant as compared to the replication-competent JFH1 
RNA. However (and unsurprisingly, given the high RSD values), this difference was 
not found to be statistically significant, even when baseline luciferase activity was 
expressed as a function of the amount of RNA added prior to electroporation 
(average for GND mutant = 0.080 ALU/µg; average for JFH1= 0.028 ALU/µg; p=0.15 
by unpaired two-tailed t-test). There is thus no evidence that the low level of 
translation by primary hepatocytes, compared with Huh7s, was associated with 
either the presence or absence of replicative capacity or function of the viral RNA, as 
the level was similarly low for both replication-competent and replication deficient 
JFH1 RNA, at the 4h baseline. 
The luciferase expression data might be taken to show that SGR-Luc-JFH1 expression 
in monocultures of human primary hepatocytes does not, on average, follow the 
same pattern as that found in Huh7 cells, especially as, after 48 hours, luciferase 
209 
activity was almost entirely lost. When the results from all batches were averaged, 
and compared as ratios of baseline levels of translation at 4 hours post-transfection, 
there was an apparent rise in the level of translation of SGR-Luc-JFH1 after 24 hours 
(both with 5 and 10 µg), compared with the replication incompetent mutant. 
However, comparison of the means in this way may be misleading, as some batches 
of primary hepatocytes gave a transient increase in expression whilst others did not. 
In any case, due perhaps to this variability, the average differences were not 
statistically significant (p=0.227 and 0.308, respectively, by unpaired t-test) and 
therefore, if the means are examined, these results provide no evidence that 
replication of the JFH1 replicon occurred in monocultures of human primary 
hepatocytes, between 4 and 48 hours post-transfection. 
As already noted above, the results from individual batches of hepatocytes showed a 
wide variation in the pattern of luciferase expression. Three batches showed a 
decline in luciferase activity at 24 hrs, whereas 2 showed evidence of a transient 
increase at the same time point. This suggests that the presence or absence of a 
transient increase in luciferase expression (and perhaps, therefore, RNA template 
replication), may be highly batch-dependent. Furthermore, it seems that some 
batches of hepatocytes may indeed be permissive for transient replication of the 
SGR-Luc-JFH1 replicon within the first 48 hours post-transfection. Unfortunately, due 
to the small numbers of "permissive batches", meaningful statistical analysis to prove 
this hypothesis is not possible. 
In the case of the replication-incompetent GND mutant, the general pattern of 
decline in luciferase expression in the human primary hepatocytes was very similar to 
that seen in the Huh7 cells. Given that there would have been very little, if any, loss 
210 
of template RNA due to proliferation in primary hepatocytes, this suggests that these 
cells may be better at either eliminating the viral RNA or degrading the luciferase 
than are Huh7 cells (as may be expected in healthy, normal cells with intact innate 
immune responses). Unexpectedly, 3 of the 5 batches of human primary 
hepatocytes, transfected with the replication-competent subgenomic JFH1 replicon 
and maintained in monoculture, also showed this pattern of declining luciferase 
expression. This suggests that some donors' hepatocytes may be more resistant to 
RNA transfection, translation, or replication and/or more able to eliminate the RNA 
template or its resultant protein(s), than those of others. These possibilities will be 
addressed further in section 5.4. 
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5.3.4. Translation and replication of the subgenomic JFH1 replicon in three- 
dimensional co-culture spheroids of human primary hepatocytes and 
rat hepatic stellate cells 
Table 5.3 and figure 5.10 show the results of experiments to transfect 3D co-cultures 
of human primary hepatocytes with subgenomic JFH1 replicon. 
Translation, of both the replication competent and GND-mutant replicons, was again 
low when compared to expression in Huh7 cells but was comparable with that 
observed with the primary hepatocyte monocultures. Unfortunately, constraints of 
experimental time, materials and availability of human tissue meant that sub-optimal 
numbers of replicate experiments were performed and therefore potential statistical 
analysis is limited; however the results are presented for completeness. 
Initially, there was again an apparent, slight translational advantage of the 
replication-deficient mutant over the intact JFH1 replicon, at 4 hours. Although this 
impression might be biased by a particularly high result from one of the two 
experiments (using 10 µg of SGR-Luc-GND-JFH1), it is clear that both batches of cells 
tested in 3D co-culture expressed more luciferase at baseline from the GND mutant 
RNA, in comparison with the replication-competent JFH1 RNA. Furthermore, both 
batches showed a dramatic decline in SGR-Luc-GND-JFH1 expression after 24hrs, but 
an increase in SGR-Luc-JFH1 RNA expression over the same time period. Again 
therefore, there is no evidence that translation was inhibited by the replicative 
capacity of the RNA. 
In a similar manner to luciferase activity in monocultures, detectable expression of 
the transfected RNA was lost by 48 hours post-transfection, for both intact and 
214 
replication-deficient RNA. When expressed as a ratio of the baseline levels of 
translation at 4 hours post-transfection, there was (again) a rise in luciferase 
expression at 24 hours, in cultures transfected with the intact JFH1 replicon. When 
using 5 µg SGR-Luc-JFH1 RNA, this increase was highly significant (159% vs. 3%; 
p=0.003 by unpaired t-test). However, given the low level of replication of these 
experiments, the results must be interpreted with caution and will be discussed 
further in section 5.4. 
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5.4. Discussion 
5.4.1. The lipid content of human primary hepatocytes in three- 
dimensional, spheroid, co-cultures 
Hepatocytes which contain too many lipid droplets are difficult to isolate in vitro due 
to their altered and varying density (as previously described in chapter 3); however, 
some level of lipid storage and metabolism appears to be required for the anchoring, 
transport and packaging of HCV proteins within host cells (1.1.2.1 and 5.1.2). Thus it 
is important to have demonstrated the presence of lipid droplets within the 
hepatocytes on the surface of hepatocyte-HSC spheroids. This observation supports 
the notion that this model is of interest in investigating the pathogenesis of HCV and, 
in particular, may be useful for validation of some of the associations between HCV 
and intracellular lipids which have been demonstrated in the Huh7 cell mode l135,169] 
Ideally, the system would be used with human, rather than rat HSCs. However it was 
not possible to isolate and durably culture sufficient numbers of human HSCs within 
the timeframe of this project, though it may be possible in future studies. 
In future experiments, it will be extremely interesting to examine lipid droplets in 
JFH1- and GND-transfected hepatocytes in monocultures and co-cultures, in order to 
determine whether replicon expression and/or culture conditions, are associated 
with any changes in the amount, and distribution, of lipid in "permissive" cell 
batches. The occurrence, and dynamics, of any lipid transfer between the two cell 
types would also be an intriguing area for investigation in the co-culture system, both 
in the presence and absence of HCV replicons (particularly, perhaps, in the presence 
of a chimeric genotype 3a/JFH1 virus, such as that described by Gottwein et a1.11701) 
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5.4.2. Translation and replication of subgenomiciFH1 RNA 
Replicon systems, and particularly the JFH1 replicons, have previously proven to be 
extremely useful tools for investigating the pathogenesis of hepatitis C. The SGR-Luc- 
JFH1 plasmid that was created using the JFH1 clone offers a simple, yet effective 
means to monitor the level of HCV expression in a cell culture systemt1661. 
Furthermore, as it derives directly from the RNA which is inserted into target cells, 
expression of the luciferase marker gene is not affected by the variables of viral 
attachment, endocytosis or endolysosomal escape. 
In the above experiments, the RNA which was derived from the SGR-Luc-1FH1 and 
GND-JFH1 sequences proved to be stable, and functional, prior to and following 
transfection, when handled and stored under the conditions described above. 
Expression in unmodified Huh7 cells resulted in the expected pattern of RNA 
replication, as shown by the increase in luciferase levels in SGR-Luc-JFH1 transfected 
cells over 48 hours and a corresponding decrease within cells transfected with a 
replication-incompetent sequence. These control experiments also showed that 
nucleofection, and the Nucleofector® kits, were compatible with (and did not inhibit) 
transfection of subgenomicJFH1 RNA. 
However, it is noteworthy that such experiments provide no conclusive evidence that 
the replicon's RNA was replicated within undivided Huh7 cells. The proliferation 
rates of transfected Huh7s were not measured during the present study. Whilst the 
data in table 5.1 imply that, given an Huh7 cell doubling time of 35-40 hours [481, 
relative translation of the replicon increased by around five-fold during this same 
period, it is possible that such an increase (whether due to replication of the 
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transcript or higher rates of translation) was facilitated by the physiological changes 
accompanying mitosis and would not occur in any undivided cells. In other words, it 
is therefore possible that most, if not all, of the increase in luciferase in the Huh? 
cells was due to (or at least facilitated by) cell proliferation. If so, this has important 
implications for the expected pattern of behaviour of the JFH1 replicons in primary 
hepatocytes. 
5.4.2.1. Translation and replication of JFH1 RNA within monocultures of 
human primary hepatocytes 
SGR-Luc-JFH1 mRNA was transfected into freshly isolated human hepatocytes, which 
were then placed into two-dimensional monoculture. In comparison with Huh7 cells, 
the initial average level of luciferase activity at 4 hours post-transfection was 
approximately 100-fold lower, using the same initial numbers of cells and amounts of 
RNA. 
This lower level is to be expected for a number of reasons. Firstly, healthy primary 
cells are likely to have much tighter control of transcriptional and translational 
processes than a tumour cell line which, almost by definition, has lost some of the 
regulation of such functions. Secondly, electroporation has been shown to cause 
significant cell damage and may induce apoptosis in some cases [171); the Huh7 
hepatocyte cell line could be expected to recover from, or resist, such effects more 
robustly than primary cells. Thirdly, HCV replication has been shown to vary in 
extent, depending upon genotype and quasispecies, but previously has been maximal 
only at about 3-5 days after inoculation of human primary hepatocytes1741. In 
addition, the number of HCV copies per hepatocyte may normally be low under in 
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vitro conditions'7S1. Lastly, it has previously been shown that [RES-dependent 
translation is not subject to the same limitations, during the mitotic phase of the cell 
cycle, as cap-dependent translation11 1. Other studies have indeed demonstrated 
that HCV (and its replicons) are translated much more readily in dividing cells than in 
tl'3 
resting or quiescent cells'1'aý 
This evidence clearly indicates that the level of replicon translation should be 
expected to be much higher in a rapidly proliferating cell line than in largely 
quiescent primary cells, due both to the subsequent proliferation of the replicon 
within those cells and to the overall increase in the total number of replicon-bearing 
cells. The findings of previous studies, to investigate replication of serum-derived 
HCV in primary hepatocytes, have been consistent with this hypothesis, generally 
demonstrating very low levels of replication 11481. A lower level of translation and/or 
replication of JFH1 in primary hepatocytes is therefore to be expected and should not 
be viewed as an insurmountable flaw because, although the generation of high levels 
of HCV proteins and/or RNA may be useful for some in vitro investigations of viral 
processes, a primary cell experimental system will offer greater potential insights 
into the balance of factors affecting host permissivity and overall pathogenesis in a 
more in vivo-like situation. 
Untransfected cells produced no measurable luciferase activity, as expected (data 
not shown). However, interpretation of the low levels of luciferase detected in the 
transfected primary hepatocytes remains doubtful, because measurement 
uncertainty was much greater than with the Huh7 cells. Between different 
hepatocyte batches, the levels of luciferase activity at the 4h baseline were found to 
be much more variable than with Huh7 cells, with a further 10- or 50-fold difference 
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between the highest and lowest levels of baseline luciferase activity, produced by 
intact or GND-mutant RNAs, respectively. 
It would have been desirable, had there been sufficient experimental reagents, time 
and opportunity, to have repeated the experiments and reported the relative 
luciferase activity per cell, by determining the DNA content of each cell lysate and 
using this to calculate the number of cells present for each reaction. Due to the 
multinucleate nature of hepatocytes, calibrated standards would have had to be 
created for each individual batch and at each separate time point, using non- 
transfected and mock-transfected cells. This would then have provided some 
extremely useful and detailed information on the amount of cell death occurring due 
to electroporation and the extent to which lower levels of translation in primary 
hepatocytes reflected a correspondingly higher rate of cell death. 
Given that primary hepatocytes are expected to be largely non-proliferating unless 
subject to specific hormonal stimulation in vitro, and that the translational capacity 
of the viral RNA had been proven in the Huh7, the low level of luciferase activity in 
primary hepatocytes may have had several further causes, as follows (i-vii) and as 
shown in figure 5.11. 
i. Firstly, much of the RNA may have been degraded by some aspect of the 
experimental process before or during transfection (figure 5.11a). However, given 
that the reagents and materials were all single-use, certified RNase-free and caused 
no such problem when used for the transfection of Huh7 cells, this seems an unlikely 
explanation. The experimental procedure and timeframes (at least from the point of 
RNA-use onwards) were identical when using either Huh7s or primary hepatocytes. 
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Due to the relatively small yields of RNA from each batch of in vitro transcription, it 
was not possible to re-test every batch to check that degradation had not occurred 
during storage; however batches 2 and 3 were re-tested, by transfection into Huh7 
cells and subsequent luciferase assay at 4 hours post-transfection, and were found to 
give similar levels of activity (>20 ALU) to those obtained when initially screened. 
Thus the RNA preparation procedures were evidently robust and reliable. 
However, if additional experiments had been possible, it would also have been 
desirable to have incorporated control cultures transfected with RNAs encoding GFP 
reporters (both monocistronic and as a fusion gene in a JFH1 HCV replicon), in order 
to determine the proportions of cells transfected. Furthermore, the use of a control 
RNA encoding the luciferase reporter would be more suitable for comparison of 
efficacy with replicon RNA and would provide some quantification of the amount of 
RNA that reaches the cytoplasm without degradation. Unfortunately there was not 
time to produce, test and use such RNA controls during the experimental period of 
this work. 
ii. Secondly, the hepatocytes might have been more permissive for the 
expression of DNA than RNA. The rationale for this would be difficult to explain, as 
DNA must undergo more stages of intra-cellular processing (such as nuclear entry, 
transcription and nuclear export) than RNA, and therefore might be expected to 
result in slower and less efficient levels of transgene expression. A direct 
comparison, based on the transfection of equal copy numbers of a DNA template and 
its own RNA transcript, would be required to investigate this issue further. 
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M. Thirdly, there may have been poor transport of RNA in the cytoplasm of 
nucleofected hepatocytes. It is conceivable that only endogenous RNA is directed to 
the endoplasmic reticulum, or recognised by the ribosomes, of primary hepatocytes 
(figure 5.11b). However, these explanations seem unlikely, given that the successful 
entry and translation of non-host RNA in primary hepatocytes has been reported in a 
number of published studiest133'1'sý 
iv. Fourthly, innate cellular responses of primary hepatocytes may identify and 
remove the transfected RNA before significant translation and/or replication can 
occur. It is thought that the 5'NTR region of HCV RNA has a protective "cap" 
function, thus should have some resistance to intra-cellular RNases. However, it is 
well recognised that the presence of double-stranded RNA usually induces a complex 
process of antiviral mechanisms within the host cell, involving the activation of, for 
example, toll-like receptor 3 (TLR-3) and the subsequent up-regulation of the 
transcription factors nuclear factor KB (NF-KB) and interferon regulatory factor 3 
(IRF-3)1176'1781. These mechanisms result in an increase in type-1 interferon 
production and a TRAIL-induced, pro-apoptotic responsetl""vaý 
Despite this, specific innate anti-viral mechanisms seem unlikely to be activated prior 
to translation of the transfected RNA and the formation of replication complexes. 
Studies of a Huh7-derived cell line have demonstrated that, although a replicon is 
clearly translated at four hours, dsRNA is not detected at this time and its synthesis 
(indicating the start of RNA replication) begins somewhere between the 4 and 24 
hour time points [1791. This observation is consistent with results, obtained using the 
subgenomic JFH1 replicon in Huh7 cells in the present study, showing similar levels of 
luciferase expression in both intact JFH1 and the replication-deficient GND mutant; 
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suggesting that expression at this time is largely due to translation of the original 
RNA. 
However, the possibility remains that, unlike Huh7 cells [2801, primary hepatocytes 
retain expression of TLR-3 and therefore possess more intact and in vivo-like 
responses to dsRNA, through which to repress the overall translational and 
replicative capacity of JFH1. If this hypothesis is correct, it could also account for the 
variability of expression dynamics seen between different batches of hepatocytes, as 
it is highly likely that the efficacy of such responses will vary (as a result of both 
nature and nurture) from person to person and may also be affected by differences 
in the time taken to regain specific functionalities and/or total functional capacity 
post-isolation and in vitro. There is also likely to be spatial and temporal variation of 
these cellular responses within each liver, as a consequence of exposure to nutrients, 
oxygen and insults (whether toxic, infectious or traumatic), which would further 
prejudice the ability of the researcher to replicate results, even within the same cell 
batch. Such variations may seem problematic but, in fact, must be essential to a 
closer understanding of the dynamics of natural HCV infection. 
Interestingly, there is some evidence that the NS3/4 protease complex interferes 
with some aspects of the innate anti-viral response of the host cell and may entirely 
abrogate it in chronically infected cells (181,1821 It may be that innate physiological 
differences, as well as the loss of the RIG1 response, make Huh7 cells more 
permissive than primary hepatocytes to this interference, at least compared with the 
early phases of primary hepatocyte infection by HCV. 
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v. Fifthly, the HCV 5' IRES and/or EMCV IRES may not have high affinity for the 
ribosomes of primary hepatocytes (figure 5.11c). Again, this seems unlikely, given 
that HCV infection becomes well established in vivo and that the EMCV IRES is 
commonly used as a particularly highly active ribosome binding sequence (clearly, it 
functions well in the Huh7 cells). It seems unlikely that ribosomes of primary 
hepatocytes would have a different structure (and hence affinity) to those of Huh? 
cells, but there might be significant differences in transcriptional regulation. Ideally 
then, further RNA controls, driven by each of these IRESs, would have been 
transfected into each batch in order to exclude this possibility. 
vi. Sixthly, human primary hepatocytes may translate replicon RNA, but the 
some of the luciferase enzyme may not be active (figure 5.11d and 5.11e). This could 
occur if the protein was not correctly folded to attain a functional tertiary structure. 
Such folding is mainly dependent on the amino acid sequence of a protein and there 
is ample evidence that the polypeptide develops activity in the Huh7 cells. However, 
the environment in which the protein is formed (and particularly whether it is 
associated with a mainly membranous or cytoplasmic environment) will also affect its 
ultimate conformation so it is possible that cellular factors could be responsible for a 
lack of function. 
Alternatively, the luciferase enzyme may be functional, but simply rapidly degraded 
by primary hepatocytes (figure 5.11f). Interestingly, a study by Garmo et al. showed 
that, although luciferase was functionally expressed following cationic lipid-mediated 
transfection of a non-replicating construct into adherent rat hepatocytes, the levels 
of activity peaked between 3 and 24 hours and declined after 24-31 hourst13o1 
Unfortunately, the data set of that study was limited, and also complicated by the 
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fact that the dynamics of expression varied depending upon the time at which 
hepatocytes were transfected, post-isolation. 
Ideally, in the present study, both hypotheses would have been disproven by 
additional experiments to transfect monocistronic luciferase-bearing control RNA 
(perhaps with the CMV-IE promoter, which had been shown to function during DNA 
transfection) into the primary hepatocytes. The accuracy of measurement of 
luciferase activity could also be improved by using a more sensitive luminometer. 
vii. Lastly, it is possible that the kinetics of HCV replicon expression in primary 
hepatocytes simply differ from those seen in Huh7 cells. A study by Lazaro et aLt82l, 
showed evidence that fetal hepatocytes transfected with RNA derived from an 
infectious genotype la replicon released HCV virions in a cyclical manner post- 
transfection (see figure 5.12). This variation was independent of the means of cell 
entry and it is possible that it resulted from fluctuating levels of replication and/or 
translation. 
Notably, HCV virion production was undetectable at 48 hours, having been readily 
measurable at 24 hours. This is consistent with the results of the present study. 
Furthermore, this fluctuation was noted to occur with variable magnitude and timing 
between different experiments and hepatocyte batches and was even absent on 
some occasions (821. It therefore seems likely that the host cell physiology strongly 
influences these fluctuations, although the underlying mechanisms involved and the 
basis of the fluctuations remain unclear. Thus it seems very likely that certain 
aspects of primary hepatocyte physiology, and their interactions with viral processes, 
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could well be the reason for the differing levels of expression between hepatocyte 
batches, observed in the experiments described here. 
An interesting observation, although it did not reach statistical significance in these 
results, was the apparent tendency for the replication-incompetent mutant to be 
expressed in primary hepatocytes (in mono- or co-culture), initially, at higher levels 
than the intact clone. A difference in baseline translational capacity or permissivity 
has not been reported in previous studies using the Huh7 cell line and, during the 
above experiments, there was no statistically significant difference between average 
baseline luciferase activities in primary hepatocytes following transfection with 
SGR-Luc-JFH1 or SGR-Luc-GND-JFH1(p = 0.409). However, if there was a mechanism 
whereby dsRNA was subjected to an interferon- or apopotic- based response, it 
would be logical for cultures containing the replication-defective GND mutant, and 
therefore not producing dsRNA as a consequence of replication of the replicon, to 
demonstrate an advantage (over those transfected with SGR-Luc-JFH1) in their 
overall levels of replicon translation, while the baseline RNA levels remained similar. 
In this scenario, as or when an increase in RNA levels began to occur in cells 
transfected with replication-competent RNA, and cellular mechanisms began to 
remove RNA from the cytoplasm of all transfected hepatocytes, the temporary 
advantage of the replication-defective GND mutant would be quickly lost. 
After 24 hours, some batches of primary hepatocytes clearly demonstrated increased 
expression of the replication-competent replicon, as compared with the replication- 
deficient mutant (and compared with the corresponding baseline levels of expression 
at 4 hours). Although experimental numbers in the present study precluded 
statistical analysis of the findings from "permissive" versus "non-permissive" batches, 
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it would be of great interest to carry out further experiments, with a greater number 
of different hepatocyte batches, and for durations of at least 10 days in both mono- 
and co-culture systems. Such experiments are essential in order to explore the 
consistency of results from "permissive" batches and record any reappearance of 
expression, as described by Lazaro et al. and shown in figure 5.121821. Simultaneous 
investigations could be made of the levels of viability, cell numbers and hepatocyte- 
specific function of these batches, over time, in order to obtain some basic 
comparative data from "permissive", versus "non-permissive", primary hepatocytes. 
Naturally, this would require the availability of large amounts of transfection 
reagents and liver samples and neither were available during the experimental 
period described here. Variation of permissivity for HCV replication is clearly seen in 
unselected (heterologous) Huh7 cell lines, as described in 5.1.2., but is somewhat 
complicated by the proliferation of the cell population. The relative lack of 
proliferation of primary hepatocytes offers a useful opportunity to explore the basis 
of permissivity for HCV replication further. 
5.4.2.2. Translation and replication of JFH1 RNA within three-dimensional 
co-cultures of human primary hepatocytes 
In a limited number of experiments, replicon-transfected human primary 
hepatocytes were grown in three-dimensional co-cultures with rat hepatic stellate 
cells (HSCs). It had previously been shown that HSCs actively organise hepatocytes 
into structured aggregates known as spheroids [721, in which a number of in vivo-like 
ultrastructural features are apparent, as described in Chapter 1. These spheroid co- 
cultures maintain higher levels of hepatocyte-specific function than monolayer 
cultures 170,721 and, furthermore, may be able to display cell-to-cell signalling and 
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responses, via the HSCs, including responses to infectious, inflammatory or fibrotic 
stimuli. As explained in Chapter 1, this model system therefore seems to offer an 
excellent experimental platform for investigating the requirements, and effects, of 
HCV replication, if it occurs in it. Furthermore, a previous study has shown that the 
efficiency of production of infectious HCV from Huh7 cells was enhanced when the 
11621 
cells were cultured in three-dimensional aggregates. 
In the present studies, subgenomic RNA of JFH1 was transfected into primary 
hepatocytes which were subsequently co-cultured to form spheroids. The pattern of 
luciferase expression, reflecting translation and replication of the replicon, was 
similar to that observed in hepatocyte monocultures. Overall, there was no 
statistically significant difference between the average absolute levels of luciferase 
activity in monocultures or co-cultures at 4,24 or 48 hours post-transfection. On 
average, however, co-cultures yielded a significantly greater increase in expression of 
the replication-competent RNA, compared to monocultures, at 24 hours post- 
transfection. Although these findings must be interpreted cautiously due to the very 
small numbers involved, they indicate either that some replication of JFH1 occurs in 
hepatocyte-HSC co-cultures, or that there was an excess of translation of luciferase 
over its degradation, during the first 24 hours. There are currently no published 
reports of replication or translation of either wild-type HCV or HCV replicons in 
hepatocyte-HSC co-cultures, therefore this result will be of immense interest if 
validated by future studies. 
Furthermore, 100% (2/2) of the cell batches tested in co-culture displayed evidence 
of this transient increase in luciferase expression at 24 hours, whereas only 40% (2/5) 
of those batches tested in monoculture showed any such increase. Thus these small 
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numbers of experiments suggest that it is likely to be misleading to analyse the 
results from all hepatocyte batches together, as above. It is clear from the individual 
batch results in tables 5.2 and 5.3 that the hepatocytes from the first two batches 
(18 and 19) produced similar (declining) patterns of replicon expression with both 
SGR-Luc-JFH1 and its GND mutant; that is, there was no evidence of replication of the 
replicon, nor or of continued significant translation of the replicon, after 4 hours. In 
contrast, another two batches (20 and 26) of primary hepatocytes transfected with 
SGR-Luc-JFH1 and grown in 3D co-culture behaved quite differently, showing a 
considerable increase in luciferase activity between 4 and 24 hours post-transfection. 
Quite surprisingly, although the relative levels of luciferase activity were low, the 
luciferase doubling time (t2) was broadly similar to that found for Huh7 cells. In the 
case of one batch (26), this increase was followed by a decline to below baseline 
after 48 hours (a corresponding measurement is not available for the other batch). 
This indicates that the replicon was being either replicated or translated (or both) 
within the cells in 3D co-culture for the first 24 h and that, thereafter, both the 
replicon and the luciferase were being eliminated. 
Thus, the evidence suggests that, in certain primary hepatocyte populations, and for 
reasons that remain unclear, the replicon was eliminated and the luciferase was 
degraded almost immediately; whereas other batches showed some evidence of 
transiently increased translation and/or replication at 24 hours before a similar, rapid 
process of elimination or degradation ensued. This is an extremely interesting (if 
tentative) observation, and is consistent with the hypothesis, described in 5.4.2.1 and 
touched upon by Lazaro et a!. 1821, that permissiveness for expression and/or 
replication is strongly influenced by heterologous aspects of the host cell phenotype 
and are not consistent for all human primary hepatocytes. 
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The data from the present study provide conflicting evidence as to whether or not 
three-dimensional co-culture influenced the manifestation of this "phenotype" (in 
those cells where it appeared to be present). Essentially, one batch (21) produced 
inconsistent results between the hepatocytes in monoculture and those in three- 
dimensional co-culture; whereby the former demonstrated a decline in luciferase 
activity after 4 hours and the latter showed a transient increase at 24 hours. There 
was no such inconsistency between culture systems using batch 26. These 
apparently discrepant results raise further interesting questions regarding the 
physiological, host cell determinants of HCV translation and replication; but 
unfortunately, due to the limited amount of data, do little to allow such questions to 
be answered. 
The potential inequalities in nutritional status between hepatocyte mono- and co- 
cultures, due to necessary differences in type and supply of cell culture media, 
further complicate the comparison of replicon expression between these two 
systems. If anything however, the hepatocytes in co-culture might have been 
expected to be less able to sustain metabolically-demanding procedures, such as 
translation and replicon processing, having had a reduced supply of both lipid and 
glucose post-transfection in comparison to monocultured cells and having been 
subject to nutrient competition from the HSCs. The fact that this hypothesis is not 
borne out by the relative measurements of replicon expression in each system thus 
provides a further, tentative, indication that co-culture with HSCs is advantageous in 
this context. 
Interestingly, a very recently published study from Buck et 01.11831 has reported on the 
infection of primary human hepatocytes, in a layered 3D co-culture with a mixture of 
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non-parenchymal liver cells, with serum-derived HCV. Their system appears to have 
produced more robust replication and infection than previous studies of primary 
hepatocytes in monoculture 1751 and there was less variation between batches (33 of 
36 were permissive to infection by high titres of serum-derived HCV). Unfortunately 
there was no comparison of the same batches in monoculture, to determine whether 
it was the culture conditions alone that increased the apparent permissiveness of the 
hepatocytes. It was also, perhaps, advantageous that these workers had the facility 
to use infectious virus and thus avoid the cellular damage caused by electroporation, 
although the use of serum-derived virus (with its numerous quasispecies) may be 
disadvantageous for future detailed analyses and comparison with the evidence 
provided by studies in cell-lines. 
However, this encouraging evidence reasserts the need to gain more experimental 
data using the present experimental models to compare the permissiveness of cells 
from the same source patient and isolation procedure in monoculture and in co- 
culture. Although the current data set is too small for meaningful statistical analysis, 
it can be seen from tables 5.2 and 5.3 that 3D co-cultures produced higher (absolute) 
levels of luciferase expression than the 2D monoculture equivalents, from both intact 
replicon and the GND mutant, at baseline and (in 3 of 4 cases) after 24 hours. This is 
consistent with the finding, of Buck et al., that three-dimensional culture enhances 
HCV virion production in primary hepatocytes and suggests that this may be due to 
increased levels of translation of HCV RNA. Subsequently, between 24 and 48 hours 
post-transfection, the rate of decline of luciferase activity in 3D co-cultures tended to 
be greater than that seen in 2D monocultures, suggesting that the former model may 
retain more effective anti-viral mechanisms than the latter. 
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Thus, taken together, these data (from both the present study and that of Buck et 
01(1931) show that interrogation of the three-dimensional co-culture system may be 
extremely useful for determining the modulating factors of HCV expression in 
primary hepatocytes. 
5.4.2.3. Summary of the expression and replication of the JFH1 clone within 
human primary hepatocytes 
In summary, the subgenomic JFH1 replicon has been expressed, at low level, in 
human primary hepatocytes. Although there was evidence of translation of replicon 
at baseline and, in some hepatocyte batches, for 24 hours post-transfection, there 
was no statistical proof that replication occurred, consistently, within the first 48 
hours of culture in the cells. Further experiments, incorporating additional controls, 
are required to determine the relative kinetics of RNA degradation, translation and 
replication, as well as the rate of luciferase clearance, in order to draw reliable 
conclusions. However, there was evidence of increased expression of the luciferase 
reporter gene in some individual batches of cells at 24 hours, suggesting either that 
some replication may have occurred, or that there was a temporary excess of 
translation over luciferase degradation. Thus there is evidence of major differences 
in permissivity for HCV translation and/or replication between (and perhaps, also, 
within) different batches of human primary hepatocytes. This is, potentially, a very 
important finding and further investigation of the factors which determine the 
permissivity (or otherwise) of different batches of cells is likely to be essential for 
understanding the in vivo pathogenesis of this virus. 
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Due to the limited opportunities to perform these experiments, only small numbers 
of data were obtained. it would be imperative to corroborate these findings by 
repeating these experiments, incorporating additional control steps to demonstrate 
that RNA, and the luciferase gene, can be efficiently transfected into and expressed 
by human primary hepatocytes under these culture conditions. It will be most 
important to perform more experiments with parallel monoculture and co-culture of 
transfected hepatocytes, in order to explore further any differences in the replicon's 
behaviour between these two models, and any variation in the differences from 
batch to batch of hepatocytes. Lastly, it would be highly desirable to transfect more 
cells on each occasion, if possible, in order to be able to follow the dynamics of 
replicon expression over a longer time period and thus determine whether 
expression is truly fully abrogated after around 48 hours or whether cyclical 
expression can be detected during more prolonged culture. 
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6. SUMMARY DISCUSSION 
Infection with the hepatitis C virus is causing an increasing burden of hepatic disease, 
worldwide. Current drug treatments are prolonged, costly and often unsuccessful. 
As a relatively recently characterised virus, and one which is extremely difficult to 
study in non-human animals or cell-cultures, there are still many aspects of its 
pathogenesis which remain unclear. Newly developed replicating clones of HCV have 
now enabled more versatile and clinically relevant models of HCV infection to be 
developed. However, animal models remain scarce and/or imperfect, while almost 
all in-vitro research is performed using a neoplastic cell line. The opportunity to 
optimise two- and three-dimensional model systems, containing healthy, adult 
human primary liver cells, in which to investigate the replicative JFH1 clone of HCV, 
formed the basis of the experimental work described in this thesis. 
There were a number of challenging aspects to this project. The relatively diverse 
nature of the aims necessitated synchronous development of several, very different, 
sub-projects. The methods for isolation of hepatocytes, and the protocols for their 
transfection, required considerable methodological development to ensure that the 
experimental procedures were sufficiently well-characterised and robust before they 
could be applied for use in pursuit of the overall aims of the project. 
The rationale for, and experimental work leading to, a fully optimised protocol for 
isolating human primary hepatocytes under local conditions has been presented in 
chapter 3. This methodological development, although not broadly novel to the 
scientific community, was essential for almost all the subsequent work carried out 
during this project and presented in the later chapters. 
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The requirement for human liver tissue presented considerable practical difficulties. 
Although a number of (at least partial) methods for isolating hepatocytes from 
human liver tissue have been published, important details have often been omitted 
from such papers. In addition, the simple fact that the outcome of the procedure is 
highly dependent on the user, location and the tissue sample itself make local 
optimisation an essential and lengthy prerequisite for any subsequent experiments. 
Obtaining source tissue samples was limited by the number of liver resection 
operations carried out, as described in chapter 3. Numerous factors led to the 
cancellation of operations (for example: patient fitness; availability of suitable post- 
operative care; or the arrival of more urgent cases). Once operations had begun, 
further problems often limited the chances of obtaining suitable tissue (for example: 
inoperability leading to termination of the procedure; unexpected distribution of 
tumour(s) within the resected specimen; destruction of the tissue (or its vasculature) 
by surgical techniques such as radio-ablation; or unintentional mishandling of the 
tissue by theatre staff). Thus, a total of only 27 specimens of tissue were obtained 
during this project, with which to optimise the methodology and investigate the 
research questions. 
In addition to the sporadic, unpredictable and, above all, limited supply of tissue 
samples, the physiological variability of the specimens obtained meant that 
quantitative (and perhaps even qualitative) results were seldom truly comparable, 
despite every effort to minimise any avoidable variation. From a practical 
perspective, liver tissue was most usually conveyed to the laboratory after a very 
lengthy surgical procedure. This generally meant that although preparation for 
receiving the tissue would have started at the beginning of the day, the process of 
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extracting the hepatocytes by perfusion was usually begun late in the working day or 
evening. The entire procedure of perfusion and isolation took at least 3-4 hours 
before secondary experiments could begin. Media exchanges and/or first endpoint 
evaluations were usually required a further 2-4 hours later. Thus secondary 
experiments, to use the cells obtained from the tissue sample, were confined to an 
unpredictable and problematic schedule. This challenge was further exacerbated by 
the susceptibility of hepatocytes to rapid degeneration during any delay. In the 
absence of a highly effective means of cell or tissue preservation, these factors 
limited the opportunity for, and potential scope of, downstream experiments, 
despite the usually high total numbers of hepatocytes isolated when human tissue 
was available. 
Both rat and human primary hepatocytes were successfully transfected in vitro, as 
described in chapter 4. Although transfection of rat hepatocytes using a cationic 
polymer resulted in only low level expression of a transfected plasmid, both rat and 
human hepatocytes were efficiently transfected by nucleofection. The validation of 
this second method presents numerous secondary opportunities to use human 
hepatocytes (whether in monoculture or co-culture) for a variety of future studies. It 
would be useful to perform prolonged studies of cell viability and differentiated 
hepatic function on transfected cells, in the future, to ensure that these 
characteristics remain maximised following nucleofection. 
Nucleofection offered much greater efficacy and efficiency, in comparison to the 
cationic polymer, PEI, and also greatly reduced variation of those parameters 
between experiments, at least in rat hepatocytes. This is an extremely valuable 
advantage when using target cells which are subject to such unavoidably high levels 
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of biological variation at source. The ability to nucleofect cells immediately after 
isolation is helpful, as it enables transfected cells to be placed into co-culture with 
untransfected cells, such as HSCs. Although the nucleofection technique results in 
loss of viability in a significant proportion of cells, the fact that the cells remain in 
fluid suspension would also allow dead cells to be extracted prior to culture, by low- 
speed centrifugation, if required. Alternatively, there are now some different 
formulations of PEI which are conjugated with galactose, in order to improve specific 
interactions with hepatocytes via the asialoglycoprotein receptor11M'1851, and thus 
have been reported to offer improved transfection efficacy in the primary 
hepatocytes of some species. 
Finally, in chapter 5, the results of experiments to examine the capacity of the JFH1 
clone to replicate within in vitro primary hepatocytes have been presented. The JFH1 
replicon showed much lower levels of reporter gene expression in human primary 
hepatocytes, in comparison to Huh7 cells. This is to be expected, due to the 
physiological and physical differences between the cell types, and may suggest that a 
higher level of translational regulation and/or innate intra-cellular immunity persists 
in the primary cells. 
Interestingly, there was a high level of variation, in both the amount and temporal 
profile, of reporter gene activity measured between different batches of 
hepatocytes, suggesting that the permissiveness of hepatocytes for expressing the 
replicon following electroporation is influenced by some physiological property (or 
properties) of the host cell. Further experiments to investigate the factor(s) 
influencing this variation will be extremely interesting and should examine possible 
correlations with the clinical and demographic details of the hepatocyte donors 
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(which was not possible during the present study and for which additional ethical 
approvals would be required), as well as assessments of the viability and function of 
the cells during culture. In addition, it may be interesting to examine whether the 
permissiveness of the hepatocyte batch correlates with the lipid content of the cells 
(both before and during 2D and 3D culture). 
There was also evidence of a temporary rise in reporter gene expression, which may 
in turn indicate an increase in RNA translation (and possible replication), in certain 
batches of hepatocytes. This occurred both in monocultured hepatocytes and in 
those placed into three-dimensional co-culture with hepatic stellate cells. The latter 
model was more likely to show increased reporter gene expression at 24 hours, but 
also tended to show an increased reduction of expression at 48 hours. Due to the 
small number of experiments, it remains unclear whether co-culture may enhance 
the expression and/or replication of HCV in primary hepatocytes and this is 
potentially an extremely interesting area for further work. The possibility that three- 
dimensional co-culture might better preserve the intra-cellular anti-viral responses of 
hepatocytes is also an exciting, and important, area for future study. 
Due to the limited availabilities of both human hepatocytes and transfection kits, at 
the time these experiments were carried out, sub-optimal numbers of experiments 
were performed and it would be desirable to carry out further work to validate these 
results. In particular, it would be important to repeat the experiments and 
incorporate two further controls. Firstly, an mRNA sequence bearing the luciferase 
marker gene only, in order to confirm that luciferase can be functionally expressed 
from a transfected RNA sequence in each batch of cells. Secondly, it would be 
helpful to transfect some cells in each batch with an mRNA sequence bearing the GFP 
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gene, in order to determine the numerical efficacy of RNA transfection for each batch 
of cells. Between them, these two additional controls would confirm that RNA can 
be successfully transfected into, and expressed by, each of the target cell batches. 
Lastly, the transfection of a luciferase-bearing DNA plasmid under the control of a 
switchable (e. g. Teton or Tet-off) promoter, would allow some measurement of the 
dynamics of luciferase degradation following translation and thus help to determine 
the relative contribution of synthesis and degradation to the overall levels of 
luciferase activity seen within each batch of hepatocytes. 
Further work could then proceed to examine the expression of the JFH1 replicon in 
both mono- and co-cultured human primary hepatocytes. Based on the recent 
evidence published by Lazaro et al. 1821, and given that human hepatocyte 
nucleofection kits are now freely commercially available, it would be prudent to 
extend the experimental period to examine the expression of the replicon over a 
period of at least 10 days. It would also be possible to transfect some cells with RNA 
generated from the pSGR-Luc-GFP-JFH1 plasmid, which encodes the fluorescent 
marker GFP in addition to the luciferase enzyme. Use of this plasmid would allow 
measured JFH1 expression (quantified by luciferase activity) to be normalised on the 
basis of overall transfection efficacy (quantified by GFP expression) for each batch, 
and thus allow easier and more robust analysis when summarising inter-experiment 
results. 
The possibility that the dynamics of JFH1 survival and expression are different in co- 
cultured primary hepatocytes, as compared to mono-cultured cells, (suggested by 
the present study and by Buck et al. (183I) is intriguing. There are several possible 
reasons for such a discrepancy to occur. Firstly, it has been demonstrated previously 
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that hepatocytes which are maintained in organised three-dimensional spheroids by 
co-culture with HSCs retain higher and more durable levels of hepatocyte-specific 
physiological functions 17°721. It would be logical to suppose that this relative increase 
in function, compared to two-dimensional mono-culture of primary hepatocytes 
from the same batch, extends to the overall translational capacity of the cells. 
Furthermore, it is possible that the HSC cell fraction, which develops an activated 
phenotype during in vitro expansion prior to co-culture, responds to the presence of 
newly isolated and transfected (and thus damaged) hepatocytes by creating a 
cytokine-led proliferative environment. A number of studies have shown that the 
expression of IRES-dependent genes is increased in dividing cells 133,1861; therefore 
proliferating hepatocytes would be expected to manifest a relative increase in 
transfected replicon expression. These hypotheses should be investigated in future 
studies to characterise the system. 
Ideally, it might be possible to identify proliferating hepatocytes (for example, using 
the thymidine-analogue 5-bromo-2'-deoxyuridine (BrdU) and a fluorescent anti-BrdU 
antibody) and to distinguish the replicon-expressing cells (for example, using a 
replicon carrying the NS5A-GFP fusion protein, as shown in figure 5.2C). The 
occurrence and intensities of both markers could then be measured at various time 
points using fluorescence-assisted cell sorting, to differentiate between (and provide 
a relative measure of) replicon replication occurring without cell division and 
replication occurring as a consequence of cell division. If necessary, hepatocyte 
proliferation could be induced artificially, using hormonal additives such as 
hepatocyte growth factor in the culture medium, in order to facilitate this. 
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However, as HSCs have been shown to maintain hepatocyte-specific functionst70721, it 
might also be expected that HSCs would maintain, and even stimulate, the intra- 
cellular interferon response in co-cultured hepatocytes, and thus result in faster 
clearance of replicon RNA and proteins (as may have happened in the present study). 
Closer examination of the differential dynamics of HCV replicon expression in the two 
culture models will therefore be of great interest, even if translation and/or 
replication is confirmed as not being sustained. RNA-interference studies, for 
example via co-transfection of the JFH1 replicons with anti-RIG1 or anti-IRF-3 RNAs, 
could elucidate the extent and level to which the interferon response occurs in each 
model. Future studies, perhaps using micro-arrays to identify any molecules 
associated with altered HSC-hepatocyte cell signalling during JFH1 expression, may 
then also be indicated. 
Unfortunately, the lengthy and challenging nature of the methodological 
optimisation required during this work meant that it was not possible to achieve the 
final aim of the project (see section 1.4) within the time available. Although it was 
disappointing not to have been able to make any meaningful measurements of 
hepatocyte function and viability in the presence of JFH1, the development of both 
the mono- and co-culture systems for human primary hepatocytes has, at least, 
facilitated the conduct of such studies in the future. 
j 
It may also be noted, from chapter 1, that the ultimate aim of the project had been 
to use the full length, infectious JFH1 clone to infect primary human hepatocytes. 
Containment level 3 facilities would have been required for this work. Although a 
considerable amount of time was spent in preparing a containment level 3 facility 
and gaining the necessary approvals for this work, ultimately, full approvals from HSE 
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and the University Safety Committees were not confirmed in time to carry out 
meaningful numbers of replicated experiments with infectious virus. This was a 
disappointing, but ultimately unavoidable, outcome of many months (>18) of 
preparation. The Standard Operating Procedures and Risk Assessments developed as 
part of the current project and designed for use of the infectious clone are now in 
use by other researchers at the University and copies are appended in Appendix 8.3. 
In summary, methods have been developed to allow HCV replicons to be transfected 
into primary human hepatocytes, for expression in two different culture systems. 
Both systems expressed the JFH1 replicon at much lower levels than Huh7 cells, as 
expected (discussed further in 5.4), but further experiments are required to 
determine whether human hepatocytes are truly less permissive for the clone; and, if 
so, why this might be. These studies have the potential to illuminate important 
mechanisms of innate resistance to HCV infection and how they may be modulated 
and, ultimately, enhanced. Furthermore, the viral mechanisms of immune evasion 
and extrinsic or intrinsic means for their down-regulation could also be investigated. 
It is unlikely that this model can be used in place of Huh7 cell cultures for routine 
viral culture experiments. There is simply insufficient opportunity to obtain human 
liver tissue, and thence cells, for such volumes of work. It is also of note that the 
materials used (in particular, the commercial digestion buffer and nucleofection kits) 
are relatively expensive. However, there certainly appears to be sufficient evidence 
to justify the use of human primary hepatocytes for further investigation of JFH1 and 
other HCV clones. The hepatocyte mono-culture model will be useful for 
comparative work during characterisation of the co-culture model and may also be of 
use for the intermediate validation of results obtained through use of HCV replicons 
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and/or infectious clones in Huh7 cell monocultures. The hepatocyte-HSC co-culture 
model, which is functionally more representative of in vivo liver cells, is likely to offer 
a better platform for such validation in the future and also offers an important 
opportunity to investigate the interactions between HCV replication and innate 
immune and inflammatory responses. Although working with these models is 
challenging, they have enormous potential to provide unique insights into the 
pathogenesis of HCV. 
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8. APPENDICES 
8.1. Appendix 1- Patient information sheet and consent form 
The following pages show the patient information sheet and consent form for 
donation of liver samples to the present study. 
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kw; J Queen's Medical Centre Nottingham hy/Iff 
University Hospital NHS Trust 
PATIENT INFORMATION SHEET 
Study Title: Enhancing the use of human liver cells within in vitro models of disease and drug 
metabolism. 
Investigators: Mr I. J. Beckingham, Professor K. Shakesheff, Mr J. S. Hammond, Dr L. I. Dexter. 
You are being asked to take part in a research study. Before you decide to contribute, it is 
important for you to understand: 
1. Why the research is important? 
2. What it will involve? 
3. What are the benefits? 
Please take time to read the following information and to discuss it with your surgeon before 
making a decision. If you are willing to take part, you will be asked to sign a consent form and 
given a copy to keep. 
What is the purpose of this study? 
The liver has many important functions within the body. Researchers use liver tissue to study 
these functions and to find better ways of treating disease. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part you are still 
free to withdraw at any time and without giving a reason. A decision to withdraw at any time, 
or a decision not to take part, will not affect the standard of care you receive. 
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What will happen to me if I decide to take part? 
You are about to undergo surgery to remove a diseased segment of your liver. The gallbladder 
is also sometimes routinely removed during this operation. Once the surgery has taken place 
and the pathologist has examined the sample the left over tissue is usually destroyed. 
What we are asking you to do is give your consent so that the remaining tissue can be used in 
research, and in doing so benefit patients of the future. The tissue would be treated as a gift; 
at no point will there be any financial benefit to you from its use. 
It is important for you to understand your decision will not affect your treatment in anyway 
and that we do not remove any additional liver or gallbladder tissue for the research. In 
addition, none of the tissue used in the research will be used for the development of cell 
lines. 
What do I have to do? 
If you do decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form. The decision to take part in this research will not affect the surgery you 
are about to undergo. 
What are the possible disadvantages and risks of taking part? 
Taking part in the study will not affect the surgery you are about to undergo. The risks and 
benefits of liver surgery will have been discussed in detail with you in clinic prior to signing 
the consent form. 
What are the possible benefits? 
There will be no direct benefit to you, but taking part in this study means that you will help 
patients of the future, by aiding in the development of new treatments. 
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What if new Information becomes available? 
The tissue that is removed will be utilised in research, but will not provide any additional 
information about your disease or its further treatment. You will not be informed of any tests 
performed on the tissue. 
Will my taking part in this study be kept confidential? 
All information resulting from you taking part in the study will be anonymous and known only 
to those conducting the research. The study records are entirely confidential and will not be 
available to anyone else. In all instances your confidentiality will be maintained in accordance 
with the 1998 Data Protection Act. 
What will happen to the results of the research study? 
The sample of tissue that you donate will be processed at the Queens Medical Centre and 
transported to The Department of Pharmaceutical Sciences, within the University of 
Nottingham and the University of Nottingham Medical School at Derby. 
Results of the study will be published in a scientific journal. You will not be identified in any of I 
these reports or publications. 
Who is funding the research? 
The research is being funded by the Engineering and Physical Sciences Research Council 
(EPSRC), the Fund for the Replacement of Animals in Medical Experiments (FRAME), the 
University of Nottingham and the Derby Hospitals NHS Foundation Trust. 
Who has reviewed this study? 
The study has been reviewed by the Nottingham Research Ethics Committee. 
If you have any further questions about the study please contact Mr John Hammond, who can 
be accessed via Mr I. J. Beckingham's secretary (tel. 0115 9249924 ext. 36753). 
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Queen's Medical Centre Nottin9ham 
University Hospital NHS Trust 
Place patient 
label here 
LJ 
CONSENT FORM 
Study Title: Enhancing the use of human liver cells within in vitro models of diseases and 
drug metabolism. 
Please ask the patient to complete the following: 
Have you read and understood the patient information sheet? Q 
Have you had an opportunity to ask questions and discuss the study? Q 
Have you received satisfactory answers to all your questions? Q 
Have you received enough information about the study? Q 
Do you understand that you are free to withdraw from the study 
at any time? Q 
without giving a reason for withdrawing? Q 
without affecting your future medical care? Q 
I agree to take part in the study Q 
Patient name 
........................................... 
Signed 
........................................... 
Date 
........................ 
Who explained this study to you? 
..................................................... 
Signed 
........................................... 
Date 
........................ 
263 
8.2 Appendix 2- Plasmid maps and information 
Plasmid map of gWizGFP, courtesy of Aldevron LLC: 
Xhol5418 adeI 183 Msc 1245 
Xma 15144 Nde 1 569 
Pvu 15019., = 
Kan' 
.. 
Sac 11988 
,. r CMVprom+intr 
Stu 14394 gWIZ-GFP 
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ORI 
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/"\ 
.M sc 
12066 
Nde12126 
BamHI 2615 
pCMV + Intron 245-1864 
GFP 1895-2614 
PoiyA 2626-2657 
pUC Od 
Ken Resistance 4637-5452 
Sequence available at: http: //www. aldevron. com/gWiz%20GFP. txt 
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Plasmid map of pMaxGFP, courtesy of Amaxa Biosystems: 
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Accessed from: http: //digital. sabanciuniv. edu/tezler/etezfulltext/aksoyiarhi. pdf 
pma xG FP 
. 
gcc 
(3486 bp) 
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Plasmid maps of pSGR-Luc-JFH1 and pSGR-Luc-GND-JFH1 are unavailable. 
Their construction is described by Targett-Adams et al. 
(1661 
The sequence of the original JFH1 virus was described by Kato et a!. 1561 
Sequence data for the JFH1 clone is available via Genbank (accession no. AB047639). 
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8.3. Appendix 3- Containment Level 3 Laboratory documents 
The following pages contain the protocols and risk assessments for working with the 
full length JFH1 replicon, at containment level 3, which were designed and written as 
part of the work of the present study. 
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8.3.1. Huh7 nucleofection with full-length HCV replicons 
Outline: This method allows transfection of full-length HCV replicons into Huh7 cells. 
Method: 
Preparation in CL3 suite (no risk of HCV infection): 
o warm PBS, PBS 5% sucrose and Huh7 media 
o aliquot media into culture plates and pre-warm in the incubator at 37°C 
o label cuvettes as required 
o transfer RNA aliquot to C13 facility from 
-80°C freezer 
o transfer Nucleofector device into MSC 
Cell preparation in CL2 facility (no risk of HCV infection): 
o trypsinise cells into a single cell suspension 
o centrifuge required number of cells at 1300rpm (in D36) 
o wash with PBS and centrifuge again 
o transfer to CL3 suite 
Nucleofection of Huh7 cells (potential very low risk of HCV infection after nucleofection): 
o resuspend cells at lm/100ul in PBS-sucrose 
o transfer RNA to cuvettes and add 100ul cells 
o nucleofect IMMEDIATELY on T14 and add IMMEDIATELY to prewarmed media in the 
plates 
o distribute evenly and return to incubator at 37°C 
Hazards: 
Full-length replicons contain all the necessary genes to produce infectious HCV particles, once 
transfected into permissive cells such as Huh7s. Genome replication has only previously been 
reported from around 12hrs post-electroporation, and detectable levels of virus in cell culture 
media have only been reported from around 24hrs post-electroporation, thus the likelihood 
of encountering infectious virus during this procedure is very low. Note that there is always a 
possible low-level biological hazard (e. g. from unidentified viruses) when working with cell 
lines and cell culture media. 
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Risks of HCV infection: 
Production of infectious virus is only possible after cells have been nucleofected. Particular 
care must therefore be taken when opening cuvettes and transferring the contents to culture 
plates. Any spillage of culture plate contents must be treated as category 3 risk. Risk of 
infection exists mainly via percutaneous inoculation, but infection via eyes or mucous 
membranes can occur. Good laboratory practice including use of PPE lowers the risk from 
such hazards. See risk assessment form for assessment of other hazards 
Controls: 
Use of sharp implements is prohibited within the CL3 suite. Follow CL3 good laboratory 
practice, wear PPE and follow CL3 waste disposal routes to reduce risk. 
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Name of Assessor: Laura Dexter Date of Assessment: 22/12/06 
Group: Tissue Engineering Date for Re-Assessment: 22/12/07 
Experiment Location: CL3 suite 
Protocol Title: Electroporation of full length iFH1 replicons into Huh7 cells 
Brief Description: This method allows transfection of full-length HCV replicons, see 
attached protocol. Infectious virus is only known to be generated after minimum of 12hrs 
culture of transfected cells, therefore at the time of the procedure there is negligible risk of 
HCV infection. 
Hazard Assessment 
Hazard Matrix Value Precaution Matrix Value 
H R C RS 
=. 
' H R C RS 
Work at CL3. 
Infection with HCV Wear CO PPE. 
contained in cells or cell 2 1 2 4 2 1 1 2 Use MSC. 
culture supernatant No use of sharps or glass. 
Keep machine, cuvettes and 
environment clean and dry Electrical hazard from Do not introduce anything 
nucleofection device if 3 1 1 3 3 1 1 3 
else into the cuvette holder 
misused Maintain yearly electrical 
testing 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigene'" to final concentration of 5%. Cell culture media, PBS or Leave overnight for disinfection before pouring down 
transfection buffer 
the sink in CO suite with copious amounts of water. 
Double contained, sealed and autoclaved through Used plastic-ware and cuvettes CL3 waste stream. 
Level of Supervision: None 
Notes: Note that there is always a possible low-level biological hazard (e. g. from 
unidentified viruses) when working with cells and cell culture media. Good laboratory 
practice including use of PPE lowers the risk from such hazards. 
There is no electrical hazard from the nucleofection device through normal use. The 
electrical contacts are enclosed and a current will only be applied when the correct cuvette 
is detected. However, it is good practice to ensure that the device is subjected to regular 
electrical testing and is kept clean and dry. 
Nucleofection buffers are physiological buffers of unknown (proprietary) composition, 
however no hazard is identified by the manufacturer. 
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8.3.2. Huh7 infection with HCV 
Outline: 
This method describes passage of infectious HCV derived from transfected cells by overlay 
infection onto naive Huh7 cultures. This may be useful to determine the tissue culture 
infectious dose 50% (TCID50) or to increase levels of excreted virus for further infections. 
Method: 
Preparation in CL3 suite (no risk of HCV infection if container remains sealed): 
o pre-warm HCV-containing media to 37°C in water bath 
Cell preparation in CL2 facility (no risk of HCV infection): 
o transfer flasks of naive cells (with fresh media) to CU suite 
Infection of Huh? cells (risk of HCV infection in culture media): 
o add appropriate amount of HCV-containing media to each flask 
o distribute evenly and return to incubator at 37°C 
Hazards: 
After passage in Huh7 cells, levels of infectious HCV in the cell culture media may be high (at 
least equivalent to those found in vivo). Care must therefore be taken in handling and storing 
this media and any spillage of culture plate contents must be treated as category 3 risk. 
. 
Note that there is always a possible low-level biological hazard (e. g. from unidentified 
viruses) when working with cell lines and cell culture media. 
Risk of HCV infection: 
Risk of infection from cells or culture media exists mainly via percutaneous inoculation, but 
infection via eyes or mucous membranes can occur. Good laboratory practice including use of 
PPE lowers the risk from such hazards. See risk assessment form for assessment of other 
hazards 
Controls: 
Use of sharp implements is prohibited within the ü3 suite. Normal rules of good laboratory 
practice, PPE and waste disposal within the CL3 suite should be followed. 
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Name of Assessor: Laura Dexter Date of Assessment: 22/12/06 
Group: Tissue Engineering Date for Re-Assessment: 22/12/07 
Experiment Location: CL3 suite 
Protocol Title: Huh7 infection with HCV 
Brief Description: This method describes passage of infectious JFH1 HCV derived from 
transfected cells by overlay infection onto naive Huh7 cultures. This may be useful to 
determine the TCIDSO or to increase levels of excreted virus for further infections. 
Infectious HCV virus may be present in cells and cell culture supernatants. 
Hazard Assessment 
Hazard Matrix Value Precaution Matrix Value 
H R C RS H R C RS 
Work at CL3. 
Infection with HCV Wear CL3 PPE. 
contained in cells or cell 2 2 2 8 2 1 1 2 Use MSC. 
culture supernatant No use of sharps or glass. 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigene"m to final concentration of 5%. 
Cell culture media, PBS leave overnight for disinfection before pouring down 
the sink in CO suite with copious amounts of water. 
Double contained, sealed and autoclaved through CL3 Used plastic-ware 
waste stream. 
Level of Supervision: None 
Notes: Note that there is always a possible low-level biological hazard (e. g. from 
unidentified viruses) when working with cells and cell culture media. Good laboratory 
practice including use of PPE lowers the risk from such hazards. 
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8.3.3. Human primary hepatocyte nucleofection with full-length HCV 
replicons 
Outline: 
This method allows transfection of full-length HCV replicons into human primary hepatocytes. 
Method: 
Preparation in CL3 suite (no risk from organism): 
o warm nucleofection buffer and NF media 
o aliquot media into culture plates and pre-warm in the incubator at 37°C 
o label cuvettes as required 
o transfer RNA aliquot to CU facility from -80°C freezer 
o transfer Nucleofector device into MSC 
Cell preparation in CL2 facility (possible risk of blood-borne virus infection from unscreened 
donors): 
o prepare a single cell suspension of human primary hepatocytes (separate protocol 
and risk assessment exists) 
o centrifuge required number of cells at 50g and 4°C (D16) 
o transfer to CU suite 
Nucleofection of Huh7 cells (additional potential low risk of HCV infection after nucleofection): 
o resuspend cells at im/100ul in NF buffer 
o transfer RNA to cuvettes and add 100ul cells to each 
o nucleofect IMMEDIATELY on Q25 (rat) or M23 (human) 
o after 15mins incubation, add to prewarmed media in the plates 
o distribute evenly and return to incubator at 37°C 
Hazards: 
Full-length replicons contain all the necessary genes to produce infectious HCV particles, once 
transfected into permissive cells such as Huh7s. In Huh7 cells, genome replication has only 
been reported from around 12hrs post-electroporation, and detectable levels of virus in cell 
culture media have only been reported from around 24hrs post-electroporation, thus the 
likelihood of encountering infectious virus during this procedure is very low. No data is yet 
available for the dynamics of replication and/or virus production in human primary 
hepatocytes. There is also a possible risk of other blood-borne virus infections from primary 
hepatocytes as the donors are not screened. Note that there is always a possible low-level 
biological hazard (e. g. from unidentified viruses) when working with cell culture media. 
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Risk of HCV Infection: 
Production of infectious virus is only possible after cells have been nucleofected. Particular 
care must therefore be taken when opening cuvettes and transferring the contents to culture 
plates and any spillage of culture plate contents must be treated as category 3 risk. 
Risk of infection exists mainly via percutaneous inoculation, but infection via eyes or mucous 
membranes can occur. Good laboratory practice including use of PPE lowers the risk from 
such hazards. See risk assessment form for assessment of other hazards 
Controls: 
Use of sharp implements is prohibited within the CL3 suite. Normal rules of good laboratory 
practice, PPE and waste disposal within the CL3 suite should be followed. 
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Name of Assessor: Laura Dexter Date of Assessment: 22/12/06 
Group: Tissue Engineering Date for Re-Assessment: 22/12/07 
Experiment Location: CL3 suite 
Protocol Title: Electroporation of full length JFH1 replicon into human primary 
hepatocytes 
Brief Description: This method allows transfection of full-length HCV replicons, see 
attached protocol. Infectious virus is only known to be generated after minimum of 
12hrs culture of transfected cells, therefore at the time of the procedure there is 
negligible risk of HCV infection. 
Hazard Assessment 
Matrix Matrix 
Hazard Precaution Value Value 
H R C RS H R C RS 
Infection with HCV (and, in Work at CO. 
the case of primary cells, Wear CU PPE. 
other blood-borne viruses 2 2 2 8 Use MSC. 2 1 1 2 
from unscreened donors) No use of sharps or 
contained in cells or cell glass. 
culture supernatant 
Keep machine, cuvettes 
and environment clean 
and dry 
Electrical hazard from Do not introduce 
nucleofection device if 3 1 1 3 3 1 1 3 
anything else into the 
misused 
cuvette holder 
Maintain yearly 
electrical testing 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigene' to final concentration of 
Cell culture media, PBS or 5%. Leave overnight for disinfection before 
transfection buffer pouring down the sink in CL3 suite with copious 
amounts of water. 
Double contained, sealed and autoclaved Used plastic-ware and cuvettes through CO waste stream. 
Level of Supervision: None 
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Notes: 
Note that there is always a possible low-level biological hazard (e. g. from unidentified 
viruses) when working with cells and cell culture media. Good laboratory practice 
including use of PPE lowers the risk from such hazards. 
There is no electrical hazard from the nucleofection device through normal use. The 
electrical contacts are enclosed and a current will only be applied when the correct 
cuvette is detected. However, it is good practice to ensure that the device is subjected 
to regular electrical testing and is kept clean and dry. 
Nucleofection buffers are physiological buffers of unknown (proprietary) composition; 
however no hazard is identified by the manufacturer. 
All workers should attend Occupational Health prior to starting work with HCV or 
human primary cells. 
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8.3.4. Human primary hepatocyte infection with HCV 
Outline: 
This method describes infection of human primary hepatocytes with infectious HCV derived 
from transfected Huh7 cells. 
Method 1- Infection of cells in suspension at TO: 
Preparation in CL3 suite (risk from organism in culture media): 
o aliquot HCV-containing media into culture plates and pre-warm in the incubator at 
37°C 
Cell preparation in CL2 facility (possible risk of blood-borne virus infection from unscreened 
donors): 
o prepare single cell suspension, in hepatocyte plating media, of human primary 
hepatocytes (separate protocol and risk assessment exists) 
o transfer to CL3 suite 
Infection of primary hepatocytes in suspension (additional risk of HCV infection from culture 
media): 
o add appropriate amount of cell suspension to each culture well 
o distribute evenly and return to incubator at 37°C 
Method 2- Infection of cells in culture at D1: 
Preparation in CO suite (no risk from organism): 
o aliquot media into culture plates and pre-warm in the incubator at 37°C 
Cell preparation in Cli facility (possible risk of blood-borne virus infection from unscreened 
donors): 
o prepare single cell suspension(s) of human primary hepatocytes (separate protocol 
and risk assessment exists) 
o add appropriate amount of cell suspension to each culture well 
o distribute evenly and return to incubator at 37°C 
Infection of cultures at DI (additional risk of HCV infection from culture media): 
o add HCV-containing media in appropriate amounts to each culture well 
o return to incubator at 37°C 
Hazards: 
After passage in Huh7 cells, levels of infectious virus in the cell culture media may be high (at 
least equivalent to those found in vivo). Care must therefore be taken in handling and storing 
this media and any spillage of culture plate contents must be treated as category 3 risk. 
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There is also a possible risk of other blood-borne virus infections from primary hepatocytes as 
the donors are not screened. Note that there is always a possible low-level biological hazard 
(e. g. from unidentified viruses) when working with cell culture media. 
Risk of HCV Infection: 
Risk of infection from cells or culture media exists mainly via percutaneous inoculation, but 
infection via eyes or mucous membranes can occur. Good laboratory practice including use of 
PPE lowers the risk from such hazards. See risk assessment form for assessment of other 
hazards 
Controls: 
Use of sharp implements is prohibited within the CL3 suite. Normal rules of good laboratory 
practice, PPE and waste disposal within the CL3 suite should be followed. 
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Name of Assessor. Laura Dexter Date of Assessment: 
Group: Tissue Engineering 22/12/06 
Experiment Location: Ct3 suite Date for Re-Assessment: 22/12/07 
Protocol Title: Human primary hepatocyte infection with infectious HCV 
Brief Description: This method describes passage of infectious JFH1 HCV derived from 
transfected Huh7 cells by overlay infection onto naive primary hepatocyte cultures. 
Infectious HCV virus may be present in cells and cell culture supernatants. 
Hazard Assessment 
Hazard Matrix Value Precaution Matrix Value 
H R C RS H R C RS 
Infection with HCV (and, in the Work at CL3. 
case of primary cells, other Wear CL3 PPE. 
blood-borne viruses from 2 2 2 8 Use MSC. 2 1 1 2 
unscreened donors) contained in No use of sharps or 
cells or cell culture supernatant glass. 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigenel to final concentration of 
Cell culture media, PBS or transfection 5%. Leave overnight for disinfection before 
buffer pouring down the sink in CL3 suite with copious 
amounts of water. 
Double contained, sealed and autoclaved Used cell culture plates or dishes 
through CL3 waste stream. 
Level of Supervision: None 
Notes: 
Note that there is always a possible low-level biological hazard (e. g. from unidentified 
viruses) when working with cells and cell culture media. Good laboratory practice including 
use of PPE lowers the risk from such hazards. 
All workers should attend Occupational Health prior to starting work with HCV or human 
primary cells. 
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8.3.5. Maintaining cell cultures containing full-length HCV 
Outline: 
This method describes maintenance of cell cultures which have been exposed to full-length 
HCV constructs and therefore may contain or produce infectious HCV. 
Method: 
Cultures must be moved to and from the incubator and MSC or microscope on a non-porous 
tray. They must be properly covered. 
To change media (RISK: cells and cell culture media may contain infectious HCV virus and, in 
the case of primary cells, other blood-borne viruses from unscreened donors): 
o Pre-warm required media in water bath 
o Assemble all required pipettes, containers and reagents into MSC 
o Remove cultures to the MSC 
o Aspirate media into Trigene to final concentration of 5%. Alternatively, if required, 
remove by pipette for storage (store in double-sealed container and swab exterior 
with a Trigene wipe prior to removal from the MSC) for assay later. 
o Add fresh media to the cultures 
o Return cultures to incubator 
Hazards: 
Levels of infectious virus in the cell culture media have the potential to be high (at least 
equivalent to those found in vivo). Care must therefore be taken in handling and storing this 
media and any spillage of culture plate contents must be treated as category 3 risk. There is 
also a possible risk of other blood-borne virus infections from primary hepatocytes as the 
donors are not screened. Note that there is always a possible low-level biological hazard (e. g. 
from unidentified viruses) when working with cell lines and cell culture media. 
Risk of HCV Infection: 
Any spillage of culture plate contents must be treated as category 3 risk. Risk of infection 
from cells or culture media exists mainly via percutaneous inoculation, but infection via eyes 
or mucous membranes can occur. Good laboratory practice including use of PPE lowers the 
risk from such hazards. See risk assessment form for assessment of other hazards 
Controls: 
Use of sharp implements is prohibited within the CL3 suite. Normal rules of good laboratory 
practice, PPE and waste disposal within the CL3 suite should be followed. 
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Name of Assessor: Laura Dexter Date of Assessment: 22/12/06 
Group: Tissue Engineering Date for Re-Assessment: 22/12/07 
Experiment Location: CL3 suite 
Protocol Title: Maintaining cultures containing full-length HCV 
Brief Description: This method describes routine care of cultures which have been 
exposed to the full length JFH1 replicon. Infectious HCV virus may be present in cells and 
cell culture supernatants. 
Hazard Assessment 
Hazard Matrix Value Precaution Matrix Value 
H R C RS H R C RS 
Infection with HCV (and, in Work at CL3. 
the case of primary cells, Wear CL3 PPE. 
other blood-borne viruses 2 2 2 8 Use MSC. 2 1 1 2 
from unscreened donors) No use of sharps or 
contained in cells or cell glass. 
culture supernatant 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigenel to final concentration of 5%. 
Cell culture media and cell Leave overnight for disinfection before pouring 
washings down the sink in CL3 suite with copious amounts of 
water. 
Used cell culture plates or dishes, Double contained, sealed and autoclaved through 
pipettes CL3 waste stream. 
Level of Supervision: None 
Notes: 
Note that there is always a possible low-level biological hazard (e. g. from unidentified 
viruses) when working with cells and cell culture media. Good laboratory practice including 
use of PPE lowers the risk from such hazards. 
All workers should attend Occupational Health prior to starting work with HCV or human 
primary cells. 
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8.3.6. Luciferase activity measurement 
Outline: 
This method describes lysis of cultures to liberate luciferase enzyme in order to quantify HCV 
replication. However, this method is used only with cells containing the sub-genomic JFH1 
replicon, therefore infectious HCV is not present at any stage. 
Materials: Promega Luciferase assay kit E1500 
Keep buffer at 
-20°C 
Keep made-up substrate at 
-70°C 
Lysis method for monolayer cultures: 
o Make sufficient ix lysis buffer (dilute 5x buffer with H20) 
o Aspirate medium 
o Wash cell layer with PBS 
o Add 1000 1x lysis buffer 
o Scrape cells into eppendorf with pipette 
o Spin at 13K for 1min (cell extract is reasonably stable once separated) 
Lysis method for spheroid co-cultures: 
o Make sufficient lx lysis buffer (dilute 5x buffer with H2O) 
o Aspirate media and loose cell aggregates from the tissue culture wells and centrifuge 
at 250g. 
o Aspirate the supernatant and retain cell pellet. 
o Add working strength lysis buffer to the drained tissue culture plates (2 ml/well) and 
scrape into tube containing cell pellet. Pipette to mix. 
o Centrifuge the suspensions at 250g to precipitate the cell fraction from the lysis 
solution (containing cell proteins). 
o Swab the tubes with trigene wipes prior to removal from the CL3 suite 
o cell lysates can be stored at 
-80°C for batch testing if required 
Reading luciferase activity using the Turner TD-20e luminometer (D36) 
o use scintillation vial inserts and caps from Hughes and Hughes (order no. 1116) 
o turn on 120s before to allow bulb to warm 
o integrate should be set at 10s 
o delay should be set at 5s 
o add 40µI cell extract to 1000 luciferase reagent and read immediately 
one at a timel 
o stand vial in chamber, press start and wait until display reads "F" 
o measurement is in arbitrary light units, display shows position of decimal point 
(dilute if necessary) 
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Hazards: 
Cells for luciferase assay will not have been transfected or infected with full-length JFH1 
therefore there is no risk that these culture may contain infectious HCV particles. Skin, eyes or 
mucous membrane may be irritated or damaged by lysis buffer concentrate (strong 
detergent). Note that there is always a possible low-level biological hazard (e. g. from 
unidentified viruses) when working with cells and cell culture media. There is also a possible 
risk of other blood-borne virus infections from primary hepatocytes as the donors are not 
screened. 
Risks of HCV infection: 
None. See risk assessment form for assessment of other hazards 
Controls: 
Use of sharp implements is prohibited within the CL3 suite. Normal rules of good laboratory 
practice, PPE and waste disposal within the CL3 suite should be followed. 
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Name of Assessor. Laura Dexter Date of Assessment: 22/12/06 
Group: Tissue Engineering Date for Re-Assessment: 22/12/07 
Experiment Location: CL3 suite 
Protocol Title: Luciferase activity measurement 
Brief Description: This method describes lysis of cultures to liberate luciferase enzyme in 
order to quantify HCV replication. However, this method is used only with cells containing 
the sub-genomic JFH1 replicon, therefore infectious HCV is not present at any stage. 
Hazard Assessment 
Hazard Matrix Value Precaution Matrix Value 
H R C RS R C RS 
Skin, eyes or mucous membrane PPE to be worn 
irritation or damage by lysis buffer 1 2 2 4 
at all times 
1 1 1 1 
concentrate (strong detergent) 
For primary cells, possible infection Wear PPE. 
with blood-borne viruses (from Use MSC. 2 1 2 4 2 1 1 2 
unscreened donors) contained in cells No use of sharps 
or cell culture supernatant or glass. 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigene' to final concentration of 5%. 
Cell culture media, PBS or lysis Leave overnight for disinfection before pouring down buffer 
the sink in CL3 suite with copious amounts of water. 
Double contained, sealed and autoclaved through CL3 
Used plastic-ware 
waste stream. 
Level of Supervision: None 
Notes: 
Note that there is always a possible low-level biological hazard (e. g. from unidentified 
viruses) when working with cells and cell culture media. Good laboratory practice including 
use of PPE lowers the risk from such hazards. 
Eppendorfs containing lysate are removed from the suite for luminometric assay - swab 
with Trigene wipe and log in lobby book as per CL3 local rules. 
All workers should attend Occupational Health prior to starting work with human primary 
cells. 
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8.3.7. Lysis of cells for quantification of viral RNA 
Outline: 
This method may be used for cells infected or transfected with full-length replicon or intact 
HCV virus. Cells and viruses are disrupted by a chaotropic agent, releasing naked RNA. Since 
RNA alone does not present an infectious risk, the lysate can be then be removed from the 
containment level 3 suite for storage (-70°C) or further processing, e. g. PCR. 
Materials: Qiagen RNeasy Mini kit (or similar) 
Method: 
Notes and preparation: 
o Up to 7x106 cells can be processed per sample, in up to a 60mm diameter dish 
o Ensure all reagents are at room temperature 
The procedure should be carried out as quickly as possible. All steps should be carried out 
within the MSC. According to the kit manufacturer, no intact virus should be present after 
lysis, however for speed of preparation homogenisation should also be carried out in the MSC 
To We cells (RISK: cells and cell culture media may contain infectious HCV virus and, in the 
case of primary cells, other blood-borne viruses from unscreened donors): 
o Completely aspirate the cell culture medium 
o Disrupt the cells by adding 350µI of buffer RLT 
o Pipette the lysate into a microcentrifuge tube and vortex or pipette to mix 
To homogenise the lysate (very low risk from organism: ) 
o Pass the lysate at least 5 times through a blunt 20G needle fitted to an RNase-free 
syringe 
Once homogenised, to reduce viscosity and disrupt high molecular weight components such 
as genomic DNA, lysates can be stored at 
-70°C for several months. 
To store lysote (no risk from organism): 
o Swab exterior surfaces of microcentrifuge tube(s) with trigene wipe 
o Change gloves and move samples out of MSC into 
-20°C freezer 
o At a convenient point, leave the CL3 suite and move the samples to the 
-80°C 
freezer. 
Hazards: 
Using Huh7 cells, detectable levels of virus in cell culture media have only been reported from 
around 24hrs post-electroporation. However, after longer passage time, levels of infectious 
virus In the cell culture media may be high (at least equivalent to those found in vivo). 
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No data is yet available for the dynamics of replication and/or virus production in human 
primary hepatocytes. Care must therefore be taken in handling and storing this media and 
any spillage of culture plate contents must be treated as category 3 risk. Note that there is 
always a possible low-level biological hazard (e. g. from unidentified viruses) when working 
with cell lines and cell culture media. The lysis buffer contains a chaotropic agent and may 
cause irritation or damage to skin or mucous membranes if prolonged contact occurs. 
Risks: 
Any spillage of culture plate contents prior to the completion of lysis must be treated as 
category 3 risk. Risk of infection exists mainly via percutaneous inoculation, but infection via 
eyes or mucous membranes can occur. Chaotropic treatment is stated by the manufacturer to 
destroy infectious particles. Whether any live virus remains cannot be determined, however 
the titres can be assumed to then be very low. Further processing of extracts may therefore 
be carried out at containment level 2. See risk assessment form for assessment of other 
hazards 
Controls: 
Use of sharp implements is prohibited within the CL3 suite. Normal rules of good laboratory 
practice, PPE and waste disposal within the CL3 suite lower the above risks if correctly 
followed. 
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Name of Assessor. Laura Dexter Date of Assessment: 22/12/06 
Group: Tissue Engineering Date for Re-Assessment: 22/12/07 
Experiment Location: CL3 suite 
Protocol Title: Lysis of cells for quantifi cation of viral RNA 
Brief Description: Cells and viruses are disrupted by a chaotropic agent, releasing naked 
RNA. Chaotropic treatment is stated by the manufacturer to destroy infectious particles. 
Whether any live virus remains cannot be determined, however the titres can be assumed to 
then be very low. The lysate can be the n be removed from the containment level 3 suite for 
storage (-70°C) or further processing, e. g. PCR. at containment level 2 
Hazard Assessment 
Hazard Matrix Value Precaution Matrix Value 
H R C RS H R C RS 
Work at CL3. 
Infection with HCV (and, in Wear CL3 PPE. 
the case of primary cells, Use MSC. 
other blood-borne viruses No use of sharps or 2 2 2 8 2 1 1 2 
from unscreened donors) glass. The microfuge 
contained in cells or cell must be placed and 
culture supernatant opened within the MSC, 
where used. 
Skin, eye or mucous 
membrane irritation or Wear PPE 1 2 2 q 1 1 1 1 
damage by lysis buffer RLT Follow GLP 
(chaotropic agent) 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigene' to final concentration of 
Cell culture media, excess lysis buffer 5%. Leave overnight for disinfection before 
and cell washings pouring down the sink in CL3 suite with copious 
amounts of water. 
Double contained, sealed and autoclaved through Used plastic-ware CO waste stream. 
Level of Supervision: None 
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Notes: 
Note that there is always a possible low-level biological hazard (e. g. from unidentified 
viruses) when working with cells and cell culture media. Good laboratory practice including 
use of PPE lowers the risk from such hazards. 
All workers should attend Occupational Health prior to starting work with HCV or human 
primary cells. 
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8.3.8. Lysis of cell-free culture media for quantification of viral RNA 
Outline: 
This method may be used for culture media from cells infected or transfected with full-length 
replicon or intact HCV virus. Virus is disrupted by a chaotropic agent, releasing naked RNA. 
Since RNA alone does not present an infectious risk, the lysate can be then be removed from 
the containment level 3 suite for storage (-70°C) or further processing, e. g. PCR. 
Materials: Qiagen Viral RNA Mini kit (or similar) 
Method: 
Notes and preparation: 
o Move the microcentrifuge into the MSC 
o Ensure all samples are at room temperature 
o Make fresh working AVL buffer solution (n x 0.56 = ml of buffer AVL required; add 
100 aliquoted carrier RNA per ml to obtain working buffer). Gently mix by inversion 
o For each sample, prepare 560µI of working AVL buffer in a 1.5 ml microcentrifuge 
tube 
The procedure should be carried out as quickly as possible. All steps should be carried out 
within the MSC. According to the kit manufacturer, no intact virus should be present after 
lysis, however for speed of preparation homogenisation should also be carried out in the 
MSC. 
To lyse virus in media (RISK: cells and cell culture media may contain infectious HCV virus and, 
in the case of primary cells, other blood-borne viruses from unscreened donors): 
o Completely aspirate the cell culture medium into a 1.5 ml microcentrifuge tube 
o Centrifuge at 1500g to remove any cellular debris 
o Add 140ul of sample supernatant to the working AVL mixture 
o Vortex for 15s and incubate at room temperature for 10 minutes. 
Viral particle lysis is complete after lysis for 10mins at room temperature and potentially 
infectious agents are inactivated. The lysate now presents negligible risk of infection and can 
be stored at 
-70°C for several months. 
To store lysate: 
o Swab exterior surfaces of microcentrifuge tube(s) with trigene wipe 
o Change gloves and move samples out of MSC into 
-20°C freezer 
o At a convenient point, leave the C13 suite and move the samples to the -80°C 
freezer. 
Hazards: 
Full-length replicons contain all the necessary genes to produce infectious HCV particles, once 
transfected into permissive cells. 
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Using Huh7 cells, detectable levels of virus in cell culture media have only been reported from 
around 24hrs post-electroporation. However, after longer passage time, levels of infectious 
virus in the cell culture media may be high (at least equivalent to those found in vivo). No data 
is yet available for the dynamics of replication and/or virus production in human primary 
hepatocytes. Care must therefore be taken in handling and storing this media and any spillage 
of culture plate contents must be treated as category 3 risk. 
Note that there is always a possible low-level biological hazard (e. g. from unidentified viruses) 
when working with cells and cell culture media. The lysis buffer contains a chaotropic agent 
and may cause irritation or damage to skin or mucous membranes if prolonged contact 
occurs. Note that there is always a possible low-level biological hazard (e. g. from unidentified 
viruses) when working with cell culture media. 
Risks: 
Any spillage of culture plate contents prior to the completion of lysis must be treated as 
category 3 risk. Risk of infection exists mainly via percutaneous inoculation, but infection via 
eyes or mucous membranes can occur. Chaotropic treatment is stated by the manufacturer to 
destroy infectious particles. Whether any live virus remains cannot be determined, however 
the titres can be assumed to then be very low. Further processing of extracts may therefore 
be carried out at containment level 2. See risk assessment form for assessment of other 
hazards 
Controls: 
Use of sharp implements is prohibited within the CL3 suite. Normal rules of good laboratory 
practice, PPE and waste disposal within the CL3 suite lower the above risks if correctly 
followed. 
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Name of Assessor: Laura Dexter Date of Assessment: 22/12/06 
Group: Tissue Engineering Date for Re-Assessment: 22/12/07 
Experiment Location: CL3 suite 
Protocol Title: Lysis of cell-free culture media for quantification of viral RNA 
Brief Description: Viruses present in the cell culture media are disrupted by a chaotropic 
agent, releasing naked RNA. Chaotropic treatment is stated by the manufacturer to destroy 
infectious particles. Whether any live virus remains cannot be determined, however the 
titres can be assumed to then be very low. Since RNA alone does not present an infectious 
risk, the lysate can be then be removed from the containment level 3 suite for storage (- 
70°C) or further processing, e. g. PCR at containment level 2. 
Hazard Assessment 
Hazard Matrix Value Precaution Matrix Value 
H R C RS H R C RS 
Work at CL3. 
Infection with HCV (and, in Wear CL3 PPE. 
the case of primary cells, Use MSC. 
other blood-borne viruses 2 2 2 8 No use of sharps or glass. 2 1 1 2 from unscreened donors) The microfuge must be 
contained in cells or cell 
placed and opened within 
culture supernatant the MSC, where used. 
Skin, eye or mucous 
membrane damage by lysis Wear PPE 1 2 2 4 1 1 1 1 buffer AVL (chaotropic Follow GLP 
agent) 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigene"A to final concentration of 5%. Cell culture media, excess lysis leave overnight for disinfection before pouring down buffer and cell washings the sink in CL3 suite with copious amounts of water. 
Double contained, sealed and autoclaved through CO Used plastic-ware 
waste stream. 
Level of Supervision: None 
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Notes: 
Note that there is always a possible low-level biological hazard (e. g. from unidentified 
viruses) when working with cell culture media. Good laboratory practice including use of PPE 
lowers the risk from such hazards. 
All workers should attend Occupational Health prior to starting work with HCV or human 
primary cells. 
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8.3.9. Disaggregating co-culture spheroids 
Outline: 
This method describes disaggregation of co-cultured human primary hepatocytes and stellate 
cells in the CL3 suite. 
Method: 
o Aspirate media and loose cell aggregates from the tissue culture wells and centrifuge 
at 250g. 
o Aspirate the supernatant and retain cell pellet. 
o Add pre-warmed Accutase to the drained tissue culture plates (2 ml/well) and 
incubate at 37°C for 5 minutes. 
o After this time, scrape wells to remove cell deposits and add whole suspension back 
to the retained cell pellets obtained from the centrifugation stage. 
o Incubate Accutase-treated cells at 37°C for a further 5 minutes. 
o Agitate the cell suspensions by gentle pipetting at approximately 2 minute intervals 
during this period. 
o Centrifuge the suspensions at 250g to precipitate the cell fraction from the enzyme 
solution. 
o Resuspend the cell pellets as required for further assay 
Hazards: 
if cells have previously been transfected with full-length JFH1 replicon, or infected with 
replicon-derived virus, infectious virus may be present. Care must therefore be taken in 
handling and storing these cultures and media and any spillage of culture plate contents must 
be treated as category 3 risk. There is also a possible risk of other blood-borne virus infections 
from primary hepatocytes as the donors are not screened. Accutase enzyme may cause 
irritation to eyes, skin or mucous membranes if prolonged contact occurs. Note that there is 
always a possible low-level biological hazard (e. g. from unidentified viruses) when working 
with cell lines and cell culture media. 
Risk of HN infection: 
Risk of infection from cells or culture media exists mainly via percutaneous inoculation, but 
infection via eyes or mucous membranes can occur. Good laboratory practice including use of 
PPE lowers the risk from such hazards. See risk assessment form for assessment of other 
hazards 
Controls: 
Use of sharp implements is prohibited within the CL3 suite. Normal rules of good laboratory 
practice, PPE and waste disposal within the CL3 suite must be followed. The centrifuge must 
be moved into the MSC for this experiment and swabbed with Trigene wipes prior to removal 
once complete. 
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Name of Assessor: Laura Dexter Date of Assessment: 22/12/06 
Group: Tissue Engineering Date for Re-Assessment: 22/12/07 
Experiment Location: CL3 suite 
Protocol Title: Disaggregating co-culture spheroids 
Brief Description: This method describes disaggregation of co-cultures in the CL3 suite. 
If cells have previously been transfected or infected with full-length JFH1 replicon infectious 
HCV virus may be present in cells and cell culture supernatants. 
Hazard Assessment 
Hazard Matrix Value Precaution Matrix Value 
H R C RS H R C RS 
Work at CL3. 
Infection with HCV (and, in Wear CL3 PPE. 
the case of primary cells, Use MSC. 
other blood-borne viruses No use of sharps or 2 2 2 8 2 1 1 2 
from unscreened donors) glass. The microfuge 
contained in cells or cell must be placed and 
culture supernatant opened within the MSC, 
where used. 
Possible irritation to eyes, 
skin or mucous membranes 1 2 2 4 
Wear PPE 
1 1 1 1 from Accutase enzyme if Follow GLP 
prolonged contact occurs 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigene'" to final concentration of 5%. 
Cell culture media, enzyme solutions Leave overnight for disinfection before pouring 
and cell washings down the sink in CL3 suite with copious amounts of 
water. 
Double contained, sealed and autoclaved through Used plastic-ware CL3 waste stream. 
Level of Supervision: None 
Notes: 
Note that there is always a possible low-level biological hazard (e. g. from unidentified 
viruses) when working with cells and cell culture media. Good laboratory practice including 
use of PPE renders the risk from such hazards negligible. 
All workers should attend Occupational Health prior to starting work with HCV or human 
primary cells. 
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8.3.10. NS5A staining of cultures 
Outline: 
This method describes quantification of infected/transfected cells by antibody staining of the 
HCV non-structural protein 5a. This is translated from both the full-length and sub-genomic 
replicons. 
Method: 
Cultures (grown on plastic coverslips within culture wells) must be moved to and from the 
incubator and MSC or microscope on a non-porous tray. They must be properly covered. 
o Aspirate media from cultures (risk from organism at this stage) 
o Fix in 4% paraformaldehyde for at least 20mins at 4°C 
o Wash x3 in PBS 1% FCS and block for 20mins with PBS 10% FCS 
o Make primary antibody solution: sheep anti-NS5a 1/5000 in PBS 1% FCS 
o Wash x3 in PBS 1% FCS and add 200µI working strength primary antibody per well for 
2hrs at RT 
o Make secondary antibody solution: donkey anti-sheep-TRITC 1/100 in PBS 1% FCS 
- 
protect from lightl 
o Wash x3 in PBS 1% FCS and add 200µI working strength secondary antibody per well 
for ihr at RT 
- 
protect from light! 
o Wash x3 in PBS 
o Wash x1 in H2O 
o Mount coverslips with Citifluor and seal with nail polish 
- 
protect from light! 
Once sealed, swab slides with trigene wipes prior to removal from the suite. 
Hazards: 
Full-length replicons contain all the necessary genes to produce infectious HCV particles, once 
transfected into permissive cells such as Huh7s. Genome replication has only been reported 
from around 12hrs post-electroporation, and detectable levels of virus in cell culture media 
have only been reported from around 24hrs post-electroporation. After this time, levels of 
infectious virus in the cell culture media may be high (at least equivalent to those found in 
vivo). Care must therefore be taken in handling this media. However, once fixed, cultures are 
considered to be hazard group 2. 
Note that there is always a possible low-level biological hazard (e. g. from unidentified viruses) 
when working with cells, cell culture media and serum (FCS). There is also a possible risk of 
other blood-borne virus infections from primary hepatocytes as the donors are not screened. 
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Risks of HCV infection: 
Any spillage of culture plate contents must be treated as category 3 risk. Risk of infection 
exists mainly via percutaneous inoculation, but infection via eyes or mucous membranes can 
occur. See separate risk assessment for details of other risks. 
Controls: 
Use of sharp implements is prohibited within the CL3 suite. Glass slides must not be used. 
Normal rules of good laboratory practice, PPE and waste disposal within the CL3 suite lower 
the above risks if correctly followed. 
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Name of Assessor: Laura Dexter Date of Assessment: 22/12/06 
Group: Tissue Engineering Date for Re-Assessment: 22/12/07 
Experiment Location: CL3 suite 
Protocol Title: NSSA staining In CL3 suite 
Brief Description: This method describes quantification of infected/transfected cells by 
antibody staining of the HCV non-structural protein 5a. This is translated from both the full- 
length and sub-genomic replicons. Infectious HCV virus may be present in cells and cell 
culture media. After fixation in paraformaldehyde, cultures are considered to be hazard 
group 2: however the entire procedure will be carried out within the MSC where possible. 
Once sealed, slides are swabbed with trigene wipes prior to removal from the suite. Glass 
slides/coverslips must not be used. 
Hazard Assessment 
Hazard Matrix Value Precaution Matrix Value 
H R C RS H R C RS 
Infection with HCV (and, in the Work at CL3. 
case of primary cells, other Wear CL3 PPE. 
blood-borne viruses from 2 2 2 8 Use MSC. 2 1 1 2 
unscreened donors) contained in No use of sharps or 
cells or cell culture supernatant glass. 
4% paraformaldehyde solution is Wear PPE 
toxic, corrosive and a possible 2 2 2 8 Ensure good 2 1 1 2 
carcinogen. ventilation (use MSC) 
Disposal Procedures 
Chemical/Buffer/Reagent Disposal Route 
Aspirated into Trigene" to final concentration of 
5%. Leave overnight for disinfection before Cell culture media and cell washings 
pouring down the sink in CL3 suite with copious 
amounts of water. 
Used cell culture plates or dishes, Double contained, sealed and autoclaved 
coverslips, slides, pipettes etc. through CL3 waste stream. 
Used and surplus 4% paraformaldehyde Double contained and disposed of through toxic 
solution waste route. 
Level of Supervision: None 
Notes: Note that there is always a possible low-level biological hazard (e. g. from 
unidentified viruses) when working with cells, cell culture media and serum. Good 
laboratory practice including use of PPE lowers the risk from such hazards. 
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